Combination therapy for treating neurodegenerative diseases

A combination therapy of PDE-5 inhibitors, GLP-1 or DPP-4 inhibitors, GIP agonists, and glucagon effectively targets multiple pathways in neurodegenerative diseases, improving cognitive function and slowing progression by reducing inflammatory markers and amyloid-beta levels.

JP2026539121APending Publication Date: 2026-11-19ARIBIO CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2026541518
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-11-14
Filing Date
2024-11-14
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current pharmacological approaches for neurodegenerative diseases often fail to effectively address the complex and multifaceted nature of these conditions, leading to limited efficacy in clinical trials, despite advancements in understanding underlying mechanisms.

Method used

A combination therapy comprising a PDE-5 inhibitor, a GLP-1 receptor agonist, a GIP agonist, and glucagon, or a PDE-5 inhibitor, a DPP-4 inhibitor, a GIP agonist, and glucagon, in specific molar ratios, is administered to treat neurodegenerative diseases.

Benefits of technology

The combination therapy shows promise in improving cognitive function, slowing disease progression, and enhancing quality of life for individuals with neurodegenerative diseases, as evidenced by reductions in inflammatory markers and amyloid-beta levels.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026539121000001_ABST
    Figure 2026539121000001_ABST
Patent Text Reader

Abstract

This disclosure provides a pharmaceutical composition for the prevention or treatment of neurodegenerative diseases, comprising a phosphodiesterase 5 inhibitor and a glucagon-like peptide 1 (GLP-1) receptor agonist or a dipeptidyl peptidase IV (DPP-4) inhibitor as active ingredients. The phosphodiesterase 5 inhibitor is selected from mirodenafil, sildenafil, vardenafil, tadalafil, udenafil, dasantafil, avanafil, and their pharmaceutically acceptable salts, solvates, and hydrates. The GLP-1 receptor agonist is selected from semaglutide, exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, tylzepatide, cotadutide, and taspoglutide. DPP-4 inhibitors are selected from sitagliptin, vildagliptin, saxagliptin, linagliptin, gemigliptin, teneligliptin, alogliptin, evogliptin, and anagliptin. This combination shows synergistic effects in reducing intracellular Aβ42, IL1β, and TNFα levels compared to the individual compounds alone.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] [CROSS-REFERENCE TO RELATED APPLICATIONS] This application claims priority based on Korean Provisional Application No. 10-2023-0156962 filed on November 14, 2023, the entire content of which is incorporated herein by reference.

[0002] The present teachings relate to methods and compositions for the treatment of neurodegenerative diseases.

BACKGROUND ART

[0003] Neurodegenerative disease is a broad term used to describe severe cognitive decline that interferes with daily life. It is not a specific disease or disorder, but a collection of symptoms that affect memory, thinking, and social function. The most common neurodegenerative disease is dementia, which is caused by Alzheimer's disease in 60% to 80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia.

[0004] With the global aging of the population, the prevalence of dementia is increasing rapidly. This trend poses significant challenges to healthcare systems, families, and societies worldwide. The progressive nature of neurodegenerative diseases leads to increasing dependence and need for care as the condition advances. Currently, there is no cure for most types of neurodegenerative diseases, and available treatments mainly focus on symptom management and slowing the progression of the disease.

[0005] Existing pharmacological approaches for treating neurodegenerative diseases typically target specific neurotransmitter systems or attempt to address the underlying pathological processes. However, the complex and multifaceted nature of neurodegenerative diseases often limits the effectiveness of single-target therapies. This has led to growing interest in combination therapies that can simultaneously address multiple aspects of the disease.

[0006] Recent research has investigated various molecular pathways and cellular mechanisms involved in the onset and progression of neurodegenerative diseases. These investigations have highlighted potential new targets for therapeutic interventions. Among these, several specific enzymes and receptors have emerged as promising candidates for drug development.

[0007] Despite advancements in our understanding of the underlying mechanisms of neurodegenerative diseases, translating this knowledge into effective treatments remains challenging. Many potential therapies that show promise in preclinical studies have failed to demonstrate significant benefits in clinical trials. This highlights the need for innovative approaches to drug discovery and development in the field of neurodegenerative disease research.

[0008] The search for more effective treatments for neurodegenerative diseases remains an active area of ​​scientific inquiry. Researchers are exploring a variety of strategies, including the repurposement of existing drugs, the development of novel compounds, and the investigation of combination therapies. The ultimate goal is to find interventions that can significantly improve cognitive function, slow disease progression, and enhance quality of life in individuals with neurodegenerative diseases. [Overview of the Initiative]

[0009] According to aspects of the present disclosure, a pharmaceutical composition for the prevention or treatment of neurodegenerative diseases is provided, comprising a PDE-5 inhibitor, a GLP-1 receptor agonist, a GIP agonist, and glucagon, wherein the molar ratio of any one member of the group to another member is approximately (1,0,0,1000) to approximately (1,000,0,0,0). Such molar ratios are described in more detail below.

[0010] According to another aspect of the present disclosure, a pharmaceutical composition for the prevention or treatment of neurodegenerative diseases is provided, comprising a PDE-5 inhibitor, a DPP-4 inhibitor, a GIP agonist, and glucagon, wherein the molar ratio of any one member of the group to any other member is approximately (1,0,0,1000) to approximately (1,000,0,0,0).

[0011] In various embodiments, the PDE-5 inhibitor may be myrodenafil, sildenafil, vardenafil, tadalafil, udenafil, dasantafil, avanafil, and their pharmaceutically acceptable salts, solvates, and hydrates, and in a further embodiment, myrodenafil. In various embodiments, the GLP-1 receptor agonist may be semaglutide, exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, tilzepatide, cotadutide, and taspoglutide, and in a further embodiment, semaglutide. In various embodiments, the DPP-4 inhibitor is sitagliptin.

[0012] According to further aspects of this disclosure, neurodegenerative diseases include Parkinson's disease (PD); sporadic or hereditary Lewy body dementia (DLB); pure autonomic neuropathy with αS deposition (PAF); multiple system atrophy (MSA); hereditary neurodegenerative diseases with intracranial iron accumulation; and accidental Lewy body disease in old age; Lewy body Alzheimer's disease; Down syndrome; progressive supranuclear palsy; essential tremor with Lewy bodies; mutated genes; and gene loci whose mutations have not yet been identified. Familial parkinsonism with or without dementia; Creutzfeldt-Jakob disease; bovine spongiform encephalopathy; secondary parkinson's disease / parkinsonism resulting from neurotoxic exposure / drug-induced parkinsonism with alpha-synuclein deposition; sporadic or hereditary spinocerebellar ataxia; amyotrophic lateral sclerosis (ALS); idiopathic REM sleep behavior disorder; and other conditions in mammals associated with central and / or peripheral alpha-synuclein accumulation in connection with a primary disease process.

[0013] According to further aspects of this disclosure, neurodegenerative diseases include Alzheimer's disease, vascular dementia, frontotemporal dementia (FTD), Lewy body dementia (LBD), mixed dementia, posterior cortical atrophy (PCA), primary progressive aphasia (PPA), corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP), idiopathic myeloma, amyloid polyneuropathy, amyloid cardiomyopathy, systemic senile amyloidosis, amyloid polyneuropathy, hereditary cerebral hemorrhage with amyloidosis, Down syndrome, scrapie, medullary thyroid carcinoma, and solitary Orthostatic atrial amyloidosis, β2-microglobulin amyloidosis, inclusion body myositis, muscular atrophy, islet of Langerhans diabetes, type 1 diabetes, insulinoma, type 2 diabetes, hereditary hemorrhagic amyloidosis (Dutch type), amyloid A (reactive) amyloidosis, secondary amyloidosis, familial Mediterranean fever, familial amyloid nephropathy with urticaria and hearing loss (Macklewells syndrome), amyloid λL chain amyloidosis, amyloid κL chain amyloidosis, idiopathic-associated amyloidosis, myeloma-associated amyloidosis, Macroglobulinemia-associated amyloidosis, Aβ2M amyloidosis (chronic hemodialysis), ATTR amyloidosis (familial amyloid polyneuropathy (Portuguese type, Japanese type, Swedish type)), familial amyloid cardiomyopathy (Danish type), isolated cardiac amyloidosis, systemic senile amyloidosis, AIAPP or amylin insulinoma, atrial natriuretic factor amyloidosis (isolated atrial amyloidosis), procalcitonin amyloidosis (medullary thyroid carcinoma), gelzolin amyloidosis This may include familial amyloidosis (Finnish type), cystatin C (hereditary cerebral hemorrhage with amyloidosis (Icelandic type)), AApo-AI amyloidosis (familial amyloid polyneuropathy - Iowa type), AApo-A-II amyloidosis, traumatic brain injury, fibrinogen-associated amyloidosis, Creutzfeldt-Jakob disease, Gerstmann-Streussler-Scheinker syndrome, bovine spongiform encephalitis, conditions associated with homozygosity of the apolipoprotein E4 allele, and Huntington's disease.

[0014] In particular, neurodegenerative diseases may include Parkinson's disease (PD), Parkinson's dementia (PDD), Lewy body dementia (DLB), multiple system atrophy (MSA), pure autonomic dysplasia (PAF), and Lewy body variants of Alzheimer's disease (LBV). In particular, neurodegenerative diseases may include Alzheimer's disease, vascular dementia, frontotemporal dementia (FTD), Lewy body dementia (LBD), mixed dementia, posterior cortical atrophy (PCA), primary progressive aphasia (PPA), corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP). In various embodiments, neurodegenerative diseases may include Lewy body dementia and Alzheimer's disease.

[0015] In various embodiments, pharmaceutical compositions are formulated for oral administration. In particular, pharmaceutical compositions are in the form of tablets or capsules.

[0016] Various methods are provided for treating neurodegenerative diseases in subjects requiring treatment, the methods comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a PDE-5 inhibitor, a GLP-1 receptor agonist, a GIP agonist, and glucagon, wherein the molar ratio of any one member of the group to another member is approximately (1,0,0,1000) to approximately (1,000,0,0,0).

[0017] Various further methods are provided for treating neurodegenerative diseases in subjects requiring treatment, the methods comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a PDE-5 inhibitor, a DPP-4 inhibitor, a GIP agonist, and glucagon, wherein the molar ratio of any one member of the group to another member is approximately (1,0,0,1000) to approximately (1,000,0,0,0).

[0018] In various embodiments, the PDE-5 inhibitor may be myrodenafil, sildenafil, vardenafil, tadalafil, udenafil, dasantafil, avanafil, and pharmaceutically acceptable salts, solvates, and hydrates thereof, and particularly may be myrodenafil. In various embodiments, the GLP-1 receptor agonist may be semaglutide, exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, tilzepatide, cotadutide, and taspoglutide, and particularly may be semaglutide. In various embodiments, the DPP-4 inhibitor may be sitagliptin, vildagliptin, saxagliptin, linagliptin, gemigliptin, teneligliptin, alogliptin, evogliptin, and anagliptin, and particularly may be sitagliptin.

[0019] In a further embodiment, neurodegenerative diseases include Parkinson's disease (PD); sporadic or hereditary Lewy body dementia (DLB); pure autonomic dysplasia with αS deposition (PAF); multiple system atrophy (MSA); hereditary neurodegenerative diseases with intracranial iron accumulation; and incidental Lewy body disease in old age; Lewy body Alzheimer's disease; Down syndrome; progressive supranuclear palsy; essential tremor with Lewy bodies; mutated genes; and dementia caused by gene loci whose mutations have not yet been identified. The group consists of familial parkinsonism with or without ulceration; Creutzfeldt-Jakob disease; bovine spongiform encephalopathy; secondary parkinson's disease / parkinsonism resulting from neurotoxic exposure / drug-induced parkinsonism with alpha-synuclein deposition; sporadic or hereditary spinocerebellar ataxia; amyotrophic lateral sclerosis (ALS); idiopathic REM sleep behavior disorder; and other conditions associated with central and / or peripheral alpha-synuclein accumulation in mammals associated with a primary disease process.

[0020] In other aspects, neurodegenerative diseases include Alzheimer's disease, vascular dementia, frontotemporal dementia (FTD), Lewy body dementia (LBD), mixed dementia, posterior cortical atrophy (PCA), primary progressive aphasia (PPA), corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP), idiopathic myeloma, amyloid polyneuropathy, amyloid cardiomyopathy, systemic senile amyloidosis, amyloid polyneuropathy, hereditary cerebral hemorrhage with amyloidosis, Down syndrome, scrapie, medullary thyroid carcinoma, and isolated atrium. Amyloidosis, β2-microglobulin amyloidosis, inclusion body myositis, muscle atrophy disease, islet diabetes, type 1 diabetes, insulinoma, type 2 diabetes, hereditary hemorrhagic amyloidosis (Dutch type), amyloid A (reactive) amyloidosis, secondary amyloidosis, familial Mediterranean fever, familial amyloid nephropathy with urticaria and hearing loss (Macklewells syndrome), amyloid λL chain amyloidosis, amyloid κL chain amyloidosis, idiopathic-associated amyloidosis, myeloma-associated amyloidosis, macrog Robulinemia-associated amyloidosis, Aβ2M amyloidosis (chronic hemodialysis), ATTR amyloidosis (familial amyloid polyneuropathy (Portuguese type, Japanese type, Swedish type)), familial amyloid cardiomyopathy (Danish type), isolated cardiac amyloidosis, systemic senile amyloidosis, AIAPP or amylin insulinoma, atrial natriuretic factor amyloidosis (isolated atrial amyloidosis), procalcitonin amyloidosis (medullary thyroid carcinoma), gelzolin amyloidosis (familial amyloidosis) The group is selected from the following: myloidosis (Finnish type), cystatin C (hereditary cerebral hemorrhage with amyloidosis (Icelandic type)), AApo-AI amyloidosis (familial amyloid polyneuropathy - Iowa type), AApo-A-II amyloidosis, traumatic brain injury, fibrinogen-associated amyloidosis, Creutzfeldt-Jakob disease, Gerstmann-Streussler-Scheinker syndrome, bovine spongiform encephalitis, conditions associated with homozygosity of the apolipoprotein E4 allele, and Huntington's disease.

[0021] In various embodiments, the neurodegenerative disease may be Parkinson's disease (PD), Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), pure autonomic failure (PAF), and the Lewy body variant of Alzheimer's disease (LBV). In various embodiments, the neurodegenerative disease may be Alzheimer's disease, vascular dementia, frontotemporal dementia (FTD), dementia with Lewy bodies (LBD), mixed dementia, posterior cortical atrophy (PCA), primary progressive aphasia (PPA), corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP). In further embodiments, the neurodegenerative disease may be dementia with Lewy bodies and Alzheimer's disease.

[0022] These and other features, aspects and advantages of the present teachings will be better understood with reference to the following description, examples and appended claims.

[0023] Those skilled in the art will understand that the drawings described below are for illustrative purposes only. The drawings are not intended to limit the scope of the present teachings in any way. [Brief Description of the Drawings]

[0024] [Figure 1] 1 is a bar graph showing the effects of AR1001 and semaglutide on IL-6 levels according to an embodiment of the present disclosure. [Figure 2] 1 is a bar graph showing the effects of AR1001 and semaglutide on IL-6 levels according to an embodiment of the present disclosure. [Figure 3] 1 is a bar graph showing the effects of AR1001 and tirzepatide on IL-6 levels according to an embodiment of the present disclosure. [Figure 4] 1 is a bar graph showing the effects of AR1001 and dulaglutide on IL-6 levels according to an embodiment of the present disclosure. [Figure 5] 1 is a bar graph showing the effects of AR1001 and semaglutide on IL-6 levels according to an embodiment of the present disclosure. [Figure 6]This is a bar graph showing the effects of AR1001 and tirzepatide on IL-6 levels according to aspects of the present disclosure. [Figure 7] This is a bar graph showing the effects of AR1001 and dulaglutide on IL-6 levels according to aspects of the present disclosure. [Figure 8] This is a bar graph showing the effects of AR1001 and exenatide on IL-6 levels according to aspects of the present disclosure. [Figure 9] This is a bar graph showing the effects of AR1001 and semaglutide on the JC-1 ratio according to one embodiment. [Figure 10] This is a bar graph showing the effects of AR1001 and exenatide on the JC-1 ratio according to one embodiment. [Figure 11] This is a bar graph showing the effects of AR1001 and semaglutide on Aβ reduction according to one embodiment. [Figure 12] This is a bar graph showing the effects of AR1001 and semaglutide on IL1β reduction according to one embodiment. [Figure 13] This is a bar graph showing the effects of AR1001 and semaglutide on TNFα reduction according to one embodiment. [Figure 14] This is a bar graph and data table showing the effects of AR1001 and sitagliptin on Aβ reduction according to one embodiment. [Figure 15] This is a bar graph and data table showing the effects of AR1001 and vildagliptin on Aβ reduction according to aspects of the present disclosure. [Figure 16] This is a bar graph and data table showing the effects of AR1001 and linagliptin on Aβ reduction according to one embodiment. [Figure 17] This is a bar graph showing the effects of AR1001 and sitagliptin on IL1β levels according to aspects of the present disclosure. [Figure 18] This is a bar graph showing the effects of AR1001 and sitagliptin on IL1β reduction according to one embodiment. [Figure 19]This is a bar graph showing the effects of AR1001 and sitagliptin on TNFα levels according to an aspect of this disclosure. [Figure 20] This bar graph shows the effects of AR1001 and sitagliptin on TNFα reduction according to one embodiment. [Figure 21] This is a bar graph showing the effects of AR1001 and linagliptin on IL1β reduction according to the embodiments of this disclosure. [Figure 22] This is a bar graph showing the effects of AR1001 and linagliptin on TNFα reduction according to one embodiment. [Modes for carrying out the invention]

[0025] Abbreviations and Definitions To facilitate understanding of the present invention, some terms and abbreviations used herein are defined as follows:

[0026] All patents, applications, published applications, and other publications cited herein constitute part of this specification by citation. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art to which the invention pertains. Chemical structures and formulas described herein are constructed in accordance with the standard rules of chemical valence known in the chemical art. Where there is a discrepancy between a described structure and the name given to it, the described structure should be given greater weight. If the stereochemistry of a structure or part of a structure is not shown in the described structure or part of a described structure, the described structure should be interpreted as encompassing all possible stereoisomers.

[0027] Any methods, devices, and materials similar or equivalent to those described herein may be used in carrying out the present invention. The following definitions are provided to facilitate the understanding of certain terms that are frequently used herein and are not intended to limit the scope of this disclosure. If there are multiple definitions for a term herein, the definition in this section shall prevail unless otherwise noted. The headings used herein are for structural purposes only and are not intended to limit the inventions described herein in any way.

[0028] The term "administer" refers to the act of delivering any combination or composition described herein to a subject by means of an oral, mucosal, topical, suppository, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal, or subcutaneous route. Parenteral administration includes intravenous, intramuscular, arterioleal, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial administration. Administration is generally performed after the onset of a disease, disorder, or condition, or its symptoms, but in some specific cases it may be performed before the onset of a disease, disorder, or condition, or its symptoms (for example, administration to patients who are susceptible to such a disease, disorder, or condition).

[0029] The terms “coadministering,” “coadministration,” or “combination” refer to the administration of two or more drugs (for example, a combination as described herein that optionally includes another activating agent, such as an antineurodegenerative agent as described herein). The timing of coadministration depends in part on the combination and the individual compositions being administered, and may include administration concurrently with, immediately before, or immediately after, the administration of one or more additional therapies, such as an antineurodegenerative agent including immunotherapy. Coadministration is intended to include administering each compound of the combination simultaneously or sequentially. Accordingly, preparations may also be combined with other activating substances if desired (for example, to reduce metabolic degradation). The compounds described herein may be used with each other and with other activating agents known to be useful in the treatment of neurodegeneration.

[0030] The terms “therapies” and “therapy” refer to any protocol(s), methods(s), and / or agents(s) that may be used to prevent, treat, manage, and / or improve (ameliorate) a disease, disorder, or condition, or one or more of its symptoms. In some specific examples, the term refers to activators such as the antineurodegenerative agents described herein. The terms “therapy” and “therapy” may also refer to antiviral therapies, antimicrobial therapies, antifungal therapies, antineurodegenerative therapies, biological therapies, supportive therapies, and / or other therapies known to those skilled in the art (e.g., medical professionals such as physicians) that are useful in treating, managing, preventing, or improving (ameliorating) a disease, disorder, or condition, or one or more of its symptoms.

[0031] The terms “patient” or “subject” refer to mammals such as humans, cattle, rats, mice, dogs, monkeys, apes, goats, sheep, cows, or deer. Generally, the patients described herein are human. The subjects described herein may be human subjects who have Alzheimer’s disease (e.g., AD, Alzheimer’s disease) or who may have Alzheimer’s disease. In these cases, whether a human subject has or may have Alzheimer’s disease can be determined by the methods disclosed in the examples provided herein and by methods commonly practiced by those skilled in the art. Human subjects who have or may have Alzheimer's disease include, for example, subjects whose cognitive function tests, such as the CDR-SB (Clinical Dementia Rating Scale Sum of Boxes), ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive Subscale), or MMSE (Mini-Mental State Examination), suggest cognitive decline or the possibility thereof. Subjects may also include human subjects with brain deposition or cerebrospinal fluid concentrations of proteins known to accumulate in Alzheimer's disease patients, such as amyloid-beta and tau proteins, or human subjects with decreased brain metabolic function or brain tissue atrophy.

[0032] The terms “to treat” or “treatment” refer to any sign of success or improvement (amelioration) of the progression, severity, and / or duration of a disease, pathology, or condition, including any objective or subjective parameters such as abatement; remission; reduction of symptoms or making the injury, pathology, or condition more tolerable to the patient; slowing the rate of degeneration or decline; making the final stage of degeneration less debilitating; or improving the patient’s physical or mental health.

[0033] The terms "AR1001" and "myrodenafil" refer to the compound 5-ethyl-2-[5-[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl-2-propoxyphenyl]-7-propyl-3H-pyrrolo[3,2-d]pyrimidine-4-one, which has the following chemical formula: [ka] Myrodenafil is a member of the pyrrolopyrimidine class, being 3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidine-4-one, which has a 5-{[4-(2-hydroxyethyl)piperazine-1-yl]sulfonyl}2-propoxyphenyl group at position 2, an ethyl group at position 5, and a propyl group at position 7. It is a phosphodiesterase type 5 inhibitor used to treat erectile dysfunction. It acts as an EC3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor and a vasodilator. It is a sulfonamide, pyrrolopyrimidine, N-alkylpiperazine, primary alcohol, and aromatic ether. Myrodenafil has been used in studies to treat and support the treatment of renal disease, urinary tract disease, renal failure, erectile dysfunction, and male erectile dysfunction. Further information on mirodenafil can be found in U.S. Patent No. 9,750,743 and in Kang, BW, Kim, F., Cho, JY. et al. Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions. Alz Res Therapy 14, 92 (2022). https: / / doi.org / 10.1186 / s13195-022-01034-3. Mirodenafil is commercially available from vendors including Cooke Chemical Co., Ltd. (#M4050735), AstaTech, Inc. (#C16519), and RR Scientific (#R772058).

[0034] The term “antineurodegenerative agent” is used in its plain, ordinary sense and refers to a composition having neuroprotective properties or the ability to inhibit the degeneration of nerve cells. This term may include neuroprotective agents known to those skilled in the art. In embodiments, an antineurodegenerative agent is a drug identified herein as having utility in a method of treating neurodegeneration. In embodiments, an antineurodegenerative agent is a drug approved by the U.S. FDA or a similar regulatory agency in a country other than the United States for the treatment of neurodegeneration. This term includes, but is not limited to, the combinations described herein and includes other antineurodegenerative agents in the context of this disclosure.

[0035] The terms “neurodegenerative disease” or “neurodegeneration” refer primarily to conditions characterized by the loss of neurons (i.e., nerve cells). The most common neurodegenerative diseases include Alzheimer’s disease and Parkinson’s disease. While several medications are currently approved to manage neurodegenerative diseases, most of them only help alleviate associated symptoms. A list of over 500 neurological disorders is provided by the National Institute of Neurological Disorders and Stroke (NINDS) and is currently available at https: / / www.ninds.nih.gov / health-information / disorders. See also Wolfe, M. The Molecular and Cellular Basis of Neurodegenerative Diseases: Underlying Mechanisms. Academic Press, April 18, 2018; Lewis, P. The Molecular and Clinical Pathology of Neurodegenerative Disease. Academic Press, December 14, 2018. For the purposes of this disclosure, the term “neurodegenerative diseases” includes these disorders, as well as, specifically, the synucleinopathy and amyloidosis and amyloidosis-related conditions described herein.

[0036] As used herein, the term "α-synuclein" refers to a protein or polypeptide (αS or αS protein), and includes single monomeric proteins or monomeric polypeptides, as well as such αS proteins and αS polypeptides in the form of oligomers (e.g., dimers, trimers, or tetramers), or lipid-associated complexes, or lipid-free forms, or aggregates, any of which may be soluble or insoluble. The term also includes αS proteins found in complex with other molecules.

[0037] The term "synucleinopathy" is used herein to name a group of neurodegenerative diseases characterized by the presence of one or more of the soluble nonfibrillary variants, soluble oligomeric isoforms, insoluble nonfibrillary variants, complexes, and insoluble fibrillary aggregates of the αS protein at elevated levels, e.g., at steady-state levels, within the cellular compartments of selective populations of neurons and glial cells. Therefore, steady-state levels of αS are understood to encompass all soluble, insoluble, and intermediate (metastable) forms of the SNCA gene product. See UniProt P37840;Gene ID:6622;NCBI Reference Sequence:NG_011851.1. These disorders are grouped as “invariant” (or “primary”) synucleinopathy and include any of the following: Parkinson’s disease (PD), e.g., sporadic parkinson’s disease / parkinsonism and familial parkinson’s disease / parkinsonism; sporadic or hereditary Lewy body dementia (DLB) (also known as diffuse Lewy body disease); pure autonomic dysregulation with αS deposition (PAF); multiple system atrophy (MSA) (cerebellar, parkinsonian, or mixed type); hereditary neurodegenerative diseases with intracranial iron accumulation (also known as Hallervordern-Spatz disease or pantothenate kinase 2-related neurodegeneration); and incidental Lewy body disease in old age. Furthermore, "variable" (or "secondary") synucleinopathy has been identified in which dysregulation of α-synuclein metabolism is recognized as a secondary event (considering the abundance of this protein in the nervous system), and this nevertheless contributes significantly to the course, penetrance, age of onset, severity, and expression of the primary disease.Diseases associated with variable synucleinopathy include, but are not limited to, Lewy body variants of Alzheimer's disease; Down syndrome; progressive supranuclear palsy; essential tremor with Lewy bodies; familial parkinsonism with or without dementia, caused by mutated genes and loci whose mutations have not yet been identified; Creutzfeldt-Jakob disease and related prion diseases such as bovine spongiform encephalopathy (mad cow disease); secondary parkinson's disease / parkinsonism resulting from neurotoxin exposure / drug-induced parkinsonism with alpha-synuclein deposition; sporadic or hereditary spinocerebellar ataxia; amyotrophic lateral sclerosis (ALS); idiopathic REM sleep behavior disorder; and other conditions associated with central and / or peripheral alpha-synuclein accumulation in mammals associated with primary disease processes. See Schlossmacher MG α-synuclein and synucleinopathies. The Dementias 2 Blue Books of Practical Neurology; Editors: Growdon JH & Rossor M N. Butterworth Heinemann, Inc., Oxford. 2007; Chapter 8: pp 184-213. Clinically, all of these related disorders are characterized by a chronic and progressive decline in motor, cognitive, behavioral, and / or autonomic function, depending on the distribution of α-synuclein abnormalities.

[0038] The term "amyloidosis" and "amyloidoses" refers to a group of diseases characterized by the accumulation of amyloid proteins in the body. Amyloid proteins can be deposited in one part of the body (called focal amyloidosis) or in multiple parts (called systemic amyloidosis). Many forms of amyloidosis exist, and the disease can be classified into four groups: primary amyloidosis, secondary amyloidosis, hereditary amyloidosis, and amyloidosis associated with normal aging. Primary amyloidosis (light chain amyloidosis) is associated with abnormalities in plasma cells, and some people with primary amyloidosis also have multiple myeloma (plasma cell cancer). Typical sites of amyloid accumulation in primary amyloidosis are the heart, lungs, skin, tongue, thyroid gland, intestines, liver, kidneys, and blood vessels. Secondary amyloidosis can develop in response to various diseases that cause persistent infection or inflammation, such as tuberculosis, rheumatoid arthritis, and familial Mediterranean fever. Typical sites of amyloid accumulation in secondary amyloidosis are the spleen, liver, kidneys, adrenal glands, and lymph nodes. Hereditary amyloidosis is found in some families, particularly those of Portuguese, Swedish, and Japanese origin. Amyloid production defects result from mutations in specific proteins in the blood. Typical sites of amyloid accumulation in hereditary amyloidosis are the nerves, heart, blood vessels, and kidneys. Alzheimer's disease is a type of focal amyloidosis in which amyloid-beta protein accumulates in the brain. This is the most common type of amyloidosis in humans and the most common form of dementia. The "amyloid hypothesis" is a leading theory that Alzheimer's disease is caused by the accumulation of beta-amyloid protein in the brain. Several studies have shown that amyloid can trigger the binding of two proteins in brain neurons, which can lead to the rapid accumulation of tau protein. Tau protein is a major driver of neurodegeneration in Alzheimer's disease. Amyloidosis can be caused by chronic inflammation or genetic mutations.There are many different types of amyloid proteins involved in amyloidosis, and the deposition of each type of amyloid can characterize different diseases.

[0039] The term "amyloidosis-related conditions" refers to diseases associated with amyloid deposition, including Alzheimer's disease, mild cognitive impairment due to Alzheimer's disease, mild Alzheimer's dementia, prodromal Alzheimer's disease, early-onset Alzheimer's disease, mild Alzheimer's disease, moderate Alzheimer's disease, early Alzheimer's disease, preclinical Alzheimer's disease, idiopathic myeloma, amyloid polyneuropathy, amyloid cardiomyopathy, systemic senile amyloidosis, amyloid polyneuropathy, hereditary cerebral hemorrhage with amyloidosis, Down syndrome, and Sucre. Ipie's disease, medullary thyroid carcinoma, isolated atrial amyloid, β2-microglobulin amyloid in dialysis patients, inclusion body myositis, β2-amyloid deposition in muscular atrophy diseases, as well as islet diabetes, type 1 insulinoma, type 2 diabetes, hereditary hemorrhagic amyloidosis (Dutch type), amyloid A (reactive), secondary amyloidosis, familial Mediterranean fever, familial amyloid nephropathy with urticaria and hearing loss (Macklewells syndrome), amyloid λL chain or amyloid κL chain (idiopathic, myeloma or macroglobulinemia-related), Aβ2M ( Chronic hemodialysis), ATTR (familial amyloid polyneuropathy (Portuguese type, Japanese type, Swedish type)), familial amyloid cardiomyopathy (Danish type), isolated cardiac amyloid, systemic senile amyloidosis, AIAPP or amylin insulinoma, atrial natriuretic factor (isolated atrial amyloid), procalcitonin (medullary thyroid carcinoma), gelzolin (familial amyloidosis (Finnish type)), cystatin C (hereditary cerebral hemorrhage with amyloidosis (Icelandic type)), AApo-A-1 (familial amyloid polyneuropathy) This may include, but is not limited to, neuropathy (Iowa type), AApo-A-II (accelerated aging in mice), head injury (traumatic brain injury), dementia, fibrinogen-associated amyloidosis; and in cases of individuals homozygous for the apolipoprotein E4 allele, conditions associated with homozygosity for the apolipoprotein E4 allele, or Huntington's disease, as well as Asor or PrP-27 (scrapey, Creutzfeldt-Jakob disease, Gerstmann-Streussler-Scheinker syndrome, bovine spongiform encephalitis), or Huntington's disease.

[0040] The term "early-onset Alzheimer's disease" or "EOAD" refers to cases of Alzheimer's disease where symptoms appear before the age of 65. EOAD includes, but is not limited to, hereditary (familial) Alzheimer's disease, as well as its phenotypic variants, including logopenic primary progressive aphasia, posterior cortical atrophy, behavioral-executive disorder Alzheimer's disease, and acalculia.

[0041] As used herein, the term “pharmaceutically acceptable” means approved by a federal or state regulatory agency, or listed in the United States Pharmacopeia or any other generally accepted pharmacopoeia for use in animals, more specifically in humans.

[0042] As used herein, the term “pharmaceutically acceptable carrier” refers to a diluent, adjuvant, excipient, or vehicle administered with the compound. Such carriers may be sterile liquids such as water and oil (including petroleum, animal, plant, or synthetic sources such as peanut oil, soybean oil, mineral oil, and sesame oil), polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents. Water is a preferred carrier when the compound is administered intravenously. Saline solutions, as well as aqueous solutions of dextrose and glycerol, can also be used as liquid carriers, particularly for injectable solutions. Suitable excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, wheat flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, dried skim milk powder, glycerol, propylene glycol, water, and ethanol. If desired, the compound may be combined with a small amount of wetting agent or emulsifier, or a pH buffer such as acetate, citrate, or phosphate. Antimicrobial agents such as benzyl alcohol or methylparaben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; and isotonic agents such as sodium chloride or dextrose can also serve as carriers. Methods for producing compounds combined with carriers are known to those skilled in the art.

[0043] As used herein, the term “pharmaceutically acceptable salt” includes salts of pharmaceutically acceptable compounds formed with free amino groups, such as those derived from hydrochloric acid, phosphoric acid, acetic acid, oxalic acid, and tartaric acid, as well as those formed with free carboxyl groups, such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxide, isopropylamine, triethylamine, 2-ethylaminoethanol, histidine, and procaine. If the compound is basic, the salt can be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic acid, benzenesulfonic acid (besylic acid), benzoic acid, camphorsulfonic acid, citric acid, ethensulfonic acid, fumaric acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucoic acid, nitric acid, pamoic acid, pantothenic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, and p-toluenesulfonic acid. Particularly preferred are besylic acid, hydrobromic acid, hydrochloric acid, phosphoric acid, and sulfuric acid. When the compound is acidic, the salt can be prepared from pharmaceutically acceptable organic and inorganic bases. Suitable organic bases include, but are not limited to, lysine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methyl-glucamine), and procaine. Suitable inorganic bases include, but are not limited to, alkali metals and alkaline earth metals such as aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc. Methods for synthesizing such salts are known to those skilled in the art.

[0044] The term "effective dose" refers to the amount of therapy (e.g., the combination provided herein, or another active agent such as an antineurodegenerative agent described herein) that is sufficient to achieve the stated purpose, or otherwise sufficient to obtain the administered effect. An effective dose may be sufficient to ameliorate the progression, onset, recurrence, severity, and / or duration of a given disease, disorder, or condition and / or associated symptoms. An effective dose may also be a "therapeutic effective dose," which refers to an amount sufficient to provide therapeutic benefits such as, for example, amelioration of the progression or worsening of a given disease, disorder, or condition, or amelioration of the recurrence, onset, or onset of a given disease, disorder, or condition, and / or to improve or enhance the preventive or therapeutic effect (may be multiple) of another therapy. A therapeutic effective dose of a composition described herein may enhance the therapeutic efficacy of another therapeutic agent.

[0045] The term "therapeutic effective dose" refers to the amount of therapy that is sufficient to achieve the stated purpose, or otherwise sufficient to obtain the effect of the administered therapy. An effective dose may be sufficient to reduce and / or improve (ameliorate) the progression, onset, recurrence, severity, and / or duration of a given disease, disorder, or condition and / or associated symptoms. An effective dose may also be a "therapeutic effective dose," which refers to an amount sufficient to provide therapeutic benefits such as, for example, amelioration of the progression or worsening of a given disease, disorder, or condition, or amelioration of the recurrence, onset, or onset of a given disease, disorder, or condition, and / or to improve or enhance the preventive or therapeutic effect (may be multiple) of another therapy. A therapeutic effective dose of a composition described herein may enhance the therapeutic efficacy of another therapeutic agent.

[0046] The term "regimen" refers to a protocol relating to the dosing and timing of the administration of one or more therapies (e.g., combinations as described herein, optionally including another active agent such as an antineurodegenerative agent as described herein) for the treatment of a disease, disorder, or condition as described herein. A regimen may include active administration periods and rest periods, as is known in the art. Active administration periods include the administration of combinations and compositions as described herein, and the period during which the efficacy of such combinations and compositions is sustained. Rest periods in regimens as described herein include periods during which the compound is not actively administered, and in some specific examples, include periods during which the efficacy of such compound may be minimized. Combinations of active administration and rest periods in regimens as described herein can increase the efficacy and / or duration of administration of combinations and compositions as described herein.

[0047] The term "enhance" means that the function or activity of a protein or cell after administration of or contact with the combination described herein is increased or improved compared to the protein or cell before such administration or contact.

[0048] Combination therapy for the treatment of neurodegenerative diseases This disclosure relates to pharmaceutical compositions and methods for the prevention or treatment of neurodegenerative diseases. More specifically, this disclosure provides a combination therapy using (1) a phosphodiesterase 5 inhibitor (PDE-5 inhibitor) in combination with (2) either a glucagon-like peptide 1 (GLP-1) receptor agonist or a dipeptidyl peptidase IV (DPP-4) inhibitor, (3) a gastric suppressant peptide (GIP, also known as a glucose-dependent insulinotropic polypeptide) agonist, and (4) glucagon, in a molar ratio more fully described below.

[0049] Neurodegenerative diseases encompass a range of cognitive impairments characterized by impairments in memory, thinking, and social functioning. With the global population aging, the prevalence of neurodegenerative diseases continues to rise, posing significant challenges to healthcare systems and societies worldwide. Current treatments for neurodegenerative diseases primarily focus on managing symptoms and slowing disease progression, but success in addressing the underlying causes of cognitive decline remains limited.

[0050] The pharmaceutical compositions described herein may offer novel approaches to treating neurodegenerative diseases by combining agents that target multiple pathways involved in the disease process. Phosphodiesterase 5 inhibitors may modulate signaling pathways related to neuronal function and survival. GLP-1 receptor agonists and DPP-4 inhibitors may affect metabolic processes and neuroprotective mechanisms in the brain.

[0051] In some embodiments, combinations of phosphodiesterase-5 inhibitors and GLP-1 receptor agonists may produce synergistic effects in reducing intracellular amyloid-beta levels and inflammatory markers associated with dementia. This combination may also demonstrate improved efficacy in maintaining mitochondrial function in nerve cells compared to either drug alone.

[0052] In another aspect, a combination of a phosphodiesterase-5 inhibitor and a DPP-4 inhibitor may exhibit enhanced neuroprotective properties and anti-inflammatory effects. This combination may provide a multi-target approach to address the complex pathophysiology of neurodegenerative diseases.

[0053] The pharmaceutical compositions described herein may be formulated according to various routes of administration and may contain specific ratios of active ingredients to optimize therapeutic efficacy. Such combinations may be used to treat or prevent various forms of neurodegenerative diseases, including but not limited to Alzheimer's disease, vascular dementia, and Lewy body dementia.

[0054] By simultaneously targeting multiple aspects of the pathology of neurodegenerative diseases, these combination therapies may offer potential benefits in efficacy and disease modification compared to existing monotherapy. The disclosed compositions and methods may provide novel options to address the growing global burden of neurodegenerative diseases and improve outcomes for affected individuals.

[0055] Gastric suppressor peptide (GIP) and glucagon-like peptide-1 (GLP-1) are two important incretin hormones that play crucial roles in glucose homeostasis and metabolism. GIP (gastric suppressor peptide) is a 42-amino acid peptide hormone secreted by K cells in the small intestine in response to nutrient intake. Its main functions include stimulating insulin secretion from pancreatic β cells in a glucose-dependent manner, promoting β cell proliferation and inhibiting apoptosis, enhancing the postprandial glucagon response, promoting fat deposition in adipose tissue, and promoting bone formation.

[0056] GLP-1 (glucagon-like peptide-1) is a 30- or 31-amino acid peptide hormone produced by L cells in the distal ileum and colon. Its main functions include stimulating insulin secretion from pancreatic β cells (glucose-dependent), inhibiting glucagon secretion from pancreatic α cells, delaying gastric emptying and reducing appetite, promoting β cell proliferation and inhibiting apoptosis, and inhibiting bone resorption.

[0057] Glucagon is a hormone produced by pancreatic alpha cells and plays a crucial role in maintaining blood glucose levels. Its main functions include stimulating glycogenolysis (conversion of stored glycogen to glucose), promoting gluconeogenesis (production of glucose from non-carbohydrate sources), reducing glucose consumption by the liver, and stimulating the breakdown of fat storage in adipose tissue.

[0058] The interaction between GIP, GLP-1, and glucagon GIP and GLP-1 work together to enhance insulin secretion and improve glucose control, while glucagon acts as an antagonistic hormone to prevent hypoglycemia. Both GIP and GLP-1 promote β-cell proliferation and survival, increasing pancreatic β-cell volume. However, GIP enhances the postprandial glucagon response, while GLP-1 suppresses it. GLP-1 has a more pronounced effect on reducing appetite and food intake compared to GIP. Due to their complementary effects, dual GIP / GLP-1 receptor agonists are being developed as a potential treatment for type 2 diabetes and obesity. These combination therapies have shown promising results in clinical trials, providing greater weight loss and better glycemic control than GLP-1 receptor agonists alone.

[0059] In conclusion, GIP, GLP-1, and glucagon form a complex regulatory system for glucose homeostasis and metabolism. Understanding their interactions and developing therapies that simultaneously target multiple hormones could lead to more effective treatments for various disorders. Quite unexpectedly, these disorders include neurodegenerative diseases, which is a feature of this invention. Surprisingly, the combination of PDE-5 inhibitors or DPP-4 inhibitors within the complex of GIP, GLP-1, and glucagon modulators enhances the therapeutic effect of any one of the individual modulators in the regulatory system, however, it is not bound by any particular theory.

[0060] PDE-5 inhibitors Phosphodiesterase-5 inhibitors may be selected from the group consisting of mirodenafil, sildenafil, vardenafil, tadalafil, udenafil, dasantafil, avanafil, and their pharmaceutically acceptable salts, solvates, and hydrates.

[0061] DPP-4 inhibitors DPP-4 inhibitors may be selected from the group consisting of sitagliptin, vildagliptin, saxagliptin, linagliptin, gemigliptin, teneligliptin, alogliptin, evogliptin, and anagliptin.

[0062] GLP-1 receptor agonist GLP-1 receptor agonists may be selected from the group consisting of semaglutide, exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, tilzepatide, cotadutide, and taspoglutide.

[0063] GIP Agonist The GIP agonist may be tilzepatide (which has dual activity as a GLP-1 receptor agonist), CT-288 (Roche), or other research-use-only compounds known to those skilled in the art.

[0064] Glucagon As mentioned above, glucagon is a peptide hormone produced by alpha cells in the pancreas and plays an extremely important role in regulating blood glucose levels.

[0065] Dual agonist and triple agonist Those skilled in the art will recognize that some compounds can act on multiple pathways. For example, tilzepatide is a dual agonist associated with the GLP-1 receptor and GIP. In another example, letatoltide and SAR441255 are triple agonists associated with the GLP-1 receptor, GIP, and glucagon.

[0066] Mole ratio In some embodiments, the pharmaceutical composition may contain a PDE-5 inhibitor, a GLP-1 receptor agonist or a DPP-4 inhibitor, a GIP agonist, and glucagon in specific molar ratios. The molar ratios of (1) PDE-5 inhibitor, (2) GLP-1 agonist or DPP-4 inhibitor, (3) GIP agonist, and (4) glucagon in a pharmaceutical composition may include the following: (100,0,0,900), (100,0,100,800), (100,0,200,700), (100,0,300,600), (100,0,400,500), (100,0,500,400), (100,0,600,300), (100,0,700,200), (100,0,800,100), (100,0, 900,0), (100,100,0,800), (100,100,100,700), (100,100,200,600), (100,100,300,500), (100,100,400,400), (100,100,500,300), (100,100,600,200), (100,100,700,100), (100,100,800,0), (100,200,0,700), (100,200,100,600), (100,200,200,500), (100,200,300, 400), (100,200,400,300), (100,200,500,200), (100,200,600,100), (100,200,700,0), (100,300,0,600), (100,300,100,500), (100,300,200,400), (100,300,300,300), (100,300,400,200), (100,300,500,100), (100,300,600,0), (100,400,0,500), (100,400,100,400) 、(100,400,200,300),(100,400,300,200),(100,400,400,100),(100,400,500,0),(100,500,0,400),(100,500,100,300),(100,500,200,200),(100,500,300,100),(100,500,400,0),(100,600,0,300),(100,600,100,200),(100,600,200,100),(100,600,300,0),(100,700,0,200)、(100,700,100,100)、(100,700,200,0)、(100,800,0,100)、(100,800,100,0)、(100,900,0,0)、(200,0,0,800)、(200,0,100,700)、(200,0,200,600)、(200,0,300,500)、(200,0,400,400)、(200,0,500,300)、(200,0,600,200)、(200,0,700,100)、(200,0,800,0)、(200,100,0,700)、(200,100,100,600)、(200,100,200,500)、(200,100,300,400)、(200,100,400,300)、(200,100,500,200)、(200,100,600,100)、(200,100,700,0)、(200,200,0,600)、(200,200,100,500)、(200,200,200,400)、(200,200,300,300)、(200,200,400,200)、(200,200,500,100)、(200,200,600,0)、(200,300,0,500)、(200,300,100,400)、(200,300,200,300)、(200,300,300,200)、(200,300,400,100)、(200,300,500,0)、(200,400,0,400)、(200,400,100,300)、(200,400,200,200)、(200,400,300,100)、(200,400,400,0)、(200,500,0,300)、(200,500,100,200)、(200,500,200,100)、(200,500,300,0)、(200,600,0,200)、(200,600,100,100)、(200,600,200,0)、(200,700,0,100)、(200,700,100,0)、(200,800,0,0)、(300,0,0,700)、(300,0,100,600)、(300,0,200,500)、(300,0,300,400)、(300,0,400,300)、(300,0,500,200)、(300,0,600,100)、(300,0,700,0)、(300,100,0,600)、(300,100,100,500)、(300,100,200,400)、(300,100,300,300)、(300,100,400,200)、(300,100,500,100)、(300,100,600,0)、(300,200,0,500)、(300,200,100,400)、(300,200,200,300)、(300,200,300,200)、(300,200,400,100)、(300,200,500,0)、(300,300,0,400)、(300,300,100,300)、(300,300,200,200)、(300,300,300,100)、(300,300,400,0)、(300,400,0,300)、(300,400,100,200)、(300,400,200,100)、(300,400,300,0)、(300,500,0,200)、(300,500,100,100)、(300,500,200,0)、(300,600,0,100)、(300,600,100,0)、(300,700,0,0)、(400,0,0,600)、(400,0,100,500)、(400,0,200,400)、(400,0,300,300)、(400,0,400,200)、(400,0,500,100)、(400,0,600,0)、(400,100,0,500)、(400,100,100,400)、(400,100,200,300)、(400,100,300,200)、(400,100,400,100)、(400,100,500,0)、(400,200,0,400)、(400,200,100,300)、(400,200,200,200)、(400,200,300,100)、(400,200,400,0)、(400,300,0,300)、(400,300,100,200)、(400,300,200,100)、(400,300,300,0)、(400,400,0,200)、(400,400,100,100)、(400,400,200,0)、(400,500,0,100)、(400,500,100,0)、(400,600,0,0)、(500,0,0,500)、(500,0,100,400)、(500,0,200,300)、(500,0,300,200)、(500,0,400,100)、(500,0,500,0), (500,100,0,400), (500,100,100,300), (500,100,200,200), (500,100,300,100), (500,100,400,0), (500,200,0,300), (500,200,100,200), (500,200,200,100), (500,200,300,0), (500,300,0,200), (500,300,100,100), (500 ,300,200,0), (500,400,0,100), (500,400,100,0), (500,500,0,0), (600,0,0,400), (600,0,100,300), (600,0,200,200), (600,0,300,100), (600,0,400,0), (600,100,0,300), (600,100,100,200), (600,100,200,100), (600,100,3 00,0), (600,200,0,200), (600,200,100,100), (600,200,200,0), (600,300,0,100), (600,300,100,0), (600,400,0,0), (700,0,0,300), (700,0,100,200), (700,0,200,100), (700,0,300,0), (700,100,0,200), (700,100,100,100), (700,100,200,0), (700,200,0,100), (700,200,100,0), (700,300,0,0), (800,0,0,200), (800,0,100,100), (800,0,200,0), (800,100,0,100), (800,100,100,0), (800,200,0,0), (900,0,0,100), (900,0,100,0), or (900,100,0,0). Each of the above example ratios is provided such that the sum of all four numbers in each ratio is 1000, but cases where the sum of all four numbers is less than 1000 are also possible. For example, (1,1,1,0), (5,1,0,0), etc.

[0067] Each of the numbers above is within the range of integers from 1 to 99, specifically 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 4 This includes 8, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99. Therefore, numbers such as "100" and "200" can be replaced with any integer from 1 to 99 in the above ratio.

[0068] In addition, any two of the above components in the above ratios are 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, 1:20, 1:21, 1:22, 1:23, 1: 24, 1:25, 1:26, 1:27, 1:28, 1:29, 1:30, 1:31, 1:32, 1:33, 1:34, 1:35, 1:36, 1:37, 1:38, 1:39, 1:40, 1:41, 1:42, 1:43, 1:44, 1:45, 1:46, 1:47, 1:48, 1:49, 1:50, 1: 51, 1:52, 1:53, 1:54, 1:55, 1:56, 1:57, 1:58, 1:59, 1:60, 1:61, 1:62, 1:63, 1:64, 1:65, 1:66, 1:67, 1:68, 1:69, 1:70, 1:71, 1:72, 1:73, 1:74, 1:75, 1:76, 1:77, 1 The individual ratios may be 1:78, 1:79, 1:80, 1:81, 1:82, 1:83, 1:84, 1:85, 1:86, 1:87, 1:88, 1:89, 1:90, 1:91, 1:92, 1:93, 1:94, 1:95, 1:96, 1:97, 1:98, 1:99, or 1:100, and values ​​in between. Furthermore, any two of the above components in the above ratios may have individual ratios of 1:100, 1:200, 1:300, 1:400, 1:500, 1:600, 1:700, 1:800, 1:900, or 1:1000, and values ​​in between. These specific molar ratios can provide different balances between the two active ingredients and may potentially optimize the therapeutic efficacy of the composition depending on the patient or condition.

[0069] The compounds of (1) PDE-5 inhibitors, (2) GLP-1 agonists or DPP-4 inhibitors, (3) GIP agonists, and (4) glucagon in molar ratios described herein include pharmaceutically acceptable salts, pharmaceutically acceptable stereoisomers, prodrugs, enantiomers, diastereomers, hydrates, cocrystals, and polymorphs thereof.

[0070] In some specific cases, the combinations include (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon, present in amounts greater than approximately 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 80 mg, 85 mg, 90 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 250 mg, or 300 mg. The combination may include (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon, present in amounts greater than approximately 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, or 300 mg.

[0071] The combination may include (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon, present in amounts greater than approximately 1 mg to 10 mg, approximately 1 mg to 25 mg, approximately 1 mg to 50 mg, approximately 5 mg to 100 mg, approximately 100 mg to 200 mg, or approximately 200 mg to 300 mg.

[0072] The combination may contain at least approximately 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 80 mg, 85 mg, 90 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 250 mg, or 300 mg of (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon. The combination may include at least approximately 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, or 300 mg of (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon. The combination may include at least approximately 1 mg to 10 mg, 1 mg to 25 mg, 1 mg to 50 mg, 5 mg to 10 mg, 5 mg to 25 mg, 5 mg to 50 mg, 10 mg to 25 mg, 10 mg to 50 mg, 50 mg to 100 mg, 100 mg to 200 mg, or 200 mg to 300 mg of (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon.

[0073] The combination may include (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon, present in amounts of approximately 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 80 mg, 85 mg, 90 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 250 mg, or 300 mg. The combination may include (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon, present in amounts of approximately 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, or 300 mg. The combination may include (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon, present in amounts of approximately 1 mg to 10 mg, approximately 1 mg to 25 mg, approximately 1 mg to 50 mg, approximately 5 mg to 10 mg, approximately 5 mg to 25 mg, approximately 10 mg to 50 mg, approximately 50 mg to 100 mg, approximately 100 mg to 200 mg, or approximately 200 mg to 300 mg.

[0074] PDE-5 inhibitors, GLP-1 agonists or DPP-4 inhibitors, GIP agonists or glucagon may be present in the combinations described herein in amounts relative to the patient's body weight (e.g., mg / kg). In some cases, (1) PDE-5 inhibitors, (2) GLP-1 agonists or DPP-4 inhibitors, (3) GIP agonists, or (4) glucagon are present in amounts corresponding to: approximately 0.0001 mg / kg to approximately 200 mg / kg, approximately 0.001 mg / kg to approximately 200 mg / kg, approximately 0.01 mg / kg to approximately 200 mg / kg, approximately 0.01 mg / kg to approximately 150 mg / kg, approximately 0.01 mg / kg to approximately 100 mg / kg, approximately 0.01 mg / kg to approximately 50 mg / kg, approximately 0.01 mg / kg to approximately 25 mg / kg, approximately 0.01 mg / kg to approximately 10 mg / kg, or approximately 0.01 mg / kg to approximately 5 mg / kg, approximately 0. 0.5 mg / kg to approximately 200 mg / kg, approximately 0.05 mg / kg to approximately 150 mg / kg, approximately 0.05 mg / kg to approximately 100 mg / kg, approximately 0.05 mg / kg to approximately 50 mg / kg, approximately 0.05 mg / kg to approximately 25 mg / kg, approximately 0.05 mg / kg to approximately 10 mg / kg, or approximately 0.05 mg / kg to approximately 5 mg / kg, approximately 0.5 mg / kg to approximately 200 mg / kg, approximately 0.5 mg / kg to approximately 150 mg / kg, approximately 0.5 mg / kg to approximately 100 mg / kg, approximately 0.5 mg / kg to approximately 50 mg / kg, approximately 0.5 mg / kg to approximately 25 mg / kg, approximately 0.5 mg / kg to approximately 10 mg / kg, or approximately 0.5 mg / kg to approximately 5 mg / kg. In other examples, (1) PDE-5 inhibitors, (2) GLP-1 agonists or DPP-4 inhibitors, (3) GIP agonists, or (4) glucagon are present in amounts corresponding to: approximately 1 mg / kg to approximately 200 mg / kg, approximately 1 mg / kg to approximately 150 mg / kg, approximately 1 mg / kg to approximately 100 mg / kg, approximately 1 mg / kg to approximately 50 mg / kg, approximately 1 mg / kg to approximately 25 mg / kg, approximately 1 mg / kg to approximately 10 mg / kg, or approximately 1 mg / kg to approximately 5 mg / kg.

[0075] In some specific cases, the therapeutically effective dose of a combination as specified herein is determined as the amount presented in the accompanying information sheet provided with that combination. The term "accompanying information sheet" refers to the instructions customarily included in the commercial packaging of a medicinal product approved by the FDA or a similar regulatory body in a country other than the United States, which may contain, for example, information about the use, dosage, administration, contraindications, and / or warnings relating to the use of such medicinal product.

[0076] At least one of the molar ratios of (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon described herein may be provided in an amount that is synergistic with another member of the group. The term synergistic means a combination described herein (e.g., (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon—optionally including co-administration with another activator such as an antineurodegenerative agent described herein) or a combination of regimens as described herein that is more effective than the additive effect of each individual therapy or regimen.

[0077] The synergistic effects of the combinations described herein may enable the use of one or more lower doses of the combination components (e.g., (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon in the molar ratios described herein). The synergistic effects may enable lower-frequency administration of at least one administered therapy (e.g., (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon in the molar ratios described herein) to subjects having the diseases, disorders, or conditions described herein. Such lower doses and reduced administration frequencies may reduce the toxicity associated with the administration of at least one therapy to a subject (e.g., (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon in the molar ratios described herein) without reducing the therapeutic efficacy. The synergistic effects described herein avoid or reduce adverse or undesirable side effects associated with the use of any of the therapies.

[0078] Pharmaceutical composition The combinations described herein can be provided as pharmaceutical compositions suitable for administration to patients as described herein via any route, including, but not limited to, the following: oral, mucosal (e.g., intranasal, inhalation, lung, sublingual, vaginal, buccal, or rectal), parenteral (e.g., subcutaneous, intravenous, bolus injection, intramuscular, or intra-arterial), topical (e.g., eye drops or other ophthalmic preparations), transdermal, or transcutaneous administration to the patient.

[0079] Examples of dosage forms include: tablets; caplets; capsules (e.g., gelatin capsules); cachets; lozenges; suppositories; powders; gels; liquid dosage forms suitable for parenteral administration to patients; and sterile solids (e.g., crystalline or amorphous solids) that can be reconfigured to provide liquid dosage forms suitable for parenteral administration to patients.

[0080] The pharmaceutical compositions and dosage forms described herein typically contain one or more excipients. Suitable excipients are well known to those skilled in the art of pharmaceuticals. Whether a particular excipient is suitable for incorporation into a pharmaceutical composition or dosage form depends on various factors, such as the intended route of administration to the patient. The pharmaceutical compositions described herein may contain other agents such as stabilizers, lubricants, buffers, and disintegrants that can reduce the rate at which the active ingredient may degrade in a particular formulation.

[0081] In some specific examples, the pharmaceutical compositions described herein may contain additional activators (e.g., antineurodegenerative agents such as those described herein) in amounts provided herein, other than those in the combinations described herein.

[0082] In one embodiment, one of (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon is provided in an oral dosage form such as a tablet or capsule. In another embodiment, one of (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon is provided as a powder (e.g., lyophilized powder) that can be resuspended in a liquid suitable for parenteral administration.

[0083] The combinations described herein may be provided in a form that is convenient for or facilitates administration to a patient. For example, the combinations may be formulated as tablets, capsules, or as a powder (e.g., lyophilized powder) that can be resuspended in a liquid suitable for parenteral administration.

[0084] The combinations described herein may be provided as controlled-release pharmaceutical products, the purpose of which is to improve pharmacotherapy beyond what can be achieved by uncontrolled-release pharmaceutical products. Controlled-release formulations can prolong the activity of a drug, reduce the frequency of administration, and improve patient adherence. In addition, controlled-release formulations can be used to influence other properties such as the time of action or the blood level of the drug, and thus may influence the occurrence of side effects (e.g., adverse effects).

[0085] method The combinations, pharmaceutical compositions, and kits described herein are useful for treating diseases and disorders, or for alleviating, improving, or eliminating the symptoms of diseases and disorders, such as neurodegenerative diseases. It should be understood that the methods described herein relate to the administration of the combinations and pharmaceutical compositions described herein, and that such combinations and pharmaceutical compositions may be provided in the form of the kits described herein. Provided herein is a method for treating neurodegeneration by administering a therapeutically effective dose of the combination described herein to a patient in need. Also provided herein is a method for managing neurodegeneration by administering a therapeutically effective dose of the combination described herein to a patient in need.

[0086] In one embodiment, a method for treating neurodegeneration provides a method for reducing the amyloid, or Aβ, load in an individual by administering a therapeutically effective dose of the combination described herein. In some embodiments, neurodegeneration is reduced by at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%.

[0087] The methods for treating neurodegeneration described herein also provide methods for increasing or otherwise prolonging the time to progression of neurodegenerative disease. The time to disease progression may be prolonged in a patient by administering a therapeutically effective dose of the combination described herein. In some embodiments, this increase is a comparison of the time to disease progression with treatment using the combination described herein and without treatment. In some embodiments, the methods described herein prolong the time to disease progression by at least one week, two weeks, three weeks, four weeks, one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, one year, two years, three years, four years, five years, ten years, fifteen years, twenty years, twenty-five years, or longer (including values ​​in between).

[0088] The methods for treating neurodegenerative diseases described herein also provide methods for increasing or otherwise extending the survival of patients diagnosed with the neurodegenerative diseases described herein. The patient's survival may be extended by administering a therapeutically effective dose of the combination described herein. In some embodiments, this increase is a comparison between survival without treatment and survival with treatment using the combination described herein. In some embodiments, the methods described herein extend survival by at least one week, two weeks, three weeks, four weeks, one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, one year, two years, three years, four years, five years, ten years, fifteen years, twenty years, twenty-five years, or longer (including values ​​in between).

[0089] The methods for treating neurodegenerative diseases described herein also provide methods for increasing progression-free survival in patients diagnosed with the neurodegenerative diseases described herein. Progression-free survival in patients may be extended by administering a therapeutically effective dose of the combination described herein. In some embodiments, this increase is a comparison between progression-free survival without treatment and progression-free survival with treatment using the combination described herein. In some embodiments, the methods described herein increase progression-free survival by at least 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, 10 years, 15 years, 20 years, 25 years, or longer (including values ​​in between).

[0090] Target neurodegenerative diseases Synucleinopathy is a group of neurodegenerative diseases characterized by the abnormal accumulation and aggregation of α-synuclein protein in various parts of the nervous system. While these diseases may share common pathological mechanisms in some cases, they often present distinct clinical features. Below is an overview of some known synucleinopathy:

[0091] Parkinson's disease (PD): PD can be characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of Lewy bodies containing aggregated α-synuclein. In some cases, patients may experience motor symptoms such as tremor, rigidity, bradykinesia, and postural instability. Non-motor symptoms may include cognitive impairment, depression, sleep disturbances, and autonomic dysfunction.

[0092] Parkinson's disease dementia (PDD): PDD can develop in some patients with long-term Parkinson's disease. It may be characterized by a decline in cognitive function, including impairments of attention, executive function, and visuospatial ability. In some cases, PDD may be associated with a more widespread distribution of Lewy bodies in the cortical and limbic regions.

[0093] Lewy body dementia (DLB): DLB can share characteristics with both Parkinson's disease (PD) and Alzheimer's disease. It can be characterized by fluctuations in cognitive function, hallucinations, and parkinsonism. In some cases, patients may experience rapid eye movement (REM) sleep behavior disorder. The distribution of Lewy bodies in DLB can be more widespread than in PD, often affecting cortical areas.

[0094] Multiple system atrophy (MSA): MSA can be characterized by a combination of parkinsonism, cerebellar symptoms, and autonomic symptoms. In some cases, it can be divided into two subtypes: MSA-P (parkinsonism-dominant) and MSA-C (cerebellar ataxia-dominant). Alpha-synuclein aggregates in MSA primarily affect oligodendrocytes and can form glial cytoplasmic inclusions.

[0095] Pure autonomic dysregulation (PAF): PAF can be characterized by progressive autonomic dysfunction without significant central nervous system involvement. In some cases, patients may experience orthostatic hypotension, gastrointestinal disorders, and genitourinary dysfunction. Alpha-synuclein aggregates may be found in peripheral autonomic neurons.

[0096] Lewy body variant (LBV) of Alzheimer's disease: LBV can represent a condition in which a patient exhibits pathological features of both Alzheimer's disease and DLB. In some cases, the patient may show cognitive decline typical of Alzheimer's disease, along with some features of DLB, such as hallucinations or fluctuations in cognitive function.

[0097] In some aspects, these synucleinopathys may share common pathological mechanisms associated with α-synuclein aggregation and neuronal dysfunction. However, the specific distribution of α-synuclein pathology and the cell types affected may differ among these disorders, contributing to their distinct clinical presentations.

[0098] The development of therapeutic strategies targeting α-synuclein aggregation, such as the lamotrigine and rivastigmine combination described in this disclosure, may be applicable to a variety of synucleinopathyes. In some cases, such approaches can address the underlying pathological processes common to these disorders, potentially opening new avenues for the prevention, mitigation, or treatment of these debilitating neurodegenerative conditions.

[0099] Alzheimer's disease (AD) is a progressive neurodegenerative disease that may be characterized by cognitive decline, memory loss, and behavioral changes. In some cases, AD can be the most common cause of dementia in older adults. The disease may be associated with the accumulation of Aβ plaques and neurofibrillary tangles, which are composed of hyperphosphorylated tau protein, in the brain.

[0100] In some embodiments, the pathological features of AD may include:

[0101] 1. Aβ plaques: These extracellular deposits may consist of aggregated β-amyloid peptides, which may originate from amyloid precursor protein (APP).

[0102] 2. Neurofibrillary tangles: These intracellular aggregates may be composed of hyperphosphorylated tau protein, which can disrupt normal neuronal function.

[0103] 3. Neuronal loss: Progressive degeneration of neurons may occur, particularly in areas such as the hippocampus and cortex.

[0104] 4. Synaptic dysfunction: Impairment of synaptic transmission and plasticity may contribute to cognitive decline.

[0105] In some cases, Alzheimer's disease (AD) can progress through several stages, from mild cognitive impairment to severe dementia. The disorder can affect various cognitive domains, including memory, language, executive function, and visuospatial abilities.

[0106] Other neurodegenerative diseases associated with AD may include:

[0107] Vascular dementia: This form of dementia can often be caused by reduced blood flow to the brain, resulting from a stroke or other vascular problems.

[0108] Frontotemporal dementia (FTD): FTD can be characterized by changes in behavior, personality, and language abilities, and often has an earlier onset than Alzheimer's disease (AD).

[0109] Lewy body dementia (LBD): This condition can share characteristics with both Alzheimer's disease (AD) and Parkinson's disease and may be characterized by cognitive fluctuations, hallucinations, and parkinsonism.

[0110] Mixed dementia: In some cases, an individual may exhibit pathological features of multiple types of dementia, such as Alzheimer's disease (AD) and vascular dementia.

[0111] Posterior cortical atrophy (PCA): This rare form of dementia may primarily affect visual processing and spatial awareness.

[0112] Primary progressive aphasia (PPA): PPA can be characterized by a progressive language impairment, which may be a variant of FTD or AD.

[0113] Corticobasal degeneration (CBD): This rare neurological disorder can affect motor and cognitive functions, often presenting with asymmetrical motor symptoms and cognitive impairments.

[0114] Progressive supranuclear palsy (PSP): PSP can be characterized by problems with balance, eye movement, and cognitive function.

[0115] Amyloidosis is also a target neurodegenerative disease of this disclosure. In some aspects, these neurodegenerative diseases may share common pathological mechanisms, such as protein aggregation, mitochondrial dysfunction, and neuroinflammation, including mechanisms involved in synucleinopathy. However, the specific proteins involved, the brain regions affected, and the clinical presentation may differ among these disorders.

[0116] The development of therapeutic strategies targeting multiple pathological processes, such as combinations of (1) PDE-5 inhibitors, (2) GLP-1 agonists or DPP-4 inhibitors, (3) GIP agonists, or (4) glucagon in molar ratios as described in this disclosure, may be applicable to a variety of neurodegenerative diseases. In some cases, such approaches can address the underlying pathological processes common to these disorders and may open new avenues for the prevention, mitigation, or treatment of these debilitating conditions.

[0117] The combinations described herein may involve the administration of each therapy (for example, (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon in the molar ratios described herein, optionally including another antineurodegenerative agent), which may be administered simultaneously or sequentially (in either order). In one embodiment, the molar ratios of (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, and (4) glucagon provided herein are administered simultaneously (for example, within at least 1 to 5 minutes of each other). In another embodiment, the molar ratios provided herein of (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, and (4) glucagon are administered sequentially (for example, within at least 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 5 hours, 10 hours, 12 hours, 1 day, 2 days, 5 days, 7 days, 14 days, or 21 days) from each other.

[0118] The combinations of the disclosure may be administered continuously, for example, once daily (QD), twice daily (BID), once weekly (QW), twice weekly (BIW), three times weekly (TIW), or once monthly (QM), or intermittently, for example, by administering BIW for three months and then resuming after one month. For example, the combinations of the disclosure may be administered on BID. The combinations of the disclosure may be administered on TIW. In some specific cases, the combinations of the disclosure may be administered two to three times per week. In another embodiment, the combinations of the disclosure are administered on QD. The combinations of the disclosure may be administered on QD for about 1 to 7 days, about 1 to 14 days, about 1 to 21 days, about 1 to 28 days, or daily until disease progression changes or unacceptable toxicity occurs. Administration of the combinations of the disclosure may depend in part on the patient's tolerance, and greater tolerance may allow for more or more frequent administration. Alternatively, if a patient exhibits poor tolerance to (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon, the amount of each individual compound may be reduced, or the frequency of administration of such combination may be reduced. The combinations disclosed herein may be administered in any regimen described herein.

[0119] For example, the combinations disclosed herein can be administered in QDs in amounts of approximately 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 80 mg, 85 mg, 90 mg, 100 mg, 125 mg, 150 mg, 175 mg, or 200 mg. For example, the combinations disclosed herein can be administered in BIW in amounts of approximately 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 80 mg, 85 mg, 90 mg, 100 mg, 125 mg, 150 mg, 175 mg, or 200 mg. For example, the combinations disclosed herein can be administered in TIW in amounts of approximately 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 80 mg, 85 mg, 90 mg, 100 mg, 125 mg, 150 mg, 175 mg, or 200 mg. For example, the combinations disclosed herein can be administered in QW amounts of approximately 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 80 mg, 85 mg, 90 mg, 100 mg, 125 mg, 150 mg, 175 mg, or 200 mg. For example, the combinations of the disclosure may be administered in amounts of approximately 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 80 mg, 85 mg, 90 mg, 100 mg, 125 mg, 150 mg, 175 mg, or 200 mg in Q2W. For example, the combinations of the disclosure may be administered in amounts of approximately 5 mg or 10 mg in QD. For example, the combinations of the disclosure may be administered in amounts of approximately 5 mg or 10 mg in BIW. For example, the combinations of the disclosure may be administered in amounts of approximately 5 mg or 10 mg in TIW.For example, the combinations disclosed herein may be administered in amounts of approximately 5 mg or approximately 10 mg at QW. For example, the combinations disclosed herein may be administered in amounts of approximately 5 mg or approximately 10 mg at Q2W. Administration of the combinations disclosed herein may be continuous. Administration of the combinations disclosed herein may be intermittent.

[0120] For example, the combinations of the disclosure can be administered in QD in amounts of approximately 1 mg to 10 mg, approximately 1 mg to 25 mg, approximately 1 mg to 50 mg, approximately 5 mg to 10 mg, approximately 5 mg to 25 mg, approximately 5 mg to 50 mg, approximately 10 mg to 25 mg, approximately 10 mg to 50 mg, approximately 50 mg to 100 mg, or approximately 100 mg to 200 mg. For example, the combinations of the disclosure can be administered in BIW in amounts of approximately 1 mg to 10 mg, approximately 1 mg to 25 mg, approximately 1 mg to 50 mg, approximately 5 mg to 10 mg, approximately 5 mg to 25 mg, approximately 5 mg to 50 mg, approximately 10 mg to 25 mg, approximately 10 mg to 50 mg, approximately 50 mg to 100 mg, or approximately 100 mg to 200 mg. For example, the combinations of the disclosure can be administered in TIW (Time-Induced Wet) doses of approximately 1 mg to 10 mg, 1 mg to 25 mg, 1 mg to 50 mg, 5 mg to 10 mg, 5 mg to 25 mg, 5 mg to 50 mg, 10 mg to 25 mg, 10 mg to 50 mg, 50 mg to 100 mg, or 100 mg to 200 mg. For example, the combinations of the disclosure can be administered in QW (Quick Wet) doses of approximately 1 mg to 10 mg, 1 mg to 25 mg, 1 mg to 50 mg, 5 mg to 10 mg, 5 mg to 25 mg, 5 mg to 50 mg, 10 mg to 25 mg, 10 mg to 50 mg, 50 mg to 100 mg, or 100 mg to 200 mg. For example, the combinations of the disclosure may be administered in amounts of approximately 1 mg to 10 mg, approximately 1 mg to 25 mg, approximately 1 mg to 50 mg, approximately 5 mg to 10 mg, approximately 5 mg to 25 mg, approximately 5 mg to 50 mg, approximately 10 mg to 25 mg, approximately 10 mg to 50 mg, approximately 50 mg to 100 mg, or approximately 100 mg to 200 mg during Q2W. Administration of the combinations of the disclosure may be continuous. Administration of the combinations of the disclosure may be intermittent.

[0121] For example, the combinations in this disclosure are QDs of approximately 0.0001 mg / kg to approximately 200 mg / kg, approximately 0.001 mg / kg to approximately 200 mg / kg, approximately 0.01 mg / kg to approximately 200 mg / kg, approximately 0.01 mg / kg to approximately 150 mg / kg, approximately 0.01 mg / kg to approximately 100 mg / kg, approximately 0.01 mg / kg to approximately 50 mg / kg, approximately 0.01 mg / kg to approximately 25 mg / kg, approximately 0.01 mg / kg to approximately 10 mg / kg, or approximately 0.01 mg / kg to approximately 5 mg / kg, approximately 0.05 mg / kg to approximately 200 mg / kg, approximately 0.05 mg / kg to approximately 150 mg / kg. It can be administered in amounts of approximately 0.05 mg / kg to approximately 100 mg / kg, approximately 0.05 mg / kg to approximately 50 mg / kg, approximately 0.05 mg / kg to approximately 25 mg / kg, approximately 0.05 mg / kg to approximately 10 mg / kg, or approximately 0.05 mg / kg to approximately 5 mg / kg, approximately 0.5 mg / kg to approximately 200 mg / kg, approximately 0.5 mg / kg to approximately 150 mg / kg, approximately 0.5 mg / kg to approximately 100 mg / kg, approximately 0.5 mg / kg to approximately 50 mg / kg, approximately 0.5 mg / kg to approximately 25 mg / kg, approximately 0.5 mg / kg to approximately 10 mg / kg, or approximately 0.5 mg / kg to approximately 5 mg / kg. For example, the combinations disclosed herein can be administered in BIW in amounts of approximately 0.0001 mg / kg to approximately 200 mg / kg, 0.001 mg / kg to approximately 200 mg / kg, approximately 0.5 mg / kg to approximately 200 mg / kg, approximately 0.5 mg / kg to approximately 150 mg / kg, approximately 0.5 mg / kg to approximately 100 mg / kg, approximately 0.5 mg / kg to approximately 50 mg / kg, approximately 0.5 mg / kg to approximately 25 mg / kg, approximately 0.5 mg / kg to approximately 10 mg / kg, or approximately 0.5 mg / kg to approximately 5 mg / kg. For example, the combinations disclosed herein can be administered in TIW in amounts of approximately 0.0001 mg / kg to approximately 200 mg / kg, approximately 0.001 mg / kg to approximately 200 mg / kg, approximately 0.5 mg / kg to approximately 200 mg / kg, approximately 0.5 mg / kg to approximately 150 mg / kg, approximately 0.5 mg / kg to approximately 100 mg / kg, approximately 0.5 mg / kg to approximately 50 mg / kg, approximately 0.5 mg / kg to approximately 25 mg / kg, approximately 0.5 mg / kg to approximately 10 mg / kg, or approximately 0.5 mg / kg to approximately 5 mg / kg.For example, the combinations disclosed herein can be administered in QW in amounts of approximately 0.0001 mg / kg to approximately 200 mg / kg, approximately 0.001 mg / kg to approximately 200 mg / kg, approximately 0.5 mg / kg to approximately 200 mg / kg, approximately 0.5 mg / kg to approximately 150 mg / kg, approximately 0.5 mg / kg to approximately 100 mg / kg, approximately 0.5 mg / kg to approximately 50 mg / kg, approximately 0.5 mg / kg to approximately 25 mg / kg, approximately 0.5 mg / kg to approximately 10 mg / kg, or approximately 0.5 mg / kg to approximately 5 mg / kg. For example, the combinations disclosed herein may be administered at Q2W in amounts of approximately 0.0001 mg / kg to approximately 200 mg / kg, approximately 0.001 mg / kg to approximately 200 mg / kg, approximately 0.5 mg / kg to approximately 200 mg / kg, approximately 0.5 mg / kg to approximately 150 mg / kg, approximately 0.5 mg / kg to approximately 100 mg / kg, approximately 0.5 mg / kg to approximately 50 mg / kg, approximately 0.5 mg / kg to approximately 25 mg / kg, approximately 0.5 mg / kg to approximately 10 mg / kg, or approximately 0.5 mg / kg to approximately 5 mg / kg. In one example, the combinations disclosed herein may be administered at QD in amounts of approximately 15 mg / kg to approximately 75 mg / kg. In another example, the combinations disclosed herein may be administered at amounts of approximately 20 mg / kg to approximately 50 mg / kg. In yet another example, the combinations of the disclosure may be administered in amounts of approximately 0.001 mg / kg, 0.01 mg / kg, 0.05 mg / kg, 0.1 mg / kg, 0.5 mg / kg, 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 10 mg / kg, 15 mg / kg, 20 mg / kg, 25 mg / kg, 30 mg / kg, 40 mg / kg, 50 mg / kg, 60 mg / kg, 70 mg / kg, 80 mg / kg, 90 mg / kg, 100 mg / kg, 125 mg / kg, 150 mg / kg, 175 mg / kg, or 200 mg / kg. Administration of the combinations of the disclosure may be continuous. Administration of the combinations of the disclosure may be intermittent.

[0122] For example, the combinations disclosed herein can be administered in QD in amounts of approximately 1 mg / kg to approximately 200 mg / kg, approximately 1 mg / kg to approximately 150 mg / kg, approximately 1 mg / kg to approximately 100 mg / kg, approximately 1 mg / kg to approximately 50 mg / kg, approximately 1 mg / kg to approximately 25 mg / kg, approximately 1 mg / kg to approximately 10 mg / kg, or approximately 1 mg / kg to approximately 5 mg / kg. For example, the combinations disclosed herein can be administered in BIW in amounts of approximately 1 mg / kg to approximately 200 mg / kg, approximately 1 mg / kg to approximately 150 mg / kg, approximately 1 mg / kg to approximately 100 mg / kg, approximately 1 mg / kg to approximately 50 mg / kg, approximately 1 mg / kg to approximately 25 mg / kg, approximately 1 mg / kg to approximately 10 mg / kg, or approximately 1 mg / kg to approximately 5 mg / kg. For example, the combinations disclosed herein can be administered in TIW (Time-Induced Wet) doses of approximately 1 mg / kg to 200 mg / kg, approximately 1 mg / kg to 150 mg / kg, approximately 1 mg / kg to 100 mg / kg, approximately 1 mg / kg to 50 mg / kg, approximately 1 mg / kg to 25 mg / kg, approximately 1 mg / kg to 10 mg / kg, or approximately 1 mg / kg to 5 mg / kg. For example, the combinations disclosed herein can be administered in QW (Quick Wet) doses of approximately 1 mg / kg to 200 mg / kg, approximately 1 mg / kg to 150 mg / kg, approximately 1 mg / kg to 100 mg / kg, approximately 1 mg / kg to 50 mg / kg, approximately 1 mg / kg to 25 mg / kg, approximately 1 mg / kg to 10 mg / kg, or approximately 1 mg / kg to 5 mg / kg. For example, the combinations disclosed herein may be administered at Q2W in amounts of approximately 1 mg / kg to 200 mg / kg, approximately 1 mg / kg to 150 mg / kg, approximately 1 mg / kg to 100 mg / kg, approximately 1 mg / kg to 50 mg / kg, approximately 1 mg / kg to 25 mg / kg, approximately 1 mg / kg to 10 mg / kg, or approximately 1 mg / kg to 5 mg / kg. In one example, the combinations disclosed herein may be administered at QD in amounts of approximately 15 mg / kg to 75 mg / kg. In another example, the combinations disclosed herein may be administered at amounts of approximately 20 mg / kg to 50 mg / kg.In yet another example, the combinations of the disclosure may be administered in amounts of approximately 0.001 mg / kg, 0.01 mg / kg, 0.05 mg / kg, 0.1 mg / kg, 0.5 mg / kg, 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 10 mg / kg, 15 mg / kg, 20 mg / kg, 25 mg / kg, 30 mg / kg, 40 mg / kg, 50 mg / kg, 60 mg / kg, 70 mg / kg, 80 mg / kg, 90 mg / kg, 100 mg / kg, 125 mg / kg, 150 mg / kg, 175 mg / kg, or 200 mg / kg. Administration of the combinations of the disclosure may be continuous. Administration of the combinations of the disclosure may be intermittent.

[0123] As used herein, the term "daily" is intended to mean that the combination of therapeutic compounds described herein, for example, (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon, is administered once or twice or more on each day over a period of time. The term "continuous" is intended to mean that the combination of therapeutic compounds described herein, for example, (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon, is administered daily without interruption for at least 10 days to 52 weeks, or even over several years. As used herein, the terms "intermittent" or "intermittently" are intended to mean stopping and starting at regular or irregular intervals. For example, intermittent administration of the therapeutic compounds in combination as described herein, such as (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon, includes administration one to six days per week (e.g., two to three times per week or QD), cyclic administration (e.g., daily administration for two to eight consecutive weeks followed by a rest period of at least one day), or administration every other day, for example.

[0124] The combinations described herein may be administered in a regimen. Such regimens may be configured to deliver therapeutically effective doses of (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, and (4) glucagon (optionally including another antineurodegenerative agent) in the molar ratios provided herein, over a predetermined period (e.g., administration time). Such regimens may be configured to limit or prevent adverse effects or undesirable complications of each component of the combinations described herein. Such regimens may be configured to produce enhanced effects (e.g., synergistic effects) of both combination therapies. Regimens useful for treating neurodegenerative diseases may include administrations of any number of days, months, or years, which may be repeated as needed. The administration period may be interrupted by rest periods that do not include the administration of at least one therapy. For example, a regimen may include administration periods of 2, 3, 5, 7, 10, 15, 21, 28, or more days. These periods may be repeated. For example, the regimen may include the number of days set as described above, and the regimen may be repeated once, twice, three times, four times, five times, six times, seven times, eight times, nine times, ten times, eleven times, twelve times, thirteen times, or more.

[0125] The regimen may include a rest period of at least one, two, three, five, seven, ten, or more days, during which at least one therapy is not administered to the patient. The rest period can be determined, for example, by monitoring the patient's response to the drug or by measuring the efficacy of the treatment. The rest period may be applicable to a single therapy, so that only one therapy of the combination described herein is discontinued during the rest period, while the other(s) continue to be administered. The rest period may be applicable to all therapies administered to the subject, so that the subject does not receive therapy for a set period during the rest period.

[0126] The regimens described herein for the treatment of neurodegenerative diseases using the combinations described herein may be continued until the progression of the disease changes or unacceptable toxicity occurs.

[0127] A regimen for the combination of the above-mentioned drugs may include, for example, administering one of the following as a first-in-time (BIW): (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon, and administering another member of the group as a second-in-time (TIW). For example, administering one of the following as a first-in-time (QD): (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon, and administering another member of the group as a second-in-time (Q2W) or fourth-in-time (Q4W). For example, administering one of the following as a BIW or TIW: (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon, and administering another member of the group as a second-in-time (Q2W). In another exemplary regimen, one of (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon may be administered via BIW or TIW, and another member of the group may be administered via BIW for two or three weeks. In yet another exemplary regimen, one of (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon may be administered via BIW or TIW, and another member of the group may be administered via Q4W. In yet another exemplary regimen, one of (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon may be administered via BIW, and another member of the group may be administered via Q2W, Q3W, or Q4W. In some specific examples, such regimens include the administration of another antineurodegenerative agent administered at Q2W, Q3W, or Q4W. In yet another exemplary regimen, one of (1) a PDE-5 inhibitor, (2) a GLP-1 agonist or DPP-4 inhibitor, (3) a GIP agonist, or (4) glucagon may be administered at TIW, and another member of that group may be administered at Q2W, Q3W, or Q4W.

[0128] It should also be understood that the combinations described herein for the treatment of neurodegenerative diseases may be administered concurrently with other active agents (e.g., antineurodegenerative agents) not present in the combinations described herein. The regimens for administering the combinations described herein (including the exemplary regimens described above) may be modified as necessary to include the administration of such active agents. The administration of such active agents (e.g., antineurodegenerative agents) may be carried out in QD, QW, QM, BID, BIW, TIW, Q2W, Q3W, or Q4W, or in accordance with the prescribing information for the antineurodegenerative agent, such as that described in the accompanying leaflet.

[0129] Table 1 in the following examples illustrates the effect of the combination of AR1001 and semaglutide on intracellular Aβ reduction. This table shows data for AR1001 alone, semaglutide alone, and combinations of the two compounds at various concentrations. In some embodiments, AR1001 can be tested at concentrations of 0.2 μM and 0.6 μM, while semaglutide can be tested at concentrations of 0.06 μM, 0.14 μM, and 0.28 μM. The data indicates that the Aβ reduction effect may be limited when AR1001 and semaglutide are used individually. For example, 0.2 μM of AR1001 alone may result in a 0.547% reduction, while 0.06 μM of semaglutide alone may result in a 0.699% reduction.

[0130] However, a synergistic effect may be observed when AR1001 and semaglutide are combined. In some cases, the combination of 0.2 μM AR1001 and 0.06 μM semaglutide can result in a 3.573% reduction in intracellular Aβ levels. This reduction may be significantly higher than the sum of the individual effects of AR1001 and semaglutide at these concentrations. The synergistic effect can be quantified by the AB / (A+B) ratio, where a value greater than 1 indicates a synergistic effect. For the aforementioned combination, the synergistic effect value was 2.87, suggesting a strong synergistic interaction.

[0131] In some aspects, other concentration combinations may also demonstrate synergistic effects. For example, 0.2 μM AR1001 combined with 0.14 μM semaglutide may result in a synergistic effect of 2.14, leading to a reduction of 5.957%. Similarly, 0.6 μM AR1001 combined with 0.06 μM semaglutide may result in a synergistic effect of 2.57, leading to a reduction of 7.264%.

[0132] The data presented in Table 1 may suggest that the combination of AR1001 and semaglutide may enhance the reduction of intracellular Aβ levels compared to either compound alone. This synergistic effect can be observed across various concentration ratios of the two compounds. These findings may indicate the potential benefits of combining AR1001 and semaglutide to address conditions associated with elevated intracellular Aβ levels.

[0133] Table 2 in the following examples illustrates the effects of the combination of AR1001 and semaglutide on IL1β levels in an LPS-induced inflammation model. This table shows data for AR1001 alone, semaglutide alone, and combinations of the two compounds at various concentrations. In some embodiments, AR1001 at concentrations of 2 μM and 6 μM can reduce IL1β levels by 0.41% and 17.43%, respectively. Semaglutide alone at concentrations of 0.6 μM, 1.4 μM, and 2.8 μM can reduce IL1β levels by 9.85%, 32.28%, and 56.66%, respectively.

[0134] When AR1001 is combined with semaglutide, a synergistic effect can be observed in reducing IL1β levels. For example, a combination of 2 μM AR1001 and 0.6 μM semaglutide can result in a synergistic effect of 1.42, leading to a 14.52% reduction in IL1β levels. In some cases, a combination of 6 μM AR1001 and 0.6 μM semaglutide demonstrates a synergistic effect of 2.06, leading to a 56.12% reduction in IL1β levels.

[0135] The synergistic effect values ​​of the tested combinations ranged from 1.42 to 2.06, indicating that the effect of combining AR1001 and semaglutide on IL1β reduction may be greater than the sum of their individual effects. In some embodiments, the degree of synergy may vary depending on the specific concentrations of AR1001 and semaglutide used in the combination.

[0136] These results suggest that the combination of AR1001 and semaglutide may enhance the anti-inflammatory effect compared to either compound alone, as measured by the reduction of IL1β levels. The synergistic interaction between AR1001 and semaglutide may contribute to their potential efficacy in addressing inflammation-related conditions.

[0137] Table 3 in the following examples illustrates the effects of the combination of AR1001 and semaglutide on TNFα levels in an LPS-induced inflammation model. This table shows data for AR1001 alone, semaglutide alone, and combinations of the two compounds at various concentrations. In some embodiments, AR1001 at concentrations of 2 μM and 6 μM can reduce TNFα levels by 6.94% and 8.92%, respectively. Semaglutide alone at concentrations of 0.6 μM, 1.4 μM, and 2.8 μM can reduce TNFα levels by 8.15%, 23.57%, and 39.78%, respectively.

[0138] A synergistic effect may be observed in the reduction of TNFα levels when AR1001 and semaglutide are combined. For example, a combination of 2 μM AR1001 and 0.6 μM semaglutide may result in a 16.17% reduction in TNFα levels, with a synergistic effect value of 1.07. This synergistic effect value is greater than 1, suggesting that this combination may be more effective in reducing TNFα levels than would be expected from the sum of their individual effects.

[0139] In some cases, increasing the concentration of semaglutide combined with 2 μM AR1001 can lead to a greater reduction in TNFα levels. For example, combining 2 μM AR1001 with 1.4 μM semaglutide may result in a 32.03% reduction, while combining it with 2.8 μM semaglutide may achieve a 52.82% reduction. The synergistic values ​​of these combinations may be 1.05 and 1.13, respectively.

[0140] The data also indicate that increasing the concentration of AR1001 to 6 μM in combination with various concentrations of semaglutide can lead to even greater reductions in TNFα levels. For example, the combination of 6 μM AR1001 and 0.6 μM semaglutide can result in a 19.76% reduction with a synergistic value of 1.16. Combining 6 μM AR1001 with 1.4 μM or 2.8 μM semaglutide can result in reductions of 35.75% and 56.68%, respectively, with synergistic values ​​of 1.10 and 1.16.

[0141] These results suggest that the combination of AR1001 and semaglutide may exhibit a synergistic effect in reducing TNFα levels across various concentration ratios. The synergistic effect values ​​in the range of 1.05–1.16 indicate that the combination may be more effective than what would be expected from the individual effects of each compound alone.

[0142] Table 4 in the following examples illustrates the combined effect of AR1001 and sitagliptin on Aβ reduction. This table shows data for various concentrations of AR1001 and sitagliptin, both individually and in combination, as well as their effects on Aβ levels. In some embodiments, AR1001 alone can reduce Aβ levels, with a 2.36% reduction observed at 0.2 μM and a 31.47% reduction at 0.6 μM. Sitagliptin alone can also exhibit an Aβ-reducing effect, with a 0.75% reduction at 1 μM and a 9.40% reduction at 2 μM.

[0143] The Aβ-reducing effect may be enhanced when AR1001 is combined with sitagliptin. For example, a combination of 0.2 μM AR1001 and 1 μM sitagliptin can result in a 5.83% reduction in Aβ levels. In some cases, increasing the sitagliptin concentration to 2 μM while maintaining AR1001 at 0.2 μM can lead to a 14.52% reduction. A combination of 0.6 μM AR1001 and 1 μM sitagliptin can result in a 35.83% reduction in Aβ levels, while increasing sitagliptin to 2 μM in this combination can result in a 45.35% reduction.

[0144] The synergistic effects of these combinations are evaluated using the AB / (A+B) ratio. A ratio greater than 1 may indicate a synergistic interaction between AR1001 and sitagliptin. In some embodiments, a combination of 0.2 μM AR1001 and 1 μM sitagliptin may show a synergistic effect with an AB / (A+B) ratio of 1.874.

[0145] These results suggest that the combination of AR1001 and sitagliptin may enhance Aβ reduction compared to either compound alone. The observed synergistic effect may vary depending on the specific concentrations and ratios of AR1001 and sitagliptin used. In some cases, the combination of these compounds may provide a more potent approach to reducing Aβ levels than using either compound individually.

[0146] In some embodiments, the combination of AR1001 and sitagliptin may show a synergistic effect in reducing IL1β levels in LPS-induced inflammation models. Referring to Table 5 in the following examples, the data show the effects of AR1001 and sitagliptin on IL1β levels, both individually and in combination.

[0147] AR1001 alone can reduce IL1β levels to varying degrees depending on the concentration used. For example, at 2 μM, AR1001 can reduce IL1β levels by 8.07%, while at 6 μM, the reduction can increase to 45.15%. Similarly, sitagliptin alone can also reduce IL1β levels, with reductions of 12.23% and 22.62% observed at concentrations of 10 μM and 20 μM, respectively.

[0148] When AR1001 and sitagliptin are combined, the reduction in IL1β levels may be greater than the sum of their individual effects. For example, a combination of 2 μM AR1001 and 10 μM sitagliptin can result in a 23.54% reduction in IL1β levels, with a synergistic effect value of 1.16. This synergistic effect value is greater than 1, suggesting that the combination may be more effective than what would be expected from simply adding up the effects of the individual compounds.

[0149] Synergistic effects can be observed across various concentration combinations. For example, 2 μM AR1001 combined with 20 μM sitagliptin may lead to a 37.69% reduction in IL1β levels, with a synergistic effect value of 1.23. Higher concentrations of AR1001 combined with sitagliptin may result in even greater reductions in IL1β levels. A combination of 6 μM AR1001 and 10 μM sitagliptin can reduce IL1β levels by 63.36%, while 6 μM AR1001 and 20 μM sitagliptin can achieve a 74.80% reduction.

[0150] These results suggest that the combination of AR1001 and sitagliptin may provide an enhanced anti-inflammatory effect compared to either compound alone. The synergistic effect values ​​ranging from 1.10 to 1.23 for various combinations indicate that this enhanced effect can be consistently observed across various concentration ratios of AR1001 and sitagliptin.

[0151] Table 6 in the following examples illustrates the effects of the combination of AR1001 and sitagliptin on TNFα levels in an LPS-induced inflammation model. This table shows data for various concentrations of AR1001 and sitagliptin, both individually and in combination. In some embodiments, AR1001 alone can reduce TNFα levels, with a 5.08% reduction observed at 2 μM and a 22.95% reduction at 6 μM. Sitagliptin alone can also show a TNFα-reducing effect, with a 0.49% reduction at 10 μM and a 16.63% reduction at 20 μM.

[0152] A synergistic effect in reducing TNFα levels may be observed when AR1001 is combined with sitagliptin. For example, a combination of 2 μM AR1001 and 10 μM sitagliptin can result in a 6.64% reduction in TNFα levels, with a synergistic effect value of 1.19. Similarly, 2 μM AR1001 combined with 20 μM sitagliptin can result in a 24.34% reduction, with a synergistic effect value of 1.12.

[0153] In some cases, higher concentrations of AR1001 combined with sitagliptin can result in even greater reductions in TNFα levels. For example, 6 μM AR1001 combined with 10 μM sitagliptin can result in a 27.84% reduction with a synergistic value of 1.19. When 6 μM AR1001 is combined with 20 μM sitagliptin, the greatest reduction of 43.99% can be observed, demonstrating a synergistic value of 1.11.

[0154] These results suggest that the combination of AR1001 and sitagliptin may produce a synergistic effect in reducing TNFα levels across various concentration ratios. Synergistic effect values ​​greater than 1 for all combinations tested indicate that the combined treatment may be more effective in reducing TNFα levels than would be expected from the sum of their individual effects.

[0155] Referring to Table 7 of the following examples, the combined effect of AR1001 and vildagliptin on Aβ reduction is presented. In some embodiments, this table may show the individual and combined effects of various concentrations of AR1001 and vildagliptin on Aβ levels. The data may indicate that when AR1001 and vildagliptin are administered together, they may result in a greater reduction in Aβ levels compared to either compound alone.

[0156] In some cases, AR1001 at concentrations of 0.2 μM and 0.6 μM, when administered alone, can reduce Aβ levels by 2.36% and 31.47%, respectively. When used alone, vildagliptin can reduce Aβ by 3.71% at a concentration of 1.0 μM and by 42.64% at a concentration of 2.0 μM.

[0157] The combination of AR1001 and vildagliptin may show a synergistic effect in reducing Aβ levels. For example, 0.2 μM AR1001 combined with 1.0 μM vildagliptin may result in a 7.34% reduction, while 0.2 μM AR1001 combined with 2.0 μM vildagliptin may lead to a 45.37% reduction. The effect of these combinations may be greater than the sum of the individual effects of each compound at the corresponding concentrations.

[0158] The synergistic effect can be quantified using the AB / (A+B) ratio, where a value greater than 1 may indicate a synergistic effect. In some embodiments, the combination of 0.2 μM AR1001 and 1.0 μM vildagliptin can show an AB / (A+B) ratio of 1.210, which suggests a synergistic interaction. The highest synergistic effect can be observed with the combination of 0.6 μM AR1001 and 1.0 μM vildagliptin, with an AB / (A+B) ratio of 1.405 and a corresponding Aβ reduction rate of 49.43%.

[0159] These results may suggest that combining AR1001 and vildagliptin at certain specific concentration ratios may lead to enhanced Aβ reduction compared to the individual compounds. The observed synergistic effect may vary depending on the specific concentrations and ratios of AR1001 and vildagliptin used in combination.

[0160] In some embodiments, the combination of AR1001 and vildagliptin may exhibit synergistic effects in reducing IL1β levels in LPS-induced inflammation models. Referring to Table 8 of the following examples, the data presented illustrate the effects of AR1001 and vildagliptin on IL1β levels, both individually and in combination.

[0161] This table shows that AR1001 alone at concentrations of 2 μM and 6 μM can reduce IL1β levels by 9.02% and 45.68%, respectively. Vildagliptin alone at concentrations of 10 μM and 20 μM can reduce IL1β levels by 1.44% and 3.82%, respectively.

[0162] When AR1001 is combined with vildagliptin, the reduction of IL1β levels can be significantly enhanced. For example, a combination of 2 μM AR1001 and 10 μM vildagliptin can result in a 24.97% reduction in IL1β levels, with a synergistic effect value of 2.39. Similarly, a combination of 2 μM AR1001 and 20 μM vildagliptin can lead to a 28.93% reduction, with a synergistic effect value of 2.25.

[0163] Higher concentrations of AR1001 combined with vildagliptin can lead to even greater reductions in IL1β levels. A combination of 6 μM AR1001 and 10 μM vildagliptin can result in a 55.26% reduction, while 6 μM AR1001 and 20 μM vildagliptin can lead to a 60.32% reduction in IL1β levels. These combinations demonstrate synergistic values ​​of 1.17 and 1.22, respectively.

[0164] The synergistic effect value, calculated as AB / (A+B), may indicate the degree of synergy between AR1001 and vildagliptin. Values ​​greater than 1 may suggest a synergistic interaction, while higher values ​​indicate a potentially stronger synergistic effect. In this case, all tested combinations of AR1001 and vildagliptin can show a synergistic effect in reducing IL1β levels, with the most pronounced synergy observed at lower AR1001 concentrations.

[0165] These results suggest that the combination of AR1001 and vildagliptin may potentially provide enhanced anti-inflammatory effects compared to either compound alone, particularly in reducing IL1β levels in LPS-induced inflammation models.

[0166] In some embodiments, the combination of AR1001 and vildagliptin may exhibit synergistic effects in reducing TNFα levels in LPS-induced inflammation models. Referring to Table 9 in the following examples, the data present experimental results evaluating the effects of AR1001 and vildagliptin on TNFα levels, both individually and in combination.

[0167] This table shows that AR1001 alone at concentrations of 2 μM and 6 μM can reduce TNFα levels by 5.12% and 23.72%, respectively. Vildagliptin alone at concentrations of 10 μM and 20 μM can reduce TNFα levels by 4.48% and 9.71%, respectively.

[0168] When AR1001 and vildagliptin are combined, the reduction in TNFα levels may be greater than the sum of their individual effects. For example, a combination of 2 μM AR1001 and 10 μM vildagliptin can result in a synergistic effect (AB / (A+B)) of 1.17, leading to an 11.19% reduction in TNFα levels. Similarly, a combination of 2 μM AR1001 and 20 μM vildagliptin can result in a synergistic effect of 1.14, leading to a 16.88% reduction.

[0169] Higher concentrations of AR1001 combined with vildagliptin may result in even greater reductions in TNFα levels. A combination of 6 μM AR1001 and 10 μM vildagliptin can yield a 33.80% reduction with a synergistic value of 1.20. The combination of 6 μM AR1001 and 20 μM vildagliptin showed a maximum reduction of 37.48%, demonstrating a synergistic value of 1.12.

[0170] In some cases, synergistic effect values ​​greater than 1 for all tested combinations may indicate that AR1001 and vildagliptin work synergistically to reduce TNFα levels in this inflammation model. The degree of synergy may vary depending on the specific concentrations and ratios of AR1001 and vildagliptin used.

[0171] The effects of the combination of AR1001 and linagliptin on Aβ reduction are shown in Table 10 of the following examples. This table shows data for various concentrations of AR1001 and linagliptin, both individually and in combination. In some embodiments, AR1001 may be tested at concentrations of 0.2 μM and 0.6 μM, while linagliptin may be tested at a concentration of 0.1 μM.

[0172] The data shows that when used alone, 0.2 μM and 0.6 μM AR1001 can result in Aβ reduction rates of 2.36% and 31.47%, respectively. 0.1 μM linagliptin alone can result in an Aβ reduction rate of 6.29%.

[0173] In some cases, the combination of AR1001 and linagliptin can result in a significantly higher reduction in Aβ than that observed with either compound alone. For example, a combination of 0.2 μM AR1001 and 0.1 μM linagliptin can result in a 15.73% reduction in Aβ levels.

[0174] The synergistic effect of these combinations can be evaluated using the AB / (A+B) ratio. A ratio greater than 1 may indicate a synergistic interaction between AR1001 and linagliptin. The combination of 0.2 μM AR1001 and 0.1 μM linagliptin shows an AB / (A+B) ratio of 1.819, suggesting a potent synergistic interaction.

[0175] The combination of 0.6 μM AR1001 and 0.1 μM linagliptin demonstrated a 46.50% reduction in Aβ, accompanied by an AB / (A+B) ratio of 1.231. This combination demonstrates a significant improvement in Aβ reduction compared to any of the compounds used individually.

[0176] These results suggest that the combination of AR1001 and linagliptin may potentially enhance the therapeutic effect in reducing Aβ levels, which could be beneficial for conditions associated with Aβ accumulation. The synergistic interactions observed at various concentration combinations may offer flexibility in drug administration strategies for potential therapeutic applications.

[0177] Table 11 of the following examples presents data on the combined effects of AR1001 and linagliptin on IL-1β levels in an LPS-induced inflammation model. In some embodiments, AR1001 and linagliptin can be tested individually and in combination at various concentrations to evaluate their effects on IL-1β production. This table may show IL-1β fold change values ​​and reduction percentages for various treatment conditions.

[0178] In some cases, AR1001 alone at concentrations of 2 μM and 6 μM can reduce IL-1β levels by 6.47% and 43.45%, respectively. Linagliptin alone at 1 μM can reduce IL-1β levels by 7.21%. When AR1001 and linagliptin are combined, the reduction in IL-1β levels may be greater than that of either compound alone. For example, a combination of 2 μM AR1001 and 1 μM linagliptin can result in a 15.62% reduction in IL-1β levels, while a combination of 6 μM AR1001 and 1 μM linagliptin can lead to a 60.50% reduction.

[0179] The synergistic effect of combining AR1001 and linagliptin can be evaluated using the AB / (A+B) ratio. In some embodiments, a ratio greater than 1 may indicate a synergistic interaction between the compounds. The data showed AB / (A+B) values ​​of 1.14 and 1.19 for the tested combinations, suggesting a synergistic effect in reducing IL-1β levels.

[0180] Table 12 in the following examples illustrates the effects of the combination of AR1001 and linagliptin on TNFα levels in an LPS-induced inflammation model. This table shows data for various concentrations of AR1001 and linagliptin, both individually and in combination. In some embodiments, AR1001 alone can reduce TNFα levels in a concentration-dependent manner. For example, 2 μM AR1001 can reduce TNFα levels by 4.77%, while 6 μM AR1001 can reduce TNFα levels by 22.31%. In some cases, 1 μM linagliptin alone can reduce TNFα levels by 11.33%.

[0181] The combination of AR1001 and linagliptin may show a synergistic effect in reducing TNFα levels. For example, when 2 μM of AR1001 is combined with 1 μM of linagliptin, the TNFα reduction can increase to 18.91%, which is higher than the sum of their individual effects. This synergistic effect is quantified by an AB / (A+B) ratio of 1.17, where a value greater than 1 indicates a synergistic effect. In some embodiments, a more pronounced synergistic effect can be observed when 6 μM of AR1001 is combined with 1 μM of linagliptin, resulting in a 40.58% reduction in TNFα levels and an AB / (A+B) ratio of 1.21.

[0182] The data in Table 12 may suggest that the combination of AR1001 and linagliptin may result in a greater reduction in TNFα levels compared to either compound alone, across various concentration combinations. This synergistic effect may be particularly evident at higher concentrations of AR1001 combined with linagliptin.

[0183] Referring to Figure 1, a bar graph illustrating the effects of AR1001 and semaglutide on reducing IL-6 levels in an LPS-induced inflammation model is shown. The y-axis of the graph represents the reduction in IL-6 levels as a percentage, ranging from 0% to 100%. The x-axis displays various treatment conditions, including LPS alone, various concentrations of AR1001 (0.1 μM, 0.5 μM, 1 μM, and 5 μM), and combinations of AR1001 with semaglutide (0.01 μM, 0.1 μM, 0.1 μM, and 0.1 μM, respectively).

[0184] In some aspects, the graph may demonstrate that AR1001 or semaglutide alone has minimal effect on IL-6 reduction compared to a control with LPS alone. However, the combination of AR1001 and semaglutide may result in a significantly greater reduction in IL-6 levels.

[0185] The data suggest that, in some specific cases, the combination of AR1001 and semaglutide may produce a synergistic effect in reducing IL-6 levels. For example, the combination of 0.5 μM AR1001 and 0.1 μM semaglutide may show the highest reduction in IL-6 levels among the tested combinations. This reduction may be significantly greater than the sum of the reductions observed individually for each compound at these concentrations.

[0186] In some embodiments, synergistic effects can be observed across various combinations of AR1001 and semaglutide concentrations. The degree of synergy may vary depending on the specific concentration used. For example, a combination of 0.1 μM AR1001 and 0.1 μM semaglutide may exhibit a different level of synergy compared to a combination of 5 μM AR1001 and 0.1 μM semaglutide.

[0187] The graph includes error bars for each condition, which may indicate variability across different samples or repeated measurements. These error bars may provide information regarding the reliability and consistency of the observed effects.

[0188] In some cases, the synergistic effects observed in this LPS-induced inflammation model may suggest potential therapeutic applications for the combination of AR1001 and semaglutide in conditions associated with elevated IL-6 levels. However, further research may be needed to fully characterize the nature and extent of this synergistic interaction across a wider concentration range and in various experimental models.

[0189] Table 13 of the following examples presents data on the effects of the combination of AR1001 and semaglutide on IL-6 levels in an LPS-induced inflammation model. This table shows various concentrations of AR1001 (0.1 μM, 0.5 μM, 1 μM, and 5 μM) and semaglutide (0.1 μM) tested individually and in combination.

[0190] In some embodiments, AR1001 alone may exhibit a modest effect on IL-6 reduction, with reduction rates ranging from 8.70% to 11.48% across the tested concentrations. 0.1 μM semaglutide alone may demonstrate a minimal IL-6 reduction of 0.99%.

[0191] The combination of AR1001 and semaglutide may demonstrate a synergistic effect in reducing IL-6 levels. For example, a combination of 0.1 μM AR1001 and 0.1 μM semaglutide can result in a 16.67% reduction in IL-6 levels, with a synergistic effect value of 1.65. This synergistic effect value is greater than 1, suggesting that the combination may be more effective than the sum of the individual effects of AR1001 and semaglutide.

[0192] In some cases, the synergistic effect may vary depending on the concentration ratio of AR1001 to semaglutide. The data shows that ratios in the range of 1:1 to 50:1 (AR1001:semaglutide) can all exhibit a synergistic effect, and the synergistic effect value is in the range of 1.16 to 1.65.

[0193] The highest IL-6 reduction of 18.61% can be observed with a combination of 0.5 μM AR1001 and 0.1 μM semaglutide, corresponding to a 5:1 ratio. This combination can demonstrate a synergistic value of 1.49.

[0194] These results suggest that in this LPS-induced inflammation model, the combination of AR1001 and semaglutide may provide enhanced anti-inflammatory effects compared to either compound alone. The synergistic interactions observed across various concentration ratios may indicate potential flexibility in drug administration strategies for the combined use of these compounds.

[0195] Referring to Figure 2, a bar graph is shown illustrating the effects of AR1001 and semaglutide on reducing IL-6 levels in an LPS-induced inflammation model. The y-axis of the graph represents the percentage reduction in IL-6 levels, ranging from 0% to 100%. The x-axis displays various treatment conditions, including LPS alone, AR1001 at concentrations of 10 μM and 20 μM, semaglutide at concentrations of 0.1 μM and 1 μM, and various combinations of AR1001 and semaglutide.

[0196] In some aspects, the graph demonstrates that the combination of AR1001 and semaglutide can result in a greater reduction in IL-6 levels compared to either compound alone. For example, when 10 μM of AR1001 is combined with 0.1 μM of semaglutide, the reduction in IL-6 levels can be approximately 30%. This reduction may be higher than the reduction observed with either AR1001 or semaglutide alone at these concentrations.

[0197] The data suggest that increasing the concentrations of both compounds may lead to enhanced IL-6 reduction. In some cases, the combination of 20 μM AR1001 and 1 μM semaglutide may result in the highest reduction in IL-6 levels, reaching approximately 55%. This reduction may be significantly greater than the reductions observed with either compound administered individually at these concentrations.

[0198] The graph includes error bars for each condition, which may indicate variability across different samples or repeated measurements. These error bars may provide information regarding the consistency and reliability of the observed effects.

[0199] In some embodiments, the synergistic effect of combining AR1001 and semaglutide may be particularly evident at higher concentrations. For example, 20 μM of AR1001 alone may reduce IL-6 levels by approximately 45%, and 1 μM of semaglutide alone may have only a minimal effect, but their combination can result in a reduction of approximately 55%, suggesting a potential synergistic interaction.

[0200] The data presented in Figure 2 support the idea that combining AR1001 with semaglutide at several specific concentrations may provide enhanced anti-inflammatory effects, such as those measured by a reduction in IL-6 levels, in this LPS-induced inflammation model. This combination approach may offer potential benefits in addressing inflammatory states in which IL-6 plays a crucial role.

[0201] Referring to Table 14 in the following examples, the data illustrate the effect of the combination of AR1001 and semaglutide on IL-6 levels in an LPS-induced inflammation model. This table presents results for various concentrations of AR1001 (10 μM and 20 μM) and semaglutide (0.1 μM and 1 μM), both individually and in combination.

[0202] In some embodiments, AR1001 alone at 10 μM and 20 μM concentrations may reduce IL-6 levels by 25.75% and 46.60%, respectively. Semaglutide alone at 0.1 μM and 1 μM concentrations may increase IL-6 levels by 19.95% and 2.26%, respectively.

[0203] When AR1001 is combined with semaglutide, a greater reduction in IL-6 levels may be observed. For example, a combination of 10 μM AR1001 and 0.1 μM semaglutide can result in a 31.33% reduction in IL-6 levels. In some cases, increasing the semaglutide concentration to 1 μM while maintaining AR1001 at 10 μM can lead to a 36.31% reduction.

[0204] The data suggests that higher concentrations of both compounds may produce more pronounced effects. For example, a combination of 20 μM AR1001 and 0.1 μM semaglutide can reduce IL-6 levels by 49.16%. The most significant reduction, 55.68%, can be observed with 20 μM AR1001 and 1 μM semaglutide.

[0205] The synergistic effect column in Table 14 shows values ​​greater than 1 for all combinations, which may indicate a synergistic interaction between AR1001 and semaglutide in reducing IL-6 levels. The highest synergistic effect value of 5.40 can be observed for the combination of 10 μM AR1001 and 0.1 μM semaglutide.

[0206] The "rate" column in Table 14 shows the ratio of AR1001 concentration to semaglutide concentration used in each combination therapy. These ratios can range from 10:1 to 200:1, allowing for the analysis of various proportional combinations and their effects on IL-6 reduction.

[0207] Referring to Figure 3, a bar graph illustrating the effects of AR1001 and tilzepatide on reducing IL-6 levels in an LPS-induced inflammation model is shown. The y-axis of the graph represents the percentage reduction in IL-6 levels, ranging from 0% to 100%. The x-axis displays various treatment conditions, including LPS alone, AR1001 at concentrations of 10 μM and 20 μM, tilzepatide at concentrations of 0.1 μM and 1 μM, and various combinations of AR1001 and tilzepatide.

[0208] In some embodiments, the graph may demonstrate that the combination of AR1001 and tilzepatide results in a greater reduction in IL-6 levels compared to the administration of either compound alone. For example, when 10 μM AR1001 is combined with 0.1 μM tilzepatide, the reduction in IL-6 levels may be significantly greater than the reduction observed with either AR1001 or tilzepatide alone at these concentrations.

[0209] The highest reduction in IL-6 can be observed with the combination of 20 μM AR1001 and 1 μM tilzepatide, reaching a reduction of nearly 90%. Since the reduction in IL-6 levels is considered greater than the sum of the reductions achieved by each compound individually, this combination may exhibit a synergistic effect.

[0210] In some cases, the graph may include error bars for each condition, illustrating the variability of various samples or repeated measurements. Asterisks above some bars may indicate statistical significance, potentially highlighting combinations that show a significantly greater reduction in IL-6 compared to the control condition or individual treatments.

[0211] The data presented in Figure 3 may suggest dose-dependent effects of both AR1001 and tilzepatide on IL-6 reduction. Furthermore, the graph may indicate a potential synergistic effect between AR1001 and tilzepatide on reducing IL-6 levels in this LPS-induced inflammation model.

[0212] Table 15 of the following examples illustrates the effects of the combination of AR1001 and tilzepatide on IL-6 levels in an LPS-induced inflammation model. This table shows data for various concentrations of AR1001 (10 μM and 20 μM) and tilzepatide (0.1 μM and 1 μM), both individually and in combination. In some embodiments, AR1001 alone at 10 μM can reduce IL-6 levels by 21.31%, while at 20 μM it can reduce IL-6 levels by 59.12%. Tilzepatide alone at 0.1 μM and 1 μM can increase IL-6 levels by 18.94% and 2.49%, respectively.

[0213] A synergistic effect in reducing IL-6 levels may be observed when AR1001 and tilzepatide are combined. For example, a combination of 10 μM AR1001 and 0.1 μM tilzepatide can result in a 59.12% reduction in IL-6 levels, with a synergistic effect value of 24.90. This synergistic effect value, calculated as (AB / A+B), represents a significantly enhanced reduction compared to the sum of the individual effects of AR1001 and tilzepatide alone.

[0214] In some cases, the combination of 10 μM AR1001 and 1 μM tilzepatide can lead to a 43.45% reduction in IL-6 levels, with a synergistic effect value of 2.31. The combination of 20 μM AR1001 and 0.1 μM tilzepatide can result in a 51.87% reduction, with a synergistic effect value of 1.29. The highest reduction in IL-6 levels (89.63%) can be observed with the combination of 20 μM AR1001 and 1 μM tilzepatide, corresponding to a synergistic effect value of 1.58.

[0215] These results suggest that various combinations of AR1001 and tilzepatide may produce synergistic effects in reducing IL-6 levels in this inflammation model, with the degree of synergy varying depending on the specific concentration and ratio used. The concentration ratios of AR1001 to tilzepatide in these combinations range from 10:1 to 200:1, providing insights into the potential optimal ratio for enhancing the anti-inflammatory effect.

[0216] Referring to Figure 4, a bar graph illustrating the effects of AR1001 and dulaglutide on reducing IL-6 levels in an LPS-induced inflammation model is shown. The graph displays the percentage reduction in IL-6 for various concentrations of AR1001 and dulaglutide, both individually and in combination. In some embodiments, the y-axis represents the IL-6 reduction as a percentage ranging from 0% to 100%, while the x-axis represents the various treatment conditions.

[0217] The graph may include error bars for each condition, indicating variability in the measurements. In some cases, certain bars are marked with asterisks, which may indicate levels of statistical significance. The overall trend suggests that the combination of AR1001 and dulaglutide can reduce IL-6 levels to a greater extent compared to administering either compound alone.

[0218] In some aspects, the graph demonstrates that AR1001 at concentrations ranging from 0.1 μM to 5 μM, when combined with dulaglutide at concentrations of 0.001 μM to 0.1 μM, can result in enhanced IL-6 reduction compared to the individual treatments. The highest reduction in IL-6 levels can be observed for specific combinations of AR1001 and dulaglutide, potentially reaching a reduction of approximately 20% to 25%.

[0219] The graph may also include control conditions and treatment with LPS alone at 100 ng / ml, providing a baseline for comparison. In some cases, the synergistic effect of the combination of AR1001 and dulaglutide may be particularly evident when compared to these control conditions.

[0220] The data presented in Figure 4 may suggest that, when administered in combination, AR1001 and dulaglutide may potentially provide enhanced anti-inflammatory effects in conditions associated with elevated IL-6 levels. However, the specific concentrations and ratios of AR1001 and dulaglutide that yield optimal IL-6 reduction may vary, and further investigation may be needed to determine the most effective treatment regimen.

[0221] Referring to Table 16 of the following examples, the effects of the combination of AR1001 and dulaglutide on IL-6 levels in an LPS-induced inflammation model are presented. This table shows data for various concentrations of AR1001 (0.1 μM to 5 μM) and dulaglutide (0.001 μM to 0.1 μM), both individually and in combination. In some embodiments, AR1001 alone may have a limited effect on IL-6 reduction, with the highest reduction observed at a concentration of 1 μM, at 8.21%. Similarly, dulaglutide alone may show a modest reduction in IL-6, with a maximum reduction of 7.82% at a concentration of 0.1 μM.

[0222] The combination of AR1001 and dulaglutide can result in enhanced IL-6 reduction compared to either compound alone. For example, the combination of 0.1 μM AR1001 and 0.01 μM dulaglutide can lead to a 9.54% reduction in IL-6 levels, which is greater than the sum of their individual effects. This synergistic effect is quantified by an AB / (A+B) value of 1.53, where a value greater than 1 indicates a synergistic effect.

[0223] In some cases, the synergistic effect may be more pronounced at certain specific concentration ratios. For example, a combination of 0.5 μM AR1001 and 0.01 μM dulaglutide (a 50:1 ratio) can result in a synergistic effect value of 1.85 and a 26.63% reduction in IL-6 levels. The highest synergistic effect (2.03) can be observed with a combination of 0.1 μM AR1001 and 0.001 μM dulaglutide (a 100:1 ratio), resulting in a 4.85% reduction in IL-6.

[0224] The data suggest that the synergistic effect may vary depending on the concentration ratio of AR1001 and dulaglutide. Ratios in the range of 1:1 to 1000:1 may exhibit a synergistic interaction, and the AB / (A+B) value is consistently greater than 1. In some embodiments, the most effective combination for IL-6 reduction may be observed in ratios between 50:1 and 500:1.

[0225] These results may suggest that combining AR1001 and dulaglutide at specific concentration ratios could potentially enhance their anti-inflammatory effects in this LPS-induced inflammation model. The observed synergistic interaction may suggest potential benefits in co-administering these compounds to reduce IL-6 levels, which could have implications for managing inflammatory states.

[0226] Referring to Figure 5, a bar graph is shown illustrating the effects of AR1001 and semaglutide on reducing IL-6 levels in a TNFα-induced inflammation model. The y-axis of the graph may represent the percentage reduction in IL-6 levels, ranging from 0% to 100%. The x-axis may display various treatment conditions, including TNFα alone, AR1001 alone at concentrations of 10 μM and 20 μM, semaglutide alone at concentrations of 0.01 μM, 0.1 μM, and 1 μM, and various combinations of AR1001 and semaglutide.

[0227] In some embodiments, the graph may demonstrate that the combination of AR1001 and semaglutide results in a greater reduction in IL-6 levels compared to either compound alone. For example, 10 μM or 20 μM of AR1001 alone may have a minimal effect on IL-6 reduction, and 0.01 μM, 0.1 μM, or 1 μM of semaglutide alone may have only a limited effect, but the combination of these compounds may show a substantially higher reduction in IL-6 levels.

[0228] The highest reduction in IL-6 levels can be observed with a combination of 20 μM AR1001 and 1 μM semaglutide. This combination demonstrates a synergistic effect, with the reduction in IL-6 levels being greater than the sum of the reductions achieved by each compound individually.

[0229] Error bars included for each data point may indicate variability across different samples or repeated measurements. The presence of these error bars may suggest that multiple experiments were performed to ensure the reliability of the results.

[0230] In some cases, the graph may include statistical significance symbols above certain bars. These symbols may indicate that the observed differences between certain treatment conditions are statistically significant, providing further support for the synergistic effect of combining AR1001 and semaglutide.

[0231] The data presented in Figure 5 may suggest that the combination of AR1001 and semaglutide may have potential therapeutic applications in conditions characterized by elevated IL-6 levels or TNFα-induced inflammation. However, it is important to note that these results are based on a specific experimental model, and further research may be needed to fully elucidate the underlying mechanisms of these synergistic effects and determine their relevance in other experimental systems or clinical settings.

[0232] Table 17 shows the effects of the combination of AR1001 and semaglutide on IL-6 levels in a TNFα-induced inflammation model. This table shows data for various concentrations of AR1001 (10 μM and 20 μM) and semaglutide (0.01 μM, 0.1 μM, and 1 μM) used alone and in combination.

[0233] In some embodiments, AR1001 alone at 10 μM can increase IL-6 levels by 7.06%, while at 20 μM it can decrease IL-6 levels by 10.41%. Semaglutide alone can increase IL-6 levels at lower concentrations (14.28% increase at 0.01 μM and 13.99% increase at 0.1 μM), but shows a smaller increase at 1 μM (3.26%).

[0234] The combination of AR1001 and semaglutide may show a synergistic effect in reducing IL-6 levels. For example, 10 μM of AR1001 combined with 0.01 μM of semaglutide can reduce IL-6 levels by 23.70% with a synergistic effect value of 1.11. The combination of 10 μM of AR1001 and 0.1 μM of semaglutide can result in a 25.34% reduction with a synergistic effect value of 1.20.

[0235] In some cases, higher concentrations of AR1001 combined with semaglutide may lead to more significant synergistic effects. The combination of 20 μM AR1001 and 0.1 μM semaglutide can reduce IL-6 levels by 24.68%, with a synergistic value of 6.89. The highest reduction in IL-6 levels (41.58%) can be observed with 20 μM AR1001 and 1 μM semaglutide, demonstrating a synergistic value of 5.81.

[0236] Synergistic effect values ​​greater than 1 for all tested combinations suggest that AR1001 and semaglutide work synergistically to reduce IL-6 levels in this TNFα-induced inflammation model. The degree of synergy may vary depending on the specific concentrations and ratios of AR1001 and semaglutide used.

[0237] Referring to Figure 6, a bar graph is shown illustrating the effects of AR1001 and tilzepatide on reducing IL-6 levels in a TNFα-induced inflammation model. The graph displays the percentage reduction in IL-6 levels on the y-axis, ranging from 0% to 100%. The x-axis shows various treatment conditions, including different concentrations of AR1001 (0.1 μM to 20 μM) and tilzepatide (0.001 μM to 1 μM), both individually and in combination.

[0238] In some embodiments, the graph may demonstrate that the combination of AR1001 and tilzepatide results in a greater reduction in IL-6 levels compared to the administration of either compound individually. For example, as indicated by the highest bar on the graph, the combination of 20 μM AR1001 and 1 μM tilzepatide may show the most significant reduction in IL-6 levels.

[0239] The graph may include error bars for each condition, which may represent the variability of various samples or repeated measurements. In some cases, asterisks above certain bars may indicate statistical significance, potentially suggesting that the differences observed between treatment conditions are unlikely to be due to chance.

[0240] AR1001 alone may exhibit a concentration-dependent effect on reducing IL-6 levels, with higher concentrations generally resulting in greater reductions. Similarly, tilzepatide administered separately may also demonstrate some ability to reduce IL-6 levels, but potentially to a lesser extent than AR1001 at the concentrations tested.

[0241] The synergistic effect of combining AR1001 and tilzepatide may be particularly evident at certain specific concentration ratios. For example, the combination of 10 μM AR1001 and 1 μM tilzepatide, and the combination of 20 μM AR1001 and 0.1 μM or 1 μM tilzepatide, may show a substantially greater reduction in IL-6 than could be expected from the sum of their individual effects.

[0242] In some aspects, these data may suggest that the combination of AR1001 and tilzepatide may provide enhanced anti-inflammatory effects in TNFα-induced inflammation models compared to either compound alone. The synergistic interaction between these compounds may potentially lead to a more effective reduction of inflammatory markers such as IL-6.

[0243] Table 18 in the following examples illustrates the effects of the combination of AR1001 and tilzepatide on IL-6 levels in a TNFα-induced inflammation model. This table shows data for various concentrations of AR1001 (ranging from 0.1 μM to 20 μM) and tilzepatide (ranging from 0.001 μM to 1 μM) used alone and in combination. In some embodiments, AR1001 alone may show a modest reduction in IL-6 levels, with a 6.48% increase at 10 μM and a 7.60% decrease at 20 μM. Tilzepatide alone may show varying effects, with an increase in IL-6 levels at lower concentrations and a slight decrease of 0.75% at 0.1 μM.

[0244] When AR1001 and tilzepatide are combined, a synergistic effect in reducing IL-6 levels may be observed. For example, a combination of 10 μM AR1001 and 1 μM tilzepatide may result in a synergistic effect value of 1.11 and a 19.26% reduction in IL-6 levels.

[0245] The data suggests that higher concentrations of both compounds may produce a more pronounced synergistic effect. For example, a combination of 20 μM AR1001 and 1 μM tilzepatide resulted in a remarkably high synergy value of 10.86, leading to a 36.01% reduction in IL-6 levels. This combination may demonstrate the potential for enhanced anti-inflammatory effects when AR1001 and tilzepatide are used together at specific concentration ratios.

[0246] In some embodiments, the synergistic effect may vary depending on the concentration ratio of AR1001 to tilzepatide. This table presents ratios ranging from 5:1 to 200:1, with each combination exhibiting a synergistic effect to varying degrees. This variability in the synergistic effect across various concentration ratios may suggest the importance of optimizing the relative concentrations of AR1001 and tilzepatide for maximum anti-inflammatory efficacy in this model.

[0247] Referring to Figure 7, a bar graph illustrating the effects of AR1001 and dulaglutide on IL-6 levels in a TNFα-induced inflammation model is shown. The y-axis of the graph represents IL-6 concentration in pg / ml, ranging from 0% to 100%. The x-axis displays various treatment conditions, including different concentrations of TNFα, AR1001, and dulaglutide. In some embodiments, the graph may demonstrate the potential synergistic effect of combining AR1001 and dulaglutide in reducing IL-6 levels compared to either compound alone.

[0248] The graph may contain multiple bars for each treatment condition, accompanied by error bars indicating measurement variability. In some cases, asterisks above certain bars may indicate the level of statistical significance for the observed effect. The legend below the graph may provide details regarding the concentrations of TNFα (5 ng / ml), AR1001 (0.1 μM to 1 μM), and dulaglutide (0.001 μM to 1 μM) used for each condition.

[0249] In some aspects, the overall trend of the data may suggest that certain combinations of AR1001 and dulaglutide are more effective in reducing IL-6 levels than TNFα treatment alone or treatment with either compound individually. For example, a combination of 0.1 μM AR1001 and 0.01 μM dulaglutide may result in lower IL-6 concentrations compared to administering either compound individually at these concentrations.

[0250] The synergistic effect of AR1001 and dulaglutide can be observed across various concentration combinations. In some cases, the most significant reduction in IL-6 levels can be achieved by specific ratios of AR1001 to dulaglutide. For example, the combination of 0.5 μM AR1001 and 0.01 μM dulaglutide may show a particularly strong synergistic effect in reducing IL-6 levels.

[0251] It is important to note that the effectiveness of combination therapy may vary depending on the specific concentrations of AR1001 and dulaglutide used. In some embodiments, certain concentration ratios may yield more optimal results than others in terms of IL-6 reduction. The data presented in Figure 7 may provide insights into potential doping strategies when combining AR1001 and dulaglutide to achieve maximum anti-inflammatory effects in a TNFα-induced inflammation model.

[0252] Table 19 in the following examples illustrates the effects of the combination of AR1001 and dulaglutide on IL-6 levels in a TNFα-induced inflammation model. This table shows data for various concentrations of AR1001 (0.1 μM to 1 μM) and dulaglutide (0.001 μM to 0.1 μM), both individually and in combination. In some embodiments, AR1001 alone may show a modest reduction in IL-6 levels, with a 2.53% reduction observed at a concentration of 1 μM. Dulaglutide alone may also show some IL-6 reduction, with a maximum reduction of 2.97% at a concentration of 0.01 μM.

[0253] When AR1001 and dulaglutide are combined, the reduction of IL-6 may be enhanced compared to either compound alone. For example, a combination of 0.1 μM AR1001 and 0.01 μM dulaglutide may result in a 19% reduction in IL-6 levels. This combination may demonstrate a synergistic effect, as indicated by an AB / (A+B) value of 6.44, which is greater than 1.

[0254] In some cases, other concentration ratios of AR1001 and dulaglutide may also show synergistic effects. For example, a combination of 0.5 μM AR1001 and 0.1 μM dulaglutide can lead to a 17.74% reduction in IL-6 levels, with an AB / (A+B) value of 4.64. Synergistic effects can be observed across various concentration ratios ranging from 1:1 to 500:1 (AR1001:dulaglutide).

[0255] The data in Table 19 may suggest that combining AR1001 and dulaglutide at several specific concentration ratios may result in enhanced IL-6 reduction compared to the individual compounds in this TNFα-induced inflammation model. These findings may indicate the potential benefits of combining these compounds to reduce inflammatory responses in several specific conditions.

[0256] Referring to Figure 8, the effect of the combination of AR1001 and exenatide on reducing IL-6 levels in primary astrocytes is illustrated by two bar graphs. Graph A shows the reduction in IL-6 levels in response to Aβ+IFNγ treatment, while graph B shows the reduction in IL-6 levels in response to STZ treatment. In some embodiments, the combination of AR1001 and exenatide may result in a greater reduction in IL-6 levels compared to either compound alone under both experimental conditions.

[0257] In Graph A, treatments may include Aβ+IFNγ alone, 1 μM AR1001, 0.1 μM and 1 μM exenatide, and combinations of AR1001 and exenatide. The combination of AR1001 and exenatide may result in a significantly higher reduction in IL-6 levels compared to the individual treatments. In some cases, the combination of 1 μM AR1001 and 0.1 μM exenatide may result in the greatest reduction in IL-6 levels in the Aβ+IFNγ-induced inflammation model.

[0258] Graph B follows a similar pattern, but STZ is used as the initial treatment. The combination of AR1001 and exenatide again demonstrates a synergistic effect in reducing IL-6 levels compared to either compound alone. In some embodiments, the combination of 1 μM AR1001 and 0.1 μM exenatide may show the most significant reduction in IL-6 levels in the STZ-induced inflammation model.

[0259] Error bars in both graphs may indicate variability across different samples or repeated measurements. Asterisks above some specific bars may indicate statistical significance, suggesting that the differences observed in IL-6 reduction between treatment conditions may be statistically meaningful.

[0260] In some cases, the synergistic effects observed in both inflammation models may suggest that the combination of AR1001 and exenatide may potentially offer enhanced anti-inflammatory benefits in primary astrocytes compared to monotherapy with either compound. This combination approach may have implications for addressing neuroinflammation associated with various neurodegenerative states.

[0261] Referring to Table 20 in the following examples, the effects of the combination of AR1001 and exenatide on IL-6 levels in an Aβ+IFNγ-induced inflammation model are presented. The data show the multiplier change and percentage reduction of IL-6 for various concentrations of AR1001 and exenatide, both individually and in combination.

[0262] In some embodiments, AR1001 alone at 1 μM may slightly increase IL-6 levels, as indicated by a negative reduction percentage of -2.75%. Exenatide alone may exhibit varying effects depending on the concentration. At 0.1 μM, exenatide may increase IL-6 levels by 5.41%, while at 1 μM, it may decrease IL-6 levels by 8.52%.

[0263] The combination of AR1001 and exenatide may demonstrate a synergistic effect in reducing IL-6 levels. For example, when 1 μM of AR1001 is combined with 0.1 μM of exenatide (in a 10:1 ratio), the reduction in IL-6 can reach 22.19%. This combination may exhibit a synergistic effect value of 4.04, showing a significantly enhanced effect compared to the individual compounds.

[0264] In some cases, a combination of 1 μM AR1001 and 1 μM exenatide (1:1 ratio) can result in an 11.45% reduction in IL-6 with a synergistic effect value of 1.40. This suggests that even at equal concentrations, AR1001 and exenatide can work synergistically to reduce IL-6 levels in this inflammation model.

[0265] The synergistic effect values ​​greater than 1 observed for both combinations indicate that the combined effect of AR1001 and exenatide may be greater than the sum of their individual effects. This synergistic interaction may potentially enhance the anti-inflammatory properties of these compounds when used together.

[0266] Table 21 of the following examples presents data on the effect of the combination of AR1001 and exenatide on IL-6 levels in an STZ-induced inflammation model using primary astrocytes. This table shows the results of various treatments, including STZ alone, AR1001 alone, exenatide alone, and combinations of AR1001 and exenatide at various concentrations.

[0267] In some embodiments, AR1001 at a concentration of 1 μM may reduce IL-6 levels by 5.29% compared to a control with STZ alone. Exenatide alone at concentrations of 0.1 μM and 1 μM may slightly increase IL-6 levels by 2.00% and 2.08%, respectively.

[0268] The combination of AR1001 and exenatide may produce a synergistic effect in reducing IL-6 levels. For example, when 1 μM of AR1001 is combined with 0.1 μM of exenatide (in a 10:1 ratio), the IL-6 reduction can reach 24.06%. This combination may exhibit a synergistic effect value of 9.46, indicating a significantly enhanced IL-6 reduction compared to the individual compounds.

[0269] In some cases, different ratios of AR1001 to exenatide can also demonstrate synergistic effects. A combination of 1 μM AR1001 and 1 μM exenatide (1:1 ratio) can reduce IL-6 levels by 6.57%, with a synergistic value of 1.39.

[0270] These results suggest that the combination of AR1001 and exenatide may provide enhanced anti-inflammatory effects in STZ-induced inflammation compared to either compound alone. The synergistic effect may vary depending on the concentration ratio of the two compounds, with a 10:1 ratio showing a particularly strong synergistic interaction in this model.

[0271] Referring to Figure 9, a bar graph illustrating the effects of AR1001 and semaglutide on the JC-1 ratio in an Aβ-induced model of mitochondrial dysfunction is shown. The JC-1 ratio, expressed as a percentage on the y-axis, may represent the mitochondrial membrane potential. In some embodiments, the x-axis displays various treatment conditions, including Aβ alone and various combinations of AR1001 and semaglutide concentrations.

[0272] The graph may demonstrate that the combination of AR1001 and semaglutide results in a higher JC-1 ratio compared to Aβ treatment alone or treatment with individual compounds. In some cases, the combination of 0.1 μM AR1001 and 0.01 μM semaglutide can result in a particularly noteworthy increase in the JC-1 ratio, suggesting a potential synergistic effect on mitochondrial function.

[0273] In this combination, the AR1001 concentration can range from 0.1 μM to 5 μM, while the semaglutide concentration can range from 0.01 μM to 1 μM. These data suggest that several specific combinations of AR1001 and semaglutide may have a synergistic effect in improving mitochondrial function in the presence of Aβ. For example, the combination of 0.1 μM AR1001 and 0.01 μM semaglutide can significantly increase the JC-1 ratio compared to what might be expected from the sum of their individual effects.

[0274] In some embodiments, the graph may include error bars for each condition, which indicate variability in various samples or repeated measurements. The presence of these error bars can provide information regarding the reliability and consistency of the observed effect.

[0275] The synergistic effect observed in the combination therapy may suggest that AR1001 and semaglutide can act through complementary mechanisms to protect mitochondrial function in the presence of Aβ. This combination approach may offer potential benefits in addressing mitochondrial dysfunction associated with several specific neurodegenerative conditions.

[0276] Referring to Table 22, the effect of the combination of AR1001 and semaglutide on the JC-1 ratio in an Aβ-induced model is presented. This table shows data for various concentrations of AR1001 and semaglutide, both individually and in combination. In some embodiments, AR1001 alone may have a limited effect on increasing the JC-1 ratio, with changes ranging from 0 to +7 at concentrations of 0.1 μM to 5 μM. Similarly, semaglutide alone may exhibit a modest increase in the JC-1 ratio, with changes of +1 to +14 at concentrations of 0.01 μM to 1 μM.

[0277] In some cases, the combination of AR1001 and semaglutide may produce a synergistic effect in increasing the JC-1 ratio. For example, the combination of 0.1 μM AR1001 and 0.01 μM semaglutide may lead to a 28% increase in the JC-1 ratio with a synergistic effect value of 23.74. This synergistic effect value, calculated as (AB / A+B), may indicate a strong positive interaction between AR1001 and semaglutide in improving mitochondrial function.

[0278] The data suggests that various concentration ratios of AR1001 to semaglutide may produce a synergistic effect. In some embodiments, ratios ranging from 1:1 to 100:1 may be effective. For example, a 10:1 ratio (0.1 μM AR1001 to 0.01 μM semaglutide) may yield a synergistic effect value of 23.74, while a 1:1 ratio (0.1 μM AR1001 to 0.1 μM semaglutide) may lead to a synergistic effect value of 2.40.

[0279] Higher concentrations of AR1001 combined with semaglutide may also demonstrate synergistic effects. For example, 5 μM AR1001 combined with 1 μM semaglutide resulted in a synergistic effect value of 1.27, increasing the JC-1 ratio by 21%. These results suggest that the combination of AR1001 and semaglutide may have potential benefits in mitigating Aβ-induced mitochondrial dysfunction across various concentration ratios.

[0280] Referring to Figure 10, a bar graph is shown illustrating the effects of AR1001 and exenatide on the JC-1 ratio in primary neurons exposed to Aβ. The JC-1 ratio can be used as an indicator of mitochondrial membrane potential, with higher ratios suggesting improved mitochondrial function. In some embodiments, the graph displays the JC-1 ratio as a percentage on the y-axis, ranging from 0% to 100%. The x-axis may represent various treatment conditions, including Aβ alone, AR1001 at concentrations of 0.1 μM and 0.5 μM, and various combinations of AR1001 and exenatide.

[0281] In some cases, combined treatment with AR1001 and exenatide may result in a higher JC-1 ratio compared to Aβ alone or each of the individual treatments. This suggests that the combination of AR1001 and exenatide may have a synergistic effect in maintaining mitochondrial membrane potential in primary neurons exposed to Aβ. The graph may contain error bars for each condition, which indicate variability across different samples or repeated measurements.

[0282] The combination of 0.1 μM AR1001 and 0.001 μM exenatide may result in a higher JC-1 ratio compared to either compound alone. Similarly, the combination of 0.5 μM AR1001 and 0.001 μM exenatide may show an even greater increase in the JC-1 ratio. These results suggest that AR1001 and exenatide may work synergistically to protect mitochondrial function in the presence of Aβ-induced stress.

[0283] In some aspects, the synergistic effects observed with the combination of AR1001 and exenatide may be due to complementary mechanisms of action. AR1001, as a PDE5 inhibitor, may increase intracellular cGMP levels, while exenatide, as a GLP-1 receptor agonist, may activate neuroprotective signaling pathways. The combination of these effects may lead to enhanced mitochondrial protection in primary neurons exposed to Aβ.

[0284] The data presented in Figure 10 may provide evidence of the potential therapeutic benefits of combining AR1001 and exenatide in treating conditions associated with mitochondrial dysfunction, such as neurodegenerative diseases. However, it is important to note that the optimal concentrations and ratios of AR1001 and exenatide to achieve the greatest synergistic effect may vary depending on the specific cellular context and experimental conditions.

[0285] Referring to Table 23, the effects of the combination of AR1001 and exenatide on the JC-1 ratio in an Aβ-induced model of mitochondrial dysfunction in primary neurons are presented. This table shows data for various concentrations of AR1001 and exenatide, both individually and in combination, in the presence of 10 μM Aβ. In some embodiments, the JC-1 ratio can be used as an indicator of mitochondrial membrane potential, with higher ratios suggesting improved mitochondrial function.

[0286] The data shows that AR1001 alone at 0.1 μM can slightly reduce the JC-1 ratio by 1%, while at 0.5 μM it can increase the ratio by 6% compared to a control with Aβ alone. Exenatide alone at 0.001 μM can increase the JC-1 ratio by 7%.

[0287] When AR1001 and exenatide are combined, a synergistic effect on the JC-1 ratio may be observed. For example, a combination of 0.1 μM AR1001 and 0.001 μM exenatide may result in a 6% increase in the JC-1 ratio, while 0.5 μM AR1001 and 0.001 μM exenatide may lead to a 15% increase. As shown by the synergistic effect values ​​of 1.15 and 1.17, respectively, the effect of these combinations may be greater than the sum of the effects of the individual compounds.

[0288] The concentration ratios of AR1001 to exenatide tested in this study were 100:1 and 500:1. In some cases, these ratios may provide an optimal synergistic effect for improving mitochondrial function in the presence of Aβ. The data suggest that the combination of AR1001 and exenatide may offer potential benefits in mitigating Aβ-induced mitochondrial dysfunction in primary neurons.

[0289] Referring to Figure 11, a bar graph illustrating the effect of combination therapy with AR1001 and semaglutide on Aβ reduction in SH-SY5Y cells is shown. The graph displays the percentage of Aβ reduction for various concentrations of AR1001 and semaglutide, both individually and in combination. In some embodiments, the combination of AR1001 and semaglutide may result in greater Aβ reduction compared to either compound alone. The best Aβ reduction may be observed for several specific concentration ratios of AR1001 and semaglutide.

[0290] In some cases, AR1001 and semaglutide may exhibit a synergistic effect on Aβ reduction at specific concentration ratios. For example, this combination may show a synergistic effect at AR1001 to semaglutide ratios of 10:3, 10:7, 10:14, 30:3, 30:7, and 30:14. These ratios may correspond to oral doses of 3 mg / day, 7 mg / day, and 14 mg / day for semaglutide, and 10 mg / day and 30 mg / day for AR1001.

[0291] The graph may include error bars for each treatment condition, indicating variability in the measurements. Statistical significance may be indicated by symbols explained in the legend accompanying the graph. The x-axis of the graph may display various concentrations of AR1001 and semaglutide, while the y-axis may represent Aβ reduction as a percentage.

[0292] In some embodiments, the combination of AR1001 and semaglutide may provide enhanced Aβ reduction compared to monotherapy with either compound. This enhanced effect may be particularly pronounced at certain specific concentration ratios, which may correspond to specific oral medication regimens. The data presented in Figure 11 may suggest the potential benefits of combining AR1001 and semaglutide to reduce Aβ levels in cellular models associated with neurodegenerative states.

[0293] Referring to Table 24, the combination of mirodenafil AR1001 and semaglutide may exhibit a synergistic effect in reducing intracellular Aβ levels. In some embodiments, the combination of mirodenafil AR1001 and semaglutide at some specific concentrations may yield a synergistic value of 2.87. This synergistic value may represent a significant enhancement in reducing intracellular Aβ levels compared to the individual effects of mirodenafil AR1001 and semaglutide alone.

[0294] TIFF2026539121000003.tif212170

[0295] In some cases, the combination of mirodenafil AR1001 and semaglutide may provide a synergistic effect value of 2.57 in reducing intracellular Aβ levels. This synergistic effect value may suggest a significant improvement in Aβ reduction when mirodenafil AR1001 and semaglutide are used in combination at specific concentrations.

[0296] The data in Table 24 may also demonstrate a synergistic effect value of 2.14 for several specific combinations of mirodenafil AR1001 and semaglutide. This synergistic effect value may indicate that the combination therapy can be more effective in reducing intracellular Aβ levels than would be expected from the sum of their individual effects.

[0297] In some embodiments, the combination of mirodenafil AR1001 and semaglutide may provide a synergistic effect value of 1.78. This synergistic effect value may suggest that the combination therapy can provide enhanced efficacy in reducing intracellular Aβ levels as compared to monotherapy with either compound.

[0298] The combined use of mirodenafil AR1001 as a specific PDE5 inhibitor with semaglutide may contribute to these observed synergistic effects. Mirodenafil AR1001 may interact with semaglutide to enhance the combined ability of both to reduce intracellular Aβ levels. The synergistic effects observed at various concentration combinations may suggest that the interaction between mirodenafil AR1001 and semaglutide is concentration-dependent and can be optimized for maximum Aβ reduction.

[0299] In some embodiments, the combination of AR1001 and semaglutide may exhibit a synergistic effect value of 1.24 in reducing intracellular Aβ levels. This synergistic effect may be observed when specific concentrations of AR1001 and semaglutide are combined. A synergistic effect value greater than 1 suggests that the combination of AR1001 and semaglutide may produce a greater reduction in intracellular Aβ levels than would be expected from the sum of their individual effects.

[0300] In other cases, the combination of AR1001 and semaglutide can demonstrate a synergistic effect of 1.44 in reducing intracellular Aβ levels. This higher synergistic effect may indicate an even more pronounced synergistic effect between AR1001 and semaglutide in reducing intracellular Aβ accumulation. The specific concentrations of AR1001 and semaglutide that produce this synergistic effect can take on various values, and the optimal ratio can be determined through experimentation.

[0301] These synergistic effects may suggest that the combination of AR1001 and semaglutide may offer enhanced therapeutic benefits in conditions associated with elevated intracellular Aβ levels. The observed synergies may allow for the use of lower doses of each compound while still achieving a significant reduction in Aβ levels, which could potentially lead to improved efficacy and reduced side effects.

[0302] Referring to Figure 12, the bar graph illustrates the effect of combination therapy with AR1001 and semaglutide on reducing IL1β in BV-2 cells. The graph shows the percentage reduction in IL1β for various concentrations of AR1001 and semaglutide, both individually and in combination. In some embodiments, the combination of AR1001 and semaglutide may result in a greater reduction in IL1β compared to either compound alone.

[0303] The x-axis of the graph shows various concentrations of AR1001 (2 μM and 6 μM) and semaglutide (0.6 μM, 1.4 μM, and 2.8 μM), while the y-axis represents the IL1β reduction percentage. Multiple bars are displayed for each treatment condition, and error bars indicate variability in the measurement.

[0304] In some cases, AR1001 alone at concentrations of 2 μM and 6 μM may result in a modest reduction in IL1β levels. Semaglutide alone at concentrations of 0.6 μM, 1.4 μM, and 2.8 μM may also show some IL1β-reducing effect. However, when AR1001 and semaglutide are combined, the reduction in IL1β can be significantly enhanced.

[0305] The graph suggests that several specific concentration ratios of AR1001 to semaglutide may be particularly effective in reducing IL1β levels. For example, the combination of 6 μM AR1001 and 0.6 μM semaglutide can result in a significant reduction in IL1β levels, potentially demonstrating a synergistic effect. Similarly, the combination of 6 μM AR1001 and 1.4 μM semaglutide may also demonstrate enhanced IL1β reduction compared to either compound alone.

[0306] In some aspects, the synergistic effect of AR1001 and semaglutide on IL1β reduction can be observed across multiple concentration ratios. The graph shows that combinations of AR1001 and semaglutide at ratios of 10:3, 10:7, 30:3, 30:7, and 30:14 all show enhanced IL1β reduction compared to the individual compounds.

[0307] The data presented in Figure 12 may suggest that combining AR1001 with semaglutide may potentially lead to improved anti-inflammatory effects in BV-2 cells, as indicated by the reduction in IL1β levels. This combination approach may provide a basis for developing more effective strategies to address inflammatory processes in several specific cellular environments.

[0308] Table 25 shows the effects of the combination of AR1001 and semaglutide on IL1β levels in an LPS-induced inflammation model. This table shows data for various concentrations of AR1001 and semaglutide, both individually and in combination. In some embodiments, AR1001 alone can reduce IL1β levels in a concentration-dependent manner. For example, 2 μM of AR1001 may result in a 0.41% reduction, while 6 μM of AR1001 may lead to a 17.43% reduction in IL1β levels.

[0309] TIFF2026539121000004.tif214170

[0310] Semaglutide alone can also show a concentration-dependent effect on IL1β reduction. In some cases, 0.6 μM semaglutide can reduce IL1β levels by 9.85%, while 1.4 μM and 2.8 μM semaglutide can result in reductions of 32.28% and 56.66%, respectively.

[0311] A synergistic effect on IL1β reduction may be observed when AR1001 and semaglutide are combined. For example, a combination of 2 μM AR1001 and 0.6 μM semaglutide may result in a 14.52% reduction in IL1β levels, with a synergistic effect value of 1.42. This synergistic effect value is greater than 1, suggesting that this combination may be more effective than the sum of the individual effects of AR1001 and semaglutide alone.

[0312] In some embodiments, higher concentrations of AR1001 combined with semaglutide may lead to more pronounced synergistic effects. For example, 6 μM AR1001 combined with 0.6 μM semaglutide may result in a 56.12% reduction in IL1β levels, with a synergistic value of 2.06. This combination may demonstrate the highest synergistic effect among the concentrations tested.

[0313] The data in Table 25 may indicate that various concentration ratios of AR1001 and semaglutide may produce a synergistic effect in reducing IL1β levels. In some cases, the synergistic effect values ​​range from 1.42 to 2.06, depending on the specific concentration combination. These results suggest that the combination of AR1001 and semaglutide may provide an enhanced anti-inflammatory effect in this LPS-induced inflammation model compared to either compound used alone.

[0314] Referring to Figure 13, a bar graph illustrating the effect of combination therapy with AR1001 and semaglutide on TNFα reduction in BV-2 cells is shown. The graph displays the percentage reduction in TNFα for various concentrations of AR1001 and semaglutide, both individually and in combination. In some embodiments, the combination of AR1001 and semaglutide may result in greater TNFα reduction compared to either compound alone.

[0315] The x-axis of the graph shows various treatment conditions, including different concentrations of AR1001 (ranging from 2 μM to 6 μM) and semaglutide (ranging from 0.6 μM to 2.8 μM). The y-axis represents TNFα reduction as a percentage, ranging from 0% to 100%. Multiple bars are displayed for each treatment condition, and error bars indicate variability in the measurement.

[0316] In some cases, the best TNFα reduction may be observed with combinations of AR1001 and semaglutide at certain specific concentration ratios. For example, the combination of 6 μM AR1001 and 2.8 μM semaglutide may show a particularly potent reduction in TNFα levels. This combination may demonstrate a synergistic effect, resulting in a greater reduction in TNFα than would be expected from the sum of their individual effects.

[0317] The graph may include a legend explaining the symbols used to indicate statistical significance and various treatment conditions. This information may be useful for interpreting the relative effectiveness of different treatment combinations.

[0318] In some embodiments, AR1001 and semaglutide may have a synergistic effect on the downregulation of TNFα expression at specific ratios. For example, synergistic ratios of AR1001 to semaglutide may include 10:3, 10:7, 10:14, 30:3, 30:7, and 30:14. These ratios may correspond to the concentrations used in studies and may provide insights into the optimal combination for TNFα reduction.

[0319] The synergistic effect observed in this study may suggest that combining AR1001 with semaglutide may potentially enhance the anti-inflammatory effect in BV-2 cells. This combination therapy approach may be superior to monotherapy in reducing TNFα levels, which could be beneficial in the context of neuroinflammatory conditions.

[0320] Referring to Table 26, the data illustrate the effect of combining mirodenafil AR1001 and semaglutide on TNFα levels in an LPS-induced inflammation model. This table presents results for various concentrations of mirodenafil AR1001 and semaglutide, both individually and in combination. In some embodiments, mirodenafil AR1001 alone can reduce TNFα levels to varying degrees depending on the concentration used. For example, at 2 μM, AR1001 can reduce TNFα levels by 6.94%, while at 6 μM, this reduction can increase to 8.92%. Similarly, semaglutide alone can show a concentration-dependent effect on TNFα reduction, with concentrations of 0.6 μM, 1.4 μM, and 2.8 μM resulting in reductions of 8.15%, 23.57%, and 39.78%, respectively.

[0321] TIFF2026539121000005.tif218170

[0322] The combination of mirodenafil AR1001 and semaglutide may produce a synergistic effect in reducing TNFα levels. In some cases, a synergistic value of 1.07 has been observed when 2 μM mirodenafil AR1001 is combined with 0.6 μM semaglutide, which indicates a greater reduction in TNFα levels than would be expected from the sum of their individual effects. The synergistic effect may be more pronounced at certain specific concentration ratios. For example, the combination of 6 μM mirodenafil AR1001 and 0.6 μM semaglutide may result in a synergistic value of 1.16, suggesting an enhanced ability to reduce TNFα levels.

[0323] In some aspects, the synergistic effect may be further increased by adjusting the concentration ratio of mirodenafil AR1001 to semaglutide. The data show that combining 6 μM mirodenafil AR1001 with 1.4 μM semaglutide can lead to a synergistic value of 1.16, potentially indicating the optimal ratio for maximizing the reduction of TNFα levels in this inflammation model. These synergies may suggest that the combination of mirodenafil AR1001 and semaglutide may provide enhanced anti-inflammatory benefits compared to either compound used alone.

[0324] Referring to Figure 14, a bar graph and data table illustrating the effects of AR1001 and sitagliptin on Aβ reduction are shown. The bar graph displays the Aβ reduction percentage on the y-axis and various concentrations of AR1001 and sitagliptin on the x-axis. In some embodiments, different colored bars may represent different treatment conditions. The greatest reduction can be observed with the combination of AR1001 and sitagliptin.

[0325] In some cases, the data table below the graph may provide detailed information regarding the concentrations of AR1001 and sitagliptin, Aβ concentration, reduction rate, and AB / (A+B) ratio. This table may include calculations for synergistic effects, and values ​​greater than 1 potentially indicate a synergistic interaction between AR1001 and sitagliptin in reducing Aβ levels.

[0326] The combination of AR1001 and sitagliptin may demonstrate enhanced Aβ reduction compared to either compound alone. For example, in some embodiments, 0.2 μM AR1001 combined with 1 μM sitagliptin may result in a 5.83% reduction in Aβ levels, while AR1001 or sitagliptin alone at these concentrations may show lower reduction rates of 2.36% and 0.75%, respectively.

[0327] In some cases, the most effective concentration ratio of AR1001 to sitagliptin can be in the range of 1:3.3 to 1:10. For example, a combination of 0.2 μM AR1001 and 2 μM sitagliptin (a ratio of 1:10) can result in an AB / (A+B) ratio of 1.235 and a 14.52% reduction in Aβ levels, suggesting a potential synergistic effect.

[0328] The statistical significance of the results may be indicated by symbols in the legend above the graph. These symbols may indicate different levels of significance when the combined treatment is compared to the treatment of the individual compounds or the control.

[0329] In some embodiments, the synergistic effect of the AR1001 and sitagliptin combination may be concentration-dependent. For example, higher concentrations of both compounds may not necessarily lead to a greater synergistic effect. This data may suggest that the optimal synergy can be achieved at a specific concentration ratio, which could be important for potential therapeutic applications.

[0330] The AB / (A+B) ratios provided in the data tables can provide a quantitative measure of synergistic effects. Values ​​greater than 1 may indicate a synergistic effect, while higher values ​​potentially suggest a stronger synergistic interaction. In some cases, these ratios can help identify the most promising combination ratios for further investigation or development.

[0331] Referring to Figure 15, a bar graph and data table illustrating the effects of AR1001 and vildagliptin on Aβ reduction are shown. The bar graph displays the Aβ reduction percentage on the y-axis and various concentrations of AR1001 and vildagliptin on the x-axis. In some embodiments, different colored bars may represent different treatment conditions. The greatest reduction can be observed with a combination of 0.6 μM AR1001 and 2.0 μM vildagliptin.

[0332] The legend above the graph may explain the symbols used to indicate statistical significance and treatment conditions. In some cases, the data table below the graph provides detailed information regarding the concentrations of AR1001 and vildagliptin, Aβ concentration, reduction rate, and AB / (A+B) ratio. This table may include calculations for synergistic effects, where values ​​greater than 1 indicate a synergistic interaction between AR1001 and vildagliptin in reducing Aβ levels.

[0333] In some embodiments, the combination of AR1001 and vildagliptin may demonstrate a synergistic effect in reducing Aβ levels compared to either compound alone. The most effective concentration ratio may be observed when AR1001 is 0.6 μM and vildagliptin is 2.0 μM. This combination may result in a higher percentage reduction in Aβ compared to other concentration combinations or individual treatments.

[0334] The statistical significance of the results may be indicated by symbols in the bar graph. In some cases, these symbols may represent different levels of significance, allowing for a quick visual assessment of which combinations result in a statistically significant reduction in Aβ levels compared to the control or individual treatments.

[0335] The AB / (A+B) ratio provided in the data table can provide a quantitative measure of the synergistic effect. A value greater than 1 may suggest that the combination of AR1001 and vildagliptin produces a greater effect than would be expected from the sum of their individual effects. In some embodiments, this synergistic effect may be particularly pronounced at certain specific concentration ratios, which can be identified by examining the AB / (A+B) values ​​across various combinations.

[0336] Referring to Figure 16, a bar graph and data table illustrating the effects of AR1001 and linagliptin on Aβ reduction are shown. The bar graph displays the Aβ reduction percentage from 0% to 100% on the y-axis and various concentrations of AR1001 and linagliptin on the x-axis. In some embodiments, different colored bars may represent different treatment conditions. The best reduction can be observed with a combination of 0.6 μM AR1001 and 0.1 μM linagliptin.

[0337] In some cases, the legend above the graph may explain the symbols used to indicate statistical significance. The data table below the graph may provide detailed information regarding the concentrations of AR1001 and linagliptin, Aβ concentration, reduction rate, and AB / (A+B) ratio. This table may include calculations for synergistic effects, where values ​​greater than 1 potentially indicate a synergistic interaction between AR1001 and linagliptin in reducing Aβ levels.

[0338] The combination of AR1001 and linagliptin may demonstrate a synergistic effect in reducing Aβ levels compared to either compound alone. For example, 0.2 μM of AR1001 alone may result in a 2.36% reduction in Aβ levels, while 0.1 μM of linagliptin alone may result in a 6.29% reduction. However, when these concentrations are combined, the reduction increases to 15.73%, and with an AB / (A+B) ratio of 1.819, a synergistic effect can be suggested.

[0339] In some embodiments, the most effective concentration ratio of AR1001 to linagliptin may be 6:1, as demonstrated by the combination of 0.6 μM AR1001 and 0.1 μM linagliptin. This combination can result in a 46.50% reduction in Aβ levels with an AB / (A+B) ratio of 1.231, demonstrating a potent synergistic effect.

[0340] The statistical significance of the results may be indicated by symbols in the bar graph. In some cases, when comparing combination therapy with individual compound therapy or a control, an asterisk or other marker may indicate a significance level such as p<0.05, p<0.01, or p<0.001.

[0341] The notes at the bottom of the figure may explain how to interpret the AB / (A+B) ratio. Values ​​less than 1 may indicate an antagonistic effect, values ​​equal to 1 may suggest an additive effect, and values ​​greater than 1 may indicate a synergistic effect between AR1001 and linagliptin in reducing Aβ levels.

[0342] The data presented in Figure 16 may demonstrate that combining AR1001 and linagliptin at specific concentration ratios may result in enhanced Aβ reduction compared to either compound alone. This synergistic effect could have implications for the development of more effective treatments for conditions associated with Aβ accumulation.

[0343] Referring to Figure 17, a bar graph illustrating the effects of AR1001 and sitagliptin on IL1β levels in an LPS-induced inflammation model is shown. The graph displays the mRNA multiplication of IL1β on the y-axis in the range of 0 to 18, while the x-axis represents various treatment conditions. In some embodiments, treatment conditions may include LPS alone, various concentrations of AR1001 (2 μM and 6 μM), and combinations of AR1001 and sitagliptin (10 μM and 20 μM).

[0344] The graph demonstrates that the combination of AR1001 and sitagliptin may result in lower IL1β mRNA duplication compared to LPS alone or individual treatments. In some cases, the lowest IL1β levels may be observed with a combination of 6 μM AR1001 and 20 μM sitagliptin. Since the reduction is considered to be greater than the sum of the reductions achieved by each compound individually, this combination may exhibit a synergistic effect in reducing IL1β levels.

[0345] The data suggest that AR1001 alone has a dose-dependent effect on IL1β reduction, with 6 μM showing a greater reduction than 2 μM. Similarly, sitagliptin alone can also demonstrate a dose-dependent effect, with 20 μM potentially being more effective than 10 μM in reducing IL1β levels.

[0346] When AR1001 and sitagliptin are combined, the reduction in IL1β levels may be more pronounced. For example, a combination of 2 μM AR1001 and 10 μM sitagliptin may show a greater reduction in IL1β levels compared to either compound alone at these concentrations. The synergistic effect is thought to be further enhanced when both compounds are used in combination at higher concentrations.

[0347] The error bars included for each condition indicate measurement variability, which can be taken into consideration when interpreting the results. Statistical significance of differences between treatment groups is indicated by symbols explained in the legend, which may allow for a more detailed analysis of observed synergistic effects.

[0348] In some aspects, these results may suggest that the combination of AR1001 and sitagliptin may potentially provide improved anti-inflammatory effects in conditions in which IL1β plays a role, such as certain neurodegenerative or inflammatory diseases. The synergistic interaction between AR1001 and sitagliptin may allow the use of lower doses of each compound while still achieving a significant reduction in inflammatory markers.

[0349] Referring to Figure 18, the bar graph illustrates the effects of AR1001 and sitagliptin on IL1β mRNA reduction in an LPS-induced inflammation model. The graph shows the percentage reduction of IL1β mRNA for various concentrations of AR1001 and sitagliptin, both individually and in combination. In some embodiments, the y-axis represents the IL1β mRNA reduction as a percentage, ranging from 0% to 100%. The x-axis may represent various concentrations of AR1001 (2 μM and 6 μM) and sitagliptin (10 μM and 20 μM).

[0350] The graph demonstrates that the combination of AR1001 and sitagliptin may result in a higher percentage reduction of IL1β mRNA compared to either compound alone. In some cases, the best reduction may be observed with a combination of 6 μM AR1001 and 20 μM sitagliptin. These data suggest a potential synergistic effect between AR1001 and sitagliptin in reducing IL1β mRNA levels.

[0351] Multiple bars may represent each treatment condition, and error bars indicate variability in the measurement. The legend in the upper right corner of the graph may explain the symbols used to indicate statistical significance for different comparisons. Statistical significance indicators allow for an assessment of the reliability and importance of the differences observed between treatment conditions.

[0352] In some aspects, the graph may reveal dose-dependent effects for both AR1001 and sitagliptin when used individually. Combination therapy may show enhanced IL1β mRNA reduction compared to the sum of the individual effects, suggesting a potential synergistic interaction between AR1001 and sitagliptin in modulating the inflammatory response.

[0353] The data presented in Figure 18 may offer insights into the potential anti-inflammatory effects of combining AR1001 and sitagliptin. This combination approach may offer advantages in reducing IL1β mRNA levels compared to monotherapy with either compound. The observed synergistic effects may have implications for developing more effective strategies for managing inflammatory conditions.

[0354] Referring to Figure 19, a bar graph illustrating the effects of AR1001 and sitagliptin on TNFα mRNA levels in an LPS-induced inflammation model is shown. The y-axis of the graph represents the change in TNFα mRNA polyploidy, while the x-axis displays various treatment conditions. In some embodiments, the graph can demonstrate that the combination of AR1001 and sitagliptin results in a lower change in TNFα mRNA polyploidy compared to LPS alone or each individual treatment.

[0355] The graph may show results for various concentrations of AR1001 (2 μM and 6 μM) and sitagliptin (10 μM and 20 μM), both individually and in combination. In some cases, the lowest TNFα levels may be observed with a combination of 6 μM AR1001 and 20 μM sitagliptin. This combination may exhibit a synergistic effect in reducing TNFα mRNA levels beyond what could be expected from the individual effects of AR1001 and sitagliptin alone.

[0356] The error bars included for each condition may indicate measurement variability. The legend in the upper right corner of the graph may explain the statistical significance symbols used and allow for comparisons between different treatment groups.

[0357] In some aspects, the graph may demonstrate a dose-dependent effect of AR1001 on TNFα mRNA reduction, with 6 μM AR1001 showing a greater effect than 2 μM AR1001. Similarly, 20 μM sitagliptin may show a more potent TNFα-reducing effect compared to 10 μM sitagliptin.

[0358] Combination therapy may show enhanced TNFα mRNA reduction compared to either compound alone. For example, the combination of 2 μM AR1001 and 10 μM sitagliptin may result in a greater reduction in TNFα mRNA levels than either 2 μM AR1001 or 10 μM sitagliptin alone. This synergistic effect may be even more pronounced with the combination of 6 μM AR1001 and 20 μM sitagliptin.

[0359] In some cases, the data presented in Figure 19 may suggest that combining AR1001 and sitagliptin may potentially enhance anti-inflammatory effects in states where TNFα plays a role. The synergistic reduction of TNFα mRNA levels observed with several specific combinations of AR1001 and sitagliptin may indicate a possible therapeutic strategy for managing inflammatory states.

[0360] Referring to Figure 20, the bar graph illustrates the effects of AR1001 and sitagliptin on TNFα mRNA reduction in an LPS-induced inflammation model. The graph shows the percentage reduction in TNFα mRNA for various concentrations of AR1001 (2 μM and 6 μM) and sitagliptin (10 μM and 20 μM), both individually and in combination. In some embodiments, the combination of AR1001 and sitagliptin may result in a higher percentage reduction in TNFα compared to either compound alone. The highest reduction may be observed for a combination of 6 μM AR1001 and 20 μM sitagliptin.

[0361] The error bars in the graph indicate variability across different samples or repeated measurements. The legend in the upper right corner explains the symbols used to indicate statistical significance for different comparisons. In some cases, the statistical significance symbol may indicate that the observed differences between treatment conditions are unlikely to have occurred by chance.

[0362] The synergistic effect of combining AR1001 and sitagliptin on reducing TNFα mRNA levels may be particularly evident when comparing combination therapy with the treatment of the individual compounds. For example, while 6 μM AR1001 or 20 μM sitagliptin alone may result in a modest reduction in TNFα mRNA levels, their combination may lead to a substantially greater reduction, suggesting a potential synergistic interaction between the two compounds in modulating the inflammatory response.

[0363] In some aspects, concentration-dependent effects of AR1001 and sitagliptin on TNFα mRNA reduction can be observed. The graph may show that increasing the concentration of either compound alone can lead to a greater reduction in TNFα mRNA levels. However, the most significant effect is observed when both compounds are combined at higher concentrations.

[0364] The data presented in Figure 20 may provide insight into the potential anti-inflammatory mechanisms of AR1001 and sitagliptin when used in combination. The synergistic effect observed in TNFα mRNA reduction may suggest that these compounds work through complementary pathways to modulate the inflammatory response in this model system.

[0365] In some aspects, the combination of mirodenafil AR1001 and sitagliptin may show synergistic effects in reducing IL1β levels in LPS-induced inflammation models. Referring to Table 27, the effects of various concentrations of mirodenafil AR1001 and sitagliptin, individually and in combination, on IL1β production were evaluated.

[0366] TIFF2026539121000006.tif160170

[0367] The data shows that mirodenafil AR1001 alone at concentrations of 2 μM and 6 μM can reduce IL1β levels by 8.07% and 45.15%, respectively. Sitagliptin alone at concentrations of 10 μM and 20 μM can reduce IL1β levels by 12.23% and 22.62%, respectively.

[0368] When myrodenafil AR1001 is combined with sitagliptin, a greater reduction in IL1β levels may be observed compared to either compound alone. For example, a combination of 2 μM myrodenafil AR1001 and 10 μM sitagliptin may result in a 23.54% reduction in IL1β levels, while a combination of 6 μM myrodenafil AR1001 and 20 μM sitagliptin may lead to a 74.80% reduction.

[0369] The synergistic effects of these combinations can be quantified by the AB / (A+B) ratio, where a value greater than 1 suggests a synergistic interaction. In some cases, the AB / (A+B) ratio for the combination of mirodenafil AR1001 and sitagliptin ranges from 1.10 to 1.23, indicating a potential synergistic effect across various concentration ratios.

[0370] These results suggest that the combination of mirodenafil AR1001 and sitagliptin may provide enhanced anti-inflammatory effects in this LPS-induced inflammation model by more effectively reducing IL1β levels than either compound alone. The observed synergistic interaction can occur at various concentration ratios of mirodenafil AR1001 and sitagliptin, potentially allowing for flexibility in drug administration strategies.

[0371] Referring to Table 28, Data Table 100 may be used to present the results of the effects of combination therapy on TNFα levels in an LPS-induced inflammation model. Data Table 100 may include columns for mirodenafil AR1001 concentration, sitagliptin concentration, LPS treatment, TNFα multiplier change, TNFα reduction percentage, and AB / (A+B) ratio. In some embodiments, Data Table 100 may be structured into sections for mirodenafil AR1001 alone, sitagliptin alone, and mirodenafil AR1001 and sitagliptin combination.

[0372] TIFF2026539121000007.tif160170

[0373] The data table may show that mirodenafil AR1001 alone at concentrations of 2 μM and 6 μM can reduce TNFα levels by 5.08% and 22.95%, respectively. In some cases, sitagliptin alone at concentrations of 10 μM and 20 μM can reduce TNFα levels by 0.49% and 16.63%, respectively.

[0374] A greater reduction in TNFα levels may be observed when mirodenafil AR1001 is combined with sitagliptin. For example, a combination of 2 μM mirodenafil AR1001 and 10 μM sitagliptin may result in a 6.64% reduction in TNFα levels. In some embodiments, the highest reduction of 43.99% may be observed with 6 μM mirodenafil AR1001 combined with 20 μM sitagliptin.

[0375] The AB / (A+B) ratio can be used to assess the potential synergistic effect between myrodenafil AR1001 and sitagliptin. In some cases, these values ​​can range from 1.11 to 1.19 for various concentration combinations. Values ​​greater than 1 may suggest a synergistic effect in reducing TNFα levels. For example, the combination of 2 μM myrodenafil AR1001 and 10 μM sitagliptin may show an AB / (A+B) value of 1.19, which indicates a potential synergistic interaction.

[0376] The data presented in this table may demonstrate that combinations of mirodenafil AR1001 and sitagliptin at various concentration ratios can result in a greater reduction in TNFα levels compared to either compound alone in this LPS-induced inflammation model.

[0377] Referring to Figure 21, a bar graph illustrating the effects of AR1001 and linagliptin on IL1β mRNA reduction in an LPS-induced inflammation model is shown. The y-axis of the graph represents IL1β mRNA reduction as a percentage, ranging from 0% to 100%. The x-axis displays various concentrations of linagliptin (0 μM, 1 μM) and AR1001 (2 μM, 6 μM), both individually and in combination.

[0378] In some aspects, the graph demonstrates that the combination of AR1001 and linagliptin may result in a higher percentage reduction of IL1β mRNA compared to either compound alone. The highest reduction can be observed with a combination of 6 μM AR1001 and 1 μM linagliptin. This combination exhibits a synergistic effect and may potentially result in a more significant reduction in IL1β mRNA levels than could be expected from the sum of the individual effects of AR1001 and linagliptin.

[0379] The graph may include error bars for each condition, which may indicate variability in various samples or repeated measurements. These error bars may provide information regarding the consistency and reliability of the observed effects.

[0380] In some cases, the legend in the upper right corner of the figure may explain the symbols used to indicate statistical significance for different comparisons. This information may be useful in interpreting the relative importance of the differences observed between treatment conditions.

[0381] The synergistic effect observed in the combination of AR1001 and linagliptin may suggest potential therapeutic advantages in using these compounds together to reduce inflammatory responses. However, it is important to note that the optimal concentration ratio and absolute concentrations of AR1001 and linagliptin can vary depending on the specific application or physiological situation.

[0382] In some embodiments, the data presented in Figure 21 may provide insights into potential mechanisms by which AR1001 and linagliptin interact to modulate inflammatory responses. The enhanced reduction of IL1β mRNA levels in the presence of both compounds may indicate complementary or synergistic effects on signaling pathways involved in inflammatory modulation.

[0383] Referring to Figure 22, a bar graph illustrating the effects of AR1001 and linagliptin on TNFα mRNA reduction in an LPS-induced inflammation model is shown. The graph displays TNFα mRNA reduction as a percentage on the y-axis, ranging from 0% to 100%. The x-axis shows various concentrations of linagliptin (0 μM, 1 μM) and AR1001 (2 μM, 6 μM), both individually and in combination.

[0384] In some aspects, the graph demonstrates that the combination of AR1001 and linagliptin may result in a higher percentage reduction of TNFα mRNA compared to either compound alone. The highest reduction can be observed with a combination of 6 μM AR1001 and 1 μM linagliptin. This combination exhibits a synergistic effect and may potentially result in a more significant reduction in TNFα mRNA levels than could be expected from the sum of their individual effects.

[0385] The graph includes error bars for each condition, which may indicate variability in various samples or repeated measurements. These error bars may provide information regarding the consistency and reliability of the observed effects.

[0386] In some cases, the statistical significance between different treatment conditions can be indicated by symbols, as explained in the legend in the upper left corner of the figure. This statistical analysis can help determine whether the differences observed between treatment groups are meaningful and not due to chance.

[0387] The synergistic effect observed in the combination of AR1001 and linagliptin may suggest potential therapeutic advantages in using these compounds together to reduce inflammatory responses. However, it is important to note that the optimal concentration ratio and absolute concentration of these compounds can vary depending on specific conditions or applications.

[0388] In some aspects, the data presented in this figure may provide insights into the potential anti-inflammatory mechanisms of AR1001 and linagliptin when used in combination. A reduction in TNFα mRNA levels may indicate a decrease in the expression of this pro-inflammatory cytokine, which may contribute to an overall reduction in the inflammatory response.

[0389] While this data shows promising results in an LPS-induced inflammation model, it should be noted that further research may be needed to fully elucidate the underlying mechanisms of the observed synergistic effects and determine the potential clinical implications of these findings.

[0390] Table 29 shows the combined effect of mirodenafil AR1001 and linagliptin on IL-1β levels in an LPS-induced inflammation model. These data indicate that mirodenafil AR1001 and linagliptin, when used together, may show a synergistic effect in reducing IL-1β levels compared to their individual effects.

[0391] TIFF2026539121000008.tif99170

[0392] In some embodiments, mirodenafil AR1001 alone can reduce IL-1β levels in a concentration-dependent manner. For example, at 2 μM, mirodenafil AR1001 can reduce IL-1β levels by 6.47%, while at 6 μM, this reduction can increase to 43.45%. Linagliptin alone at 1 μM can reduce IL-1β levels by 7.21%.

[0393] When mirodenafil AR1001 and linagliptin are combined, the reduction in IL-1β levels may be greater than the sum of their individual effects. For example, a combination of 2 μM mirodenafil AR1001 and 1 μM linagliptin can result in a 15.62% reduction in IL-1β levels. This combination may produce a synergistic effect, as indicated by an AB / (A+B) ratio of 1.14.

[0394] In some cases, increasing the concentration of mirodenafil AR1001 in a combination may lead to a greater reduction in IL-1β levels. The combination of 6 μM mirodenafil AR1001 and 1 μM linagliptin resulted in a 60.50% reduction in IL-1β levels with an AB / (A+B) ratio of 1.19, suggesting a more potent synergistic effect.

[0395] The synergistic effects observed in these combinations may suggest that mirodenafil AR1001 and linagliptin work through complementary mechanisms to reduce IL-1β levels in this inflammatory model. These findings may suggest the potential benefits of combining mirodenafil AR1001 and linagliptin to manage inflammatory conditions associated with elevated IL-1β levels.

[0396] Table 30 shows the effects of the combination of mirodenafil AR1001 and linagliptin on TNFα levels in an LPS-induced inflammation model. The data show the change in TNFα multiplier and the percentage reduction for various concentrations of mirodenafil AR1001 and linagliptin, both individually and in combination.

[0397] TIFF2026539121000009.tif90170

[0398] In some embodiments, mirodenafil AR1001 alone can reduce TNFα levels in a concentration-dependent manner. For example, at 2 μM, mirodenafil AR1001 can reduce TNFα levels by 4.77%, while at 6 μM, this reduction can increase to 22.31%.

[0399] Linagliptin, when used alone at a concentration of 1 μM, can reduce TNFα levels by 11.33%. This reduction may be greater than that observed with lower concentrations of mirodenafil AR1001, but smaller than that observed at higher concentrations.

[0400] The combination of mirodenafil AR1001 and linagliptin may produce a synergistic effect in reducing TNFα. When 2 μM mirodenafil AR1001 is combined with 1 μM linagliptin, the reduction in TNFα can increase to 18.91%. This combination may produce a synergistic value of 1.17, as indicated by the AB / (A+B) ratio.

[0401] In some cases, a more pronounced synergistic effect may be observed when using higher concentrations of mirodenafil AR1001. A combination of 6 μM mirodenafil AR1001 and 1 μM linagliptin can result in a 40.58% reduction in TNFα levels. This combination yields a synergistic value of 1.21, suggesting an enhanced synergistic effect between the two compounds at these concentrations.

[0402] A synergistic effect value greater than 1 for both combinations may indicate that the combination of mirodenafil AR1001 and linagliptin may result in a greater reduction in TNFα levels than would be expected from the sum of their individual effects. This synergistic interaction may suggest potential benefits in combining these compounds to reduce inflammatory responses in certain specific conditions. [Examples]

[0403] The aspects of this instruction may be further understood in light of the following embodiments, but these should not be interpreted as limiting the scope of this instruction in any way.

[0404] Example 1. Evaluation of combination therapy with mirodenafil and semaglutide. (1) Determination of the effect of reducing intracellular Aβ42 To investigate the synergistic effect of the combination of myrodenafil and semaglutide on the reduction of intracellular Aβ422, an Amyloid beta 42 Human ELISA was performed. Cells were treated with Aβ at a final concentration of 5 μM, myrodenafil at final concentrations of 0.2 μM and 0.6 μM, and semaglutide at final concentrations of 0.06 μM, 0.14 μM, and 0.27 μM, diluted in DMEM (1% FBS, 1% penicillin / streptomycin), and incubated in an incubator at 37°C and 5% CO2 for 24 hours. The experiment was performed as described in the Human Aβ42 ELISA Kit, Ultrasensitive (invitrogen). First, the cell culture medium was removed, then the cells were treated with 0.2 ml of RIPA lysis buffer, and the cells were disrupted using a Cell Bioruptor for 15 minutes. The mixture was centrifuged at 14000 rpm at 4°C for 10 minutes, the supernatant was collected, and 50 μl of the lysate was added to each well of a Human Aβ42 ELISA Kit (invitrogen) plate. 50 μl of Hu Aβ42 detection antibody solution was added to each well, and the mixture was incubated at room temperature for 3 hours. Each well was emptied and washed with 200 μl of wash buffer (repeated 4 times). 100 μl of anti-rabbit IgGHRP solution was added to each well, and the mixture was left at room temperature for 30 minutes. Each well was then emptied and washed with 200 μl of wash buffer (repeated 4 times). 100 μl of stabilized chromogenic substrate was added, and the mixture was incubated at room temperature for 30 minutes. Immediately after adding 100 μl of stop solution, absorbance was measured at 450 nm using a plate reader, and the results are shown in Table 1 below. The experiment was repeated three times, and statistical analysis was performed using Student's t-test. All significance tests were performed at the P<0.05 level.

[0405] In the table below, the combination index is as follows: (combined effect of A and B) / (A alone + B alone) = 1: additive effect, >1: synergistic effect.

[0406] TIFF2026539121000010.tif107170

[0407] As shown in Table 1 above, the Aβ reduction rate was significantly increased with the combination of mirodenafil and semaglutide compared to the Aβ reduction rates of mirodenafil and semaglutide alone. Specifically, the Aβ reduction rates of 0.547% and 0.699% for mirodenafil 0.2 μM and semaglutide 0.6 μM, respectively, were found to be significantly higher than the combined reduction rates of mirodenafil 0.2 μM and semaglutide 0.6 μM. However, the Aβ reduction rate of 3.573 was found to be significantly higher than the combined reduction rates of mirodenafil and semaglutide alone. Therefore, the combination of mirodenafil and semaglutide demonstrated a synergistic effect in Aβ reduction compared to mirodenafil and semaglutide alone.

[0408] (2) Confirmation of reduction of inflammatory factors To investigate the synergistic effect of the combination of myrodenafil and semaglutide on reducing inflammatory factors, assays were performed using the Mouse IL-1β ELISA Kit and the Mouse TNFα ELISA Kit. Mice were treated with LPS (10 ng / mL → 100 ng / mL), mirodenafil at concentrations of 2 μM and 6 μM, and semaglutide at concentrations of 0.6 μM, 1.4 μM, and 2.8 μM, and incubated for 24 hours in a 37°C, 5% CO2 incubator. After 24 hours, the cultures from each group were collected in 15 ml conical tubes, and the Mouse IL-1β ELISA (Abcam, ab197742) and Mouse TNF alpha ELISA Kit (Abcam, ab208348) were performed according to the methods specified in the manuals. The results are shown in Tables 2 and 3 below.

[0409] TIFF2026539121000011.tif135170

[0410] As shown in Table 2 above, the IL1β reduction rate was significantly increased with the combination of mirodenafil and semaglutide compared to the IL1β reduction rates of mirodenafil and semaglutide alone. Specifically, the IL1β reduction rates for mirodenafil 2 μM and semaglutide 6 μM alone were 0.41% and 9.85%, respectively, but the IL1β reduction rate for the combination of mirodenafil 2 μM and semaglutide 6 μM was 14.52%, which was significantly higher than the combined reduction rates of mirodenafil and semaglutide alone. Therefore, the combination of mirodenafil and semaglutide demonstrated a synergistic effect in reducing IL1β compared to mirodenafil and semaglutide alone.

[0411] TIFF2026539121000012.tif135170

[0412] As can be seen from Table 3 above, TNFα reduction was significantly increased with the combination of mirodenafil and semaglutide compared to TNFα reduction with mirodenafil or semaglutide alone. Specifically, the TNFα reduction rates for mirodenafil 2 μM and semaglutide 6 μM alone were 6.94% and 8.15%, respectively, but the TNFα reduction rate for the combination of mirodenafil 2 μM and semaglutide 6 μM was 16.17%, which was significantly higher than the combined reduction rates of mirodenafil and semaglutide alone. Therefore, the combination of mirodenafil and semaglutide demonstrated a synergistic effect in TNFα reduction compared to mirodenafil or semaglutide alone.

[0413] Example 2. Evaluation of combination therapy with mirodenafil and sitagliptin (1) Determination of the effect of reducing intracellular Aβ42 To investigate the synergistic effect of the combination of myrodenafil and sitagliptin on reducing intracellular Aβ422, an Amyloid beta 42 Human ELISA was performed. Cells were treated with Aβ at a final concentration of 5 μM, myrodenafil at final concentrations of 0.2 μM and 0.6 μM, and sitagliptin at final concentrations of 1 μM and 2 μM, diluted in DMEM (1% FBS, 1% penicillin / streptomycin), and incubated for 24 hours at 37°C in a 5% CO2 incubator. Subsequently, the experiment was carried out according to the method specified in the Human Aβ42 ELISA Kit, Ultrasensitive (invitrogen), as in Example 1 above, and the results are shown in Table 4 below.

[0414] TIFF2026539121000013.tif101170

[0415] As shown in Table 4 above, the Aβ reduction rate was significantly increased with the combination of mirodenafil and sitagliptin compared to the Aβ reduction rates of mirodenafil and sitagliptin alone. Specifically, the Aβ reduction rates for mirodenafil 0.2 μM and sitagliptin 1 μM alone were 2.36% and 0.75%, respectively, but the Aβ reduction rate for the combination of mirodenafil 0.2 μM and sitagliptin 1 μM was 5.83%, which was significantly higher than the combined reduction rates of mirodenafil and sitagliptin alone. Therefore, the combination of mirodenafil and sitagliptin demonstrated a synergistic effect in Aβ reduction compared to mirodenafil and sitagliptin alone.

[0416] (2) Confirmation of reduction of inflammatory factors To determine the synergistic effect of the combination of mirodenafil and sitagliptin on reducing inflammatory factors, assays were performed using the Mouse IL1β ELISA Kit and the Mouse TNFα ELISA Kit, using the same method as in Example 1 above. The results are shown in Tables 5 and 6 below.

[0417] TIFF2026539121000014.tif132170

[0418] As shown in Table 5 above, the IL1β reduction rate was significantly increased with the combination of mirodenafil and sitagliptin compared to the IL1β reduction rates with mirodenafil and sitagliptin alone. Specifically, the IL1β reduction rates for mirodenafil 2 μM and sitagliptin 10 μM alone were 8.07% and 12.23%, respectively, but the IL1β reduction rate for the combination of mirodenafil 2 μM and sitagliptin 10 μM was 23.54%, which was significantly higher than the combined reduction rates of mirodenafil and sitagliptin alone. Therefore, the combination of mirodenafil and sitagliptin demonstrated a synergistic effect in reducing IL1β compared to mirodenafil and sitagliptin alone.

[0419] TIFF2026539121000015.tif106170

[0420] As shown in Table 6 above, the reduction in TNFα was significantly increased with the combination of mirodenafil and sitagliptin compared to the reduction of TNFα with mirodenafil and sitagliptin alone. Specifically, the TNFα reduction rates for mirodenafil 2 μM and sitagliptin 10 μM alone were 5.08% and 0.49%, respectively, but the TNFα reduction rate for the combination of mirodenafil 2 μM and sitagliptin 10 μM was 6.64%, which was significantly higher than the combined reduction rates of mirodenafil and sitagliptin alone. Therefore, the combination of mirodenafil and sitagliptin demonstrated a synergistic effect in reducing TNFα compared to mirodenafil and sitagliptin alone.

[0421] Example 3. Evaluation of combination therapy with mirodenafil and vildagliptin (1) Determination of the effect of reducing intracellular Aβ42 To investigate the synergistic effect of combining myrodenafil and vildagliptin on reducing intracellular Aβ422, an Amyloid beta 42 Human ELISA was performed. Cells were treated with Aβ at a final concentration of 5 μM, myrodenafil at final concentrations of 0.2 μM and 0.6 μM, and vildagliptin at final concentrations of 1 μM and 2 μM, diluted in DMEM (1% FBS, 1% penicillin / streptomycin), and incubated for 24 hours at 37°C in a 5% CO2 incubator. Subsequently, the experiment was carried out according to the method specified in the Human Aβ42 ELISA Kit, Ultrasensitive (invitrogen), as in Example 1 above, and the results are shown in Table 7 below.

[0422] TIFF2026539121000016.tif101170

[0423] As shown in Table 7 above, the reduction in Aβ was significantly increased with the combination of mirodenafil and vildagliptin compared to the reduction of Aβ with mirodenafil or vildagliptin alone. Specifically, the Aβ reduction rates for mirodenafil 0.2 μM and vildagliptin 1 μM alone were 2.36% and 3.71%, respectively, but the Aβ reduction rate for the combination of mirodenafil 0.2 μM and vildagliptin 1 μM was 7.34%, which was significantly higher than the combined reduction rates of mirodenafil and vildagliptin alone. Therefore, the combination of mirodenafil and vildagliptin demonstrated a synergistic effect in Aβ reduction compared to mirodenafil or vildagliptin alone.

[0424] (2) Confirmation of reduction of inflammatory factors To investigate the synergistic effect of the combination of mirodenafil and vildagliptin on reducing inflammatory factors, assays were performed using the Mouse IL1β ELISA Kit and the Mouse TNFα ELISA Kit, using the same method as in Example 1 above. The results are shown in Tables 8 and 9 below.

[0425] TIFF2026539121000017.tif106170

[0426] As can be seen from Table 8 above, the reduction in IL1β was significantly increased with the combination of mirodenafil and vildagliptin compared to the reduction of IL1β with mirodenafil or vildagliptin alone. Specifically, the IL1β reduction rates for mirodenafil 2 μM and vildagliptin 10 μM alone were 9.02% and 1.44%, respectively, but the IL1β reduction rate for the combination of mirodenafil 2 μM and vildagliptin 10 μM was 24.97%, which was significantly higher than the combined reduction rates of mirodenafil and vildagliptin alone. Therefore, the combination of mirodenafil and vildagliptin demonstrated a synergistic effect in reducing IL1β compared to mirodenafil or vildagliptin alone.

[0427] TIFF2026539121000018.tif106170

[0428] As shown in Table 9 above, the reduction in TNFα was significantly increased with the combination of mirodenafil and vildagliptin compared to the reduction of TNFα with mirodenafil or vildagliptin alone. Specifically, the TNFα reduction rates for mirodenafil 2 μM and vildagliptin 10 μM alone were 5.12% and 4.48%, respectively, but the TNFα reduction rate for the combination of mirodenafil 2 μM and vildagliptin 10 μM was 11.19%, which was significantly higher than the combined reduction rates of mirodenafil and vildagliptin alone. Therefore, the combination of mirodenafil and vildagliptin demonstrated a synergistic effect in reducing TNFα compared to mirodenafil or vildagliptin alone.

[0429] Example 4. Evaluation of combination therapy with mirodenafil and linagliptin (1) Determination of the effect of reducing intracellular Aβ42 To determine the synergistic effect of the combination of myrodenafil and linagliptin on the reduction of intracellular Aβ422, an Amyloid beta 42 Human ELISA was performed. Cells were treated with Aβ at a final concentration of 5 μM, myrodenafil at final concentrations of 0.2 μM and 0.6 μM, and linagliptin at final concentrations of 0.1 μM, diluted in DMEM (1% FBS, 1% penicillin / streptomycin), and incubated for 24 hours at 37°C in a 5% CO2 incubator. Subsequently, the experiment was carried out according to the method specified in the Human Aβ42 ELISA Kit, Ultrasensitive (invitrogen), as in Example 1 above, and the results are shown in Table 10 below.

[0430] TIFF2026539121000019.tif77170

[0431] As shown in Table 10 above, the Aβ reduction rate was significantly increased with the combination of mirodenafil and linagliptin compared to the Aβ reduction rates of mirodenafil and linagliptin alone. Specifically, the Aβ reduction rates for mirodenafil 0.2 μM and linagliptin 0.1 μM alone were 2.36% and 6.29%, respectively, but the Aβ reduction rate for the combined mirodenafil 0.2 μM and linagliptin 0.1 μM was 15.73%, which was significantly higher than the combined reduction rates of mirodenafil and linagliptin alone. Therefore, the combination of mirodenafil and linagliptin demonstrated a synergistic effect in Aβ reduction compared to mirodenafil and linagliptin alone.

[0432] (2) Confirmation of reduction of inflammatory factors To determine the synergistic effect of the combination of mirodenafil and linagliptin on reducing inflammatory factors, assays were performed using the Mouse IL1β ELISA Kit and the Mouse TNFα ELISA Kit, using the same method as in Example 1 above. The results are shown in Tables 11 and 12 below.

[0433] TIFF2026539121000020.tif96170

[0434] As can be seen from Table 11 above, the reduction of IL1β was significantly increased with the combination of mirodenafil and linagliptin compared to the reduction of IL1β with mirodenafil or linagliptin alone. Specifically, the IL1β reduction rates for mirodenafil 2 μM and linagliptin 1 μM alone were 96.47% and 7.21%, respectively, but the IL1β reduction rate for the combination of mirodenafil 2 μM and linagliptin 1 μM was 15.62%, which was significantly higher than the combined reduction rates of mirodenafil and linagliptin alone. Therefore, the combination of mirodenafil and linagliptin demonstrated a synergistic effect in reducing IL1β compared to mirodenafil or linagliptin alone.

[0435] TIFF2026539121000021.tif68170

[0436] As shown in Table 12 above, the reduction in TNFα was significantly increased with the combination of mirodenafil and linagliptin compared to the reduction of TNFα with mirodenafil or linagliptin alone. Specifically, the TNFα reduction rates for 2 μM mirodenafil and 1 μM linagliptin alone were 4.77% and 11.33%, respectively, but the TNFα reduction rate for the combined 2 μM mirodenafil and 1 μM linagliptin was 18.92%, which was significantly higher than the combined reduction rates for mirodenafil and linagliptin alone. Therefore, the combination of mirodenafil and linagliptin demonstrated a synergistic effect in reducing TNFα compared to mirodenafil or linagliptin alone.

[0437] Example 5 HMC3 cell culture method The human microglia cell line HMC3 used in the experiment was cultured and maintained in DMED / F12 complete medium (HyClone) containing 10% fetal bovine serum (FBS, HyClone) and 1% antibiotic-antifungal agent (GIBCO) in a humidified CO2 incubator (Thermos Fisher Scientific) at 37°C and 5% CO2. 2 × 10⁶ cells were placed in each 96-well plate. 3 Cells were seeded and incubated for 24 hours in a humidified CO2 incubator as described above. Furthermore, the cells were treated with or without LPS (100 ng / ml) or TNFα (5 ng / ml) using the drugs AR1001 and GLP-1 agonists (semaglutide, liraglutide, tylzepatide, dulaglutide) individually or in combination at concentrations of 0.001 M, 0.01 M, 0.1 M, and 1 M.

[0438] Measurement of IL-6 by ELISA IL-6 in the culture supernatant was assayed by enzyme-linked immunosorbent assay (ELISA). The assay was performed using Purified Rat Anti-Human IL-6 and Biotin Rat Anti-Human IL-6 (BD Bioscience Pharmaingen, California, USA). IL-6 levels were derived from a standard curve using Thermo Scientific SkanIt Software (Thermos Fisher Scientific, Waltham, Massachusetts, USA).

[0439] Measurement results of pro-inflammatory cytokines (IL-6) in an LPS-induced inflammation model As can be seen from Figures 1 to 3, in LPS-induced inflammation, IL-6 levels were not significantly reduced when mirodenafil and a GLP-1 agonist (semaglutide, liraglutide, tylzepatide, dulaglutide) were administered alone. However, IL-6 levels were significantly reduced when mirodenafil + semaglutide, mirodenafil + tylzepatide, or mirodenafil + dulaglutide were combined. However, the combination of mirodenafil + liraglutide did not show a significant effect.

[0440] As shown in Figure 1 and Table 1, there was no difference in dose-dependent LPS-induced inflammatory response (IL-6) with mirodenafil or semaglutide. However, when administered together, mirodenafil 0.1 μM + semaglutide 0.1 μM (1:1) showed a reduction of 16.67, mirodenafil 0.5 μM + semaglutide 0.1 μM (5:1) showed a reduction of 18.61, mirodenafil 1 μM + semaglutide 0.1 μM (10:1) showed a reduction of 14.20, and mirodenafil 5 μM + semaglutide 0.1 μM (50:1) showed a reduction of 12.26. Therefore, it was demonstrated that administering mirodenafil and semaglutide together (1:1 to 50:1) has a synergistic effect in reducing IL-6 compared to administering them individually.

[0441] TIFF2026539121000022.tif154170

[0442] As shown in Figure 2 and Table 2, co-administration of high doses of mirodenafil and semaglutide was also effective. Mirodenafil 10 μM + semaglutide 0.1 μM (100:1) showed a reduction of 31.33, mirodenafil 10 μM + semaglutide 1 μM (10:1) showed 36.31, mirodenafil 20 μM + semaglutide 0.1 μM (200:1) showed 49.16, and mirodenafil 20 μM + semaglutide 1 μM (20:1) showed 55.68. Therefore, it was demonstrated that administering mirodenafil and semaglutide together (10:1 to 200:1) had a synergistic effect in reducing IL-6 compared to administering them individually.

[0443] TIFF2026539121000023.tif165170

[0444] As shown in Figure 3 and Table 3, there was no effect when low concentrations of mirodenafil and tirzepatide were administered together, but a significant effect was observed when high concentrations of mirodenafil and tirzepatide were administered together. It was confirmed that mirodenafil 10 μM + tirzepatide 0.1 μM (100:1) showed a reduction effect of 59.12, mirodenafil 10 μM + tirzepatide 1 μM (10:1) showed 43.45, mirodenafil 20 μM + semaglutide 0.1 μM (200:1) showed 51.87, and mirodenafil 20 μM + semaglutide 1 μM (20:1) showed 89.63. Therefore, it was demonstrated that administering mirodenafil and semaglutide together (10:1 to 200:1) had a synergistic effect in reducing IL-6 compared to administering them individually.

[0445] TIFF2026539121000024.tif165170

[0446] As shown in Figure 4 and Table 4, there was no difference in dose-dependent LPS-induced inflammatory response (IL-6) with mirodenafil or dulaglutide. However, when administered together, mirodenafil 0.1 μM + dulaglutide 0.001 μM (100:1) was 4.85, mirodenafil 0.1 μM + dulaglutide 0.01 μM (10:1) was 9.54, mirodenafil 0.1 μM + dulaglutide 0.1 μM (1:1) was 9.31, and mirodenafil 0.5 μM + dulaglutide 0.001 μM (500:1) was 15.22. It was confirmed that the following reduction effects were observed: mirodenafil 0.5 μM + dulaglutide 0.01 μM (50:1) resulted in a reduction of 26.63, mirodenafil 1 μM + dulaglutide 0.001 μM (1000:1) resulted in a reduction of 22.16, mirodenafil 1 μM + dulaglutide 0.01 μM (100:1) resulted in a reduction of 16.42, and mirodenafil 1 μM + dulaglutide 0.1 μM (10:1) resulted in a reduction of 21.15. Therefore, it was demonstrated that administering mirodenafil and semaglutide together (1:1 to 1000:1) has a synergistic effect in reducing IL-6 compared to administering them individually.

[0447] TIFF2026539121000025.tif189170

[0448] Measurement results of pro-inflammatory cytokines (IL-6) in a TNFα-induced inflammation model As can be seen in Figures 5 and 6, in TNFα-induced inflammation, IL-6 levels were not significantly reduced when mirodenafil and a GLP-1 agonist (semaglutide, liraglutide, tylzepatide, dulaglutide) were administered alone. However, IL-6 levels were significantly reduced when mirodenafil + semaglutide, mirodenafil + tylzepatide, or mirodenafil + dulaglutide were combined. However, the combination of mirodenafil + liraglutide did not show a significant effect.

[0449] As shown in Figure 5 and Table 5, there was no effect when low concentrations of mirodenafil and semaglutide were administered together, but a significant effect was observed when high concentrations of mirodenafil and semaglutide were administered together. It was confirmed that mirodenafil 10 μM + semaglutide 0.01 μM (1000:1) showed a reduction of 23.70, mirodenafil 10 μM + semaglutide 0.1 μM (100:1) showed 25.34, mirodenafil 10 μM + semaglutide 1 μM (10:1) showed 27.54, mirodenafil 20 μM + semaglutide 0.1 μM (200:1) showed 24.68, and mirodenafil 20 μM + semaglutide 1 μM (20:1) showed a reduction of 41.58. Therefore, it was demonstrated that administering mirodenafil and semaglutide together (10:1 to 1000:1) had a synergistic effect in reducing IL-6 compared to administering them individually.

[0450] TIFF2026539121000026.tif180170

[0451] As shown in Figure 6 and Table 6, there was no difference in dose-dependent TNFα-induced inflammatory response (IL-6) with mirodenafil or tilzepatide. However, when administered together, mirodenafil 0.1 μM + tilzepatide 0.001 μM (100:1) was 20.51, mirodenafil 0.1 μM + tilzepatide 0.01 μM (10:1) was 13.27, mirodenafil 0.5 μM + tilzepatide 0.1 μM (5:1) was 11.19, and mirodenafil 1 μM + tilzepatide It was confirmed that 0.1 μM of tilzepatide (10:1) showed a reduction effect of 14.54, 10 μM of mirodenafil + 1 μM of tilzepatide (10:1) showed a reduction effect of 19.26, 20 μM of mirodenafil + 0.1 μM of tilzepatide (200:1) showed a reduction effect of 15.16, and 20 μM of mirodenafil + 1 μM of tilzepatide (20:1) showed a reduction effect of 36.01. Therefore, it was demonstrated that administering mirodenafil and tilzepatide together (1:1 to 200:1) has a synergistic effect in reducing IL-6 compared to administering them individually.

[0452] TIFF2026539121000027.tif153170

[0453] As shown in Figure 7 and Table 7, there was no difference in dose-dependent TNFα-induced inflammatory response (IL-6) with mirodenafil or dulaglutide. However, when administered together, the values ​​were 12.05 for mirodenafil 0.1 μM + dulaglutide 0.001 μM (100:1), 19 for mirodenafil 0.1 μM + dulaglutide 0.01 μM (10:1), 12.64 for mirodenafil 0.1 μM + dulaglutide 0.1 μM (1:1), and 13.7 for mirodenafil 0.5 μM + dulaglutide 0.001 μM (500:1). 6. It was confirmed that the reduction effects were 15.31 for mirodenafil 0.5 μM + dulaglutide 0.01 μM (50:1), 17.74 for mirodenafil 0.5 μM + dulaglutide 0.1 μM (5:1), 14.12 for mirodenafil 1 μM + dulaglutide 0.01 μM (100:1), and 8.16 for mirodenafil 1 μM + dulaglutide 0.1 μM (10:1). Therefore, it was demonstrated that administering mirodenafil and semaglutide together (1:1 to 500:1) has a synergistic effect in reducing IL-6 compared to administering them individually.

[0454] TIFF2026539121000028.tif126170

[0455] Example 6 Method for culturing primary astrocytes Primary cultures of mouse cortical neurons were prepared from pregnant mice (TP14.5-15.5). Generally, the meninges-free cortex was dissociated in 0.125% (w / v) trypsin at 37°C. Tissue fragments were mechanically dissociated in culture medium [DMEM / F12 (Hyclone) containing 10% fetal bovine serum (FBS, HyClone) and 1% antibiotic-antifungal agent (GIBCO)] in a humidified CO2 incubator (Thermos Fisher Scientific) at 37°C and 5% CO2 by repeated, gentle pipetting using wide- and narrow-nose flame-polished Pasteur pipettes. Cells were counted and then plated into multi-well (96-well; SPL, Korea) containers at a cell density of 30,000 cells per well. The cultures were grown in a humidified atmosphere of 37°C and 5% CO2 / 95% air. The culture was used in the experiment 7 days after in vitro incubation (in vitro days: DIV).

[0456] Measurement of IL-6 by ELISA IL-6 in the culture supernatant was assayed by enzyme-linked immunosorbent assay (ELISA). The assay was performed using Purified Rat Anti-Human IL-6 and Biotin Rat Anti-Human IL-6 (BD Bioscience Pharmaingen, California, USA). IL-6 levels were derived from a standard curve using Thermo Scientific SkanIt Software (Thermos Fisher Scientific, Waltham, Massachusetts, USA).

[0457] Measurement results of pro-inflammatory cytokines (IL-6) in Aβ+IFNr or STZ-induced inflammation models As shown in Figure 8 and Tables 8 and 9, IL-6, an inflammatory marker, was detected in primary astrocytes after treatment with Aβ (10 μM / ml) + IFNr (20 ng / ml) or STZ (10 mM / ml). When administered together, mirodenafil 1 μM + exenatide 0.1 μM (10:1) showed a reduction of 22.19, and mirodenafil 1 μM + exenatide 1 μM (11:1) showed a reduction of 11.45. Therefore, it was demonstrated that administering mirodenafil and exenatide together (1:1 to 10:1) had a synergistic effect in reducing IL-6 compared to administering them individually. Similar to the case of Aβ + IFNr, IL-6 was also reduced when mirodenafil + exenatide was administered simultaneously with STZ.

[0458] TIFF2026539121000029.tif113170

[0459] TIFF2026539121000030.tif115170

[0460] Example 3 Method for culturing primary neuron cultures Primary cultures of mouse cortical neurons were prepared from pregnant mice (TP14.5-15.5). Generally, meningeal-free cortex was dissociated in 0.125% (w / v) trypsin at 37°C. Tissue fragments were mechanically dissociated by repeated, gentle pipetting using wide- and narrow-nose flame-polished Pasteur pipettes in Neurobasal medium (Gibco, Grand Island, New York, USA) supplemented with 2% B27® Supplement (50×) and serum-free (Gibco®). Cells were counted and then plated at a cell density of 30,000 cells per well into poly-L-lysine (5 g / ml) coated multi-well (96 wells; SPL, Korea). The cultures were grown at 37°C in a humidified atmosphere of 5% CO2 / 95% air. The culture was used in the experiment 7 days after in vitro incubation (in vitro days: DIV).

[0461] Mitochondrial membrane potential (JC-1 assay) Following 48 hours of incubation at 37°C and 5% CO2, mitochondrial membrane potential was evaluated using the JC-1 assay. The JC-1 Mitochondrial Membrane Potential Assay Kit (ab113850, Abcam) was used according to the manufacturer's protocol, and cells were stained for 10 minutes in a CO2 incubator. Fluorescence measurements were performed using a microplate reader (Varioskan LUX), and the results were expressed as the ratio of aggregates (535 nm, red) to monomers (475 nm, green).

[0462] Measurement results of the JC-1 ratio in Aβ-induced primary neurons As shown in Figure 9 and Table 10, the decrease in the JC-1 ratio (aggregates / monomers) in primary neurons after Aβ treatment was compared with the change in the JC-1 ratio in drug-treated groups. There was no difference in dose-dependent Aβ-induced mitochondrial damage (JC-1) with mirodenafil or semaglutide. However, when administered together, the following increased effects were observed: mirodenafil 0.1 μM + semaglutide 0.01 μM (10:1) increased the number of cells by 28; mirodenafil 0.1 μM + dulaglutide 0.1 μM (1:1) increased the number of cells by 18; mirodenafil 0.5 μM + dulaglutide 0.01 μM (50:1) increased the number of cells by 6; mirodenafil 0.5 μM + dulaglutide 0.01 μM (50:1) increased the number of cells by 14; mirodenafil 1 μM + dulaglutide 0.01 μM (100:1) increased the number of cells by 14; and mirodenafil 5 μM + dulaglutide 1 μM (5:1) increased the number of cells by 21. Therefore, it was demonstrated that administering mirodenafil and semaglutide together (1:1 to 100:1) has a synergistic effect on JC-1 induction compared to administering them individually.

[0463] TIFF2026539121000031.tif177170

[0464] As shown in Figure 10 and Table 11, the decrease in the JC-1 ratio (aggregates / monomers) in primary neurons after Aβ treatment was compared with the change in the JC-1 ratio in the drug-treated groups. There was no difference in dose-dependent Aβ-induced mitochondrial damage (JC-1) with mirodenafil or exenatide. However, when administered together, mirodenafil 0.1 μM + exenatide 0.001 μM (100:1) showed an increase of 6, and mirodenafil 0.5 μM + dulaglutide 0.001 μM (500:1) showed an increase of 15. Therefore, it was demonstrated that administering mirodenafil and exenatide together (1:1 to 100:1) has a synergistic effect on JC-1 induction compared to administering them individually.

[0465] TIFF2026539121000032.tif115170

[0466] statistical analysis Values ​​are presented as mean ± SD, and statistical significance was analyzed using one-way analysis of variance (ANOVA).

[0467] Other embodiments The above detailed description is provided to assist those skilled in the art in carrying out the invention. However, since these embodiments are intended to be illustrative of some aspects of the invention, the invention described and claimed in this patent document should not be limited in scope by the specific embodiments disclosed herein. Any equivalent embodiments are intended to fall within the scope of the invention. In fact, in addition to those shown and described herein, various modifications of the invention will become apparent to those skilled in the art from the foregoing description without departing from the spirit or scope of this inventive discovery. Such modifications are also intended to fall within the scope of the appended claims.

[0468] References All publications, patents, patent applications, and other documents cited herein are, in any way, part of this Specification, as if each individual publication, patent, patent application, or other document were clearly and individually indicated to be part of this Specification by any way. No reference to any document herein should be construed as an admission that such document is prior art of the present invention.

Claims

1. A pharmaceutical composition for the prevention or treatment of neurodegenerative diseases, PDE-5 inhibitors and GLP-1 receptor agonists and GIP agonists and, Glucagon and, A pharmaceutical composition comprising the above, wherein the molar ratio of any one member of the above group to another member is approximately (1, 0, 0, 1000) to approximately (1000, 0, 0, 0).

2. A pharmaceutical composition for the prevention or treatment of neurodegenerative diseases, PDE-5 inhibitors and DPP-4 inhibitors and GIP agonists and, Glucagon and, A pharmaceutical composition comprising the above, wherein the molar ratio of any one member of the above group to another member is approximately (1, 0, 0, 1000) to approximately (1000, 0, 0, 0).

3. A pharmaceutical composition for the prevention or treatment of neurodegenerative diseases, PDE-5 inhibitors and GLP-1 receptor agonists and A pharmaceutical composition comprising the above, wherein the molar ratio of any one member of the above group to another member is approximately (1, 0, 0, 1000) to approximately (1000, 0, 0, 0).

4. A pharmaceutical composition for the prevention or treatment of neurodegenerative diseases, PDE-5 inhibitors and A dual agonist of a GLP-1 receptor agonist and a GIP agonist, A pharmaceutical composition comprising the above, wherein the molar ratio of any one member of the above group to another member is approximately (1, 0, 0, 1000) to approximately (1000, 0, 0, 0).

5. A pharmaceutical composition for the prevention or treatment of neurodegenerative diseases, PDE-5 inhibitors and A triple agonist consisting of a GLP-1 receptor agonist, a GIP agonist, and a glucagon agonist, A pharmaceutical composition comprising the above, wherein the molar ratio of any one member of the above group to another member is approximately (1, 0, 0, 1000) to approximately (1000, 0, 0, 0).

6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the PDE-5 inhibitor is selected from the group consisting of mirodenafil, sildenafil, vardenafil, tadalafil, udenafil, dasantafil, avanafil, and pharmaceutically acceptable salts, solvates, and hydrates thereof.

7. The pharmaceutical composition according to any one of claims 1 to 5, wherein the GLP-1 receptor agonist is selected from the group consisting of semaglutide, exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, tilzepatide, cotadutide, and taspoglutide.

8. The pharmaceutical composition according to claim 6, wherein the PDE-5 inhibitor is mirodenafil and a pharmaceutically acceptable salt thereof.

9. The pharmaceutical composition according to claim 7, wherein the GLP-1 receptor agonist is semaglutide.

10. The pharmaceutical composition according to claim 2, wherein the DPP-4 inhibitor is sitagliptin.

11. The aforementioned neurodegenerative diseases include Parkinson's disease (PD); sporadic or hereditary Lewy body dementia (DLB); pure autonomic neuropathy with αS deposition (PAF); multiple system atrophy (MSA); hereditary neurodegenerative diseases with intracranial iron accumulation; and incidental Lewy body disease in old age; Lewy body Alzheimer's disease; Down syndrome; progressive supranuclear palsy; essential tremor with Lewy bodies; mutated genes; and familial parkinary disease with or without dementia caused by gene loci whose mutations have not yet been identified. A pharmaceutical composition according to any one of claims 1 to 5, selected from the group consisting of: sonism; Creutzfeldt-Jakob disease; bovine spongiform encephalopathy; secondary parkinson's disease / parkinsonism resulting from neurotoxin exposure / drug-induced parkinsonism with alpha-synuclein deposition; sporadic or hereditary spinocerebellar ataxia; amyotrophic lateral sclerosis (ALS); idiopathic REM sleep behavior disorder; and other conditions associated with central and / or peripheral alpha-synuclein accumulation in mammals associated with a primary disease process.

12. The aforementioned neurodegenerative diseases include Alzheimer's disease, vascular dementia, frontotemporal dementia (FTD), Lewy body dementia (LBD), mixed dementia, posterior cortical atrophy (PCA), primary progressive aphasia (PPA), corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP), idiopathic myeloma, amyloid polyneuropathy, amyloid cardiomyopathy, systemic senile amyloidosis, amyloid polyneuropathy, hereditary cerebral hemorrhage with amyloidosis, Down syndrome, scrapie, medullary thyroid carcinoma, isolated atrial amyloidosis, and β2- Microglobulin amyloidosis, inclusion body myositis, muscular atrophy, islet diabetes, type 1 diabetes, insulinoma, type 2 diabetes, hereditary hemorrhagic amyloidosis (Dutch type), amyloid A (reactive) amyloidosis, secondary amyloidosis, familial Mediterranean fever, familial amyloid nephropathy with urticaria and hearing loss (Macklewells syndrome), amyloid λL chain amyloidosis, amyloid κL chain amyloidosis, idiopathic-associated amyloidosis, myeloma-associated amyloidosis, macroglobulinemia-associated amyloidosis Aβ2M amyloidosis (chronic hemodialysis), ATTR amyloidosis (familial amyloid polyneuropathy (Portuguese type, Japanese type, Swedish type)), familial amyloid cardiomyopathy (Danish type), isolated cardiac amyloidosis, systemic senile amyloidosis, AIAPP or amylin insulinoma, atrial natriuretic factor amyloidosis (isolated atrial amyloidosis), procalcitonin amyloidosis (medullary thyroid carcinoma), gelzolin amyloidosis (familial amyloidosis (Finnish type)), cis A pharmaceutical composition according to any one of claims 1 to 5, selected from the group consisting of Tatin C (hereditary cerebral hemorrhage with amyloidosis (Icelandic type)), AApo-A-I amyloidosis (familial amyloid polyneuropathy - Iowa type), AApo-A-II amyloidosis, traumatic brain injury, fibrinogen-related amyloidosis, Creutzfeldt-Jakob disease, Gerstmann-Streussler-Scheinker syndrome, bovine spongiform encephalitis, a condition associated with homozygosity of the apolipoprotein E4 allele, and Huntington's disease.

13. The pharmaceutical composition according to any one of claims 1 to 5, wherein the neurodegenerative disease is selected from the group consisting of Parkinson's disease (PD), Parkinson's dementia (PDD), Lewy body dementia (DLB), multiple system atrophy (MSA), pure autonomic dysplasia (PAF), and Lewy body variant (LBV) of Alzheimer's disease.

14. The pharmaceutical composition according to any one of claims 1 to 5, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, vascular dementia, frontotemporal dementia (FTD), Lewy body dementia (LBD), mixed dementia, posterior cortical atrophy (PCA), primary progressive aphasia (PPA), corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP).

15. The pharmaceutical composition according to any one of claims 1 to 5, wherein the neurodegenerative disease is selected from the group consisting of Lewy body dementia and Alzheimer's disease.

16. A pharmaceutical composition according to any one of claims 1 to 5, formulated for oral administration.

17. The pharmaceutical composition according to claim 16, which is in the form of a tablet or a capsule.

18. A method for treating neurodegenerative diseases in subjects requiring treatment, wherein the method is Administering a therapeutically effective amount of a pharmaceutical composition containing a PDE-5 inhibitor, a GLP-1 receptor agonist, a GIP agonist, and glucagon to the subject. Includes, A method wherein the molar ratio of any one member of the group to another member is approximately (1, 0, 0, 1000) to approximately (1000, 0, 0, 0).

19. A method for treating neurodegenerative diseases in subjects requiring treatment, wherein the method is Administering a therapeutically effective amount of a pharmaceutical composition containing a PDE-5 inhibitor, a DPP-4 inhibitor, a GIP agonist, and glucagon to the subject. Includes, A method wherein the molar ratio of any one member of the group to another member is approximately (1, 0, 0, 1000) to approximately (1000, 0, 0, 0).

20. A method for treating neurodegenerative diseases in subjects requiring treatment, wherein the method is Administering a therapeutically effective amount of a pharmaceutical composition comprising a PDE-5 inhibitor and a dual agonist of the GLP-1 receptor and GIP to the subject. Includes, A method wherein the molar ratio of any one member of the group to another member is approximately (1, 0, 0, 1000) to approximately (1000, 0, 0, 0).

21. A method for treating neurodegenerative diseases in subjects requiring treatment, wherein the method is Administering a therapeutically effective amount of a pharmaceutical composition containing a PDE-5 inhibitor and a triple agonist of GLP-1 receptor, GIP, and glucagon to the subject. Includes, A method wherein the molar ratio of any one member of the group to another member is approximately (1, 0, 0, 1000) to approximately (1000, 0, 0, 0).

22. The method according to any one of claims 18 to 21, wherein the PDE-5 inhibitor is selected from the group consisting of mirodenafil, sildenafil, vardenafil, tadalafil, udenafil, dasantafil, avanafil, and pharmaceutically acceptable salts, solvates, and hydrates thereof.

23. The method according to any one of claims 18 to 21, wherein the PDE-5 inhibitor is mirodenafil.

24. The method according to claim 19, wherein the DPP-4 inhibitor is selected from the group consisting of sitagliptin, vildagliptin, saxagliptin, linagliptin, gemigliptin, teneligliptin, alogliptin, evogliptin, and anagliptin.

25. The method according to claim 24, wherein the DPP-4 inhibitor is sitagliptin.

26. The aforementioned neurodegenerative diseases include Parkinson's disease (PD); sporadic or hereditary Lewy body dementia (DLB); pure autonomic neuropathy with αS deposition (PAF); multiple system atrophy (MSA); hereditary neurodegenerative diseases with intracranial iron accumulation; and incidental Lewy body disease in old age; Lewy body Alzheimer's disease; Down syndrome; progressive supranuclear palsy; essential tremor with Lewy bodies; mutated genes; and familial parkinary disease with or without dementia caused by gene loci whose mutations have not yet been identified. The method according to any one of claims 18 to 21, selected from the group consisting of: soniness; Creutzfeldt-Jakob disease; bovine spongiform encephalopathy; secondary parkinson's disease / parkinsonism resulting from neurotoxin exposure / drug-induced parkinsonism with alpha-synuclein deposition; sporadic or hereditary spinocerebellar ataxia; amyotrophic lateral sclerosis (ALS); idiopathic REM sleep behavior disorder; and other conditions associated with central and / or peripheral alpha-synuclein accumulation in mammals associated with a primary disease process.

27. The aforementioned neurodegenerative diseases include Alzheimer's disease, vascular dementia, frontotemporal dementia (FTD), Lewy body dementia (LBD), mixed dementia, posterior cortical atrophy (PCA), primary progressive aphasia (PPA), corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP), idiopathic myeloma, amyloid polyneuropathy, amyloid cardiomyopathy, systemic senile amyloidosis, amyloid polyneuropathy, hereditary cerebral hemorrhage with amyloidosis, Down syndrome, scrapie, medullary thyroid carcinoma, isolated atrial amyloidosis, and β2- Microglobulin amyloidosis, inclusion body myositis, muscular atrophy, islet diabetes, type 1 diabetes, insulinoma, type 2 diabetes, hereditary hemorrhagic amyloidosis (Dutch type), amyloid A (reactive) amyloidosis, secondary amyloidosis, familial Mediterranean fever, familial amyloid nephropathy with urticaria and hearing loss (Macklewells syndrome), amyloid λL chain amyloidosis, amyloid κL chain amyloidosis, idiopathic-associated amyloidosis, myeloma-associated amyloidosis, macroglobulinemia-associated amyloidosis Aβ2M amyloidosis (chronic hemodialysis), ATTR amyloidosis (familial amyloid polyneuropathy (Portuguese type, Japanese type, Swedish type)), familial amyloid cardiomyopathy (Danish type), isolated cardiac amyloidosis, systemic senile amyloidosis, AIAPP or amylin insulinoma, atrial natriuretic factor amyloidosis (isolated atrial amyloidosis), procalcitonin amyloidosis (medullary thyroid carcinoma), gelzolin amyloidosis (familial amyloidosis (Finnish type)), The method according to any one of claims 18 to 21, selected from the group consisting of statin C (hereditary cerebral hemorrhage with amyloidosis (Icelandic type)), AApo-A-I amyloidosis (familial amyloid polyneuropathy - Iowa type), AApo-A-II amyloidosis, traumatic brain injury, fibrinogen-related amyloidosis, Creutzfeldt-Jakob disease, Gerstmann-Streussler-Scheinker syndrome, bovine spongiform encephalitis, a condition associated with homozygosity of the apolipoprotein E4 allele, and Huntington's disease.

28. The method according to any one of claims 18 to 21, wherein the neurodegenerative disease is selected from the group consisting of Parkinson's disease (PD), Parkinson's disease dementia (PDD), Lewy body dementia (DLB), multiple system atrophy (MSA), pure autonomic dysplasia (PAF), and Lewy body variant (LBV) of Alzheimer's disease.

29. The method according to any one of claims 18 to 21, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, vascular dementia, frontotemporal dementia (FTD), Lewy body dementia (LBD), mixed dementia, posterior cortical atrophy (PCA), primary progressive aphasia (PPA), corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP).

30. The method according to any one of claims 18 to 21, wherein the neurodegenerative disease is selected from the group consisting of Lewy body dementia and Alzheimer's disease.